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Abstract 
 
Chronic growth hormone (GH) excess, acromegaly, causes a specific cardiomyopathy, which 
remains poorly understood.  The pattern of hypertrophy is distinct from other forms of cardiac 
disease and begins to appear before hypertension or diabetes.  GH deficiency (GHD) also 
causes cardiovascular problems, with reduced ability to mount a cardiovascular response to 
exercise.  Acromegaly and GHD patients have increased cardiac mortality.  
 
Cardiac magnetic resonance imaging (CMR) is the gold standard for assessment of cardiac 
mass and provides data on cardiac function, fibrosis, valve function and ischaemia.  This 
study used CMR to assess 23 patients with acromegaly or GHD, before and after treatment 
of their GH disorder, and 23 healthy controls.  Patients with acromegaly demonstrated 
increased left ventricular mass index (LVMi), end diastolic volume index, stroke volume index 
and cardiac index, which persisted at one year, despite treatment of underlying disease.  
Patients with GHD demonstrated LVMi at the bottom (males) or beneath (females) published 
normal references ranges, which increased with one year of GH replacement. 
 
The mechanisms by which GH influences cardiac tissue are poorly understood.  Adenosine 
monophosphate-activated protein kinase (AMPK) is an energy-regulator enzyme, which 
interacts with several metabolic hormones.  Mutations in AMPK cause arrhythmias and 
cardiac hypertrophy.  AMPK activation may be a mechanism by which GH causes some of its 
cardiac effects. 
 
This study used primary cardiomyocytes and mouse and rat models of GH excess and 
deficiency to study the effects of GH on cardiac AMPK.  Acute GH treatment increased 
AMPK activity in both in vivo and in vitro studies; acute IGF-I treatment had the opposite 
effect.  In 2 and 8 month old bovine GH-overexpresing (bGH) and GH receptor knock out 
(GHRKO) mice, functional AMPK assay did not demonstrate any difference in cardiac AMPK 
activity between transgenics and controls.  However, Western blotting for Threonine-172 
phospho (p)AMPK levels, a marker of AMPK activity, demonstrated increased cardiac 
pAMPK in 2 month old bGH mice and a reduction in cardiac pAMPK levels in 8 month old 
animals.  A trend towards the same findings was seen in GHRKO mice.  This indicates that 
both GH and IGF-I interact with myocardial AMPK, apparently via different mechanisms. 
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1 Introduction 
 
1.1 Heart function and structure 
The heart is the first functional organ in the human embryo and begins beating approximately 
21 days after conception.  Less than 50% of cardiomyocytes will regenerate throughout life, so 
the majority of the cells developed in utero will need to function for the entirety of the life of the 
individual1.  In order to determine the impact of a disease or its treatment on the heart, methods 
for measuring cardiac structure and function are required.  In clinical practice, the patient 
examination, electrocardiogram (ECG) or chest radiograph provide initial information.  However, 
the data that can be gathered from these are limited.  Hence, several forms of cardiac imaging 
have been developed and cardiac volume and function surrogate end-points have been 
established to allow for further assessment2. 
 
One of the more established surrogate end-points of cardiac function is left ventricular ejection 
fraction (EF).  This is the volume of blood pumped out to the ventricle as a percentage of the 
total blood in the ventricle when maximally full, per heartbeat, and is presented as a fraction.  
EF makes the assumption that the fraction of blood expelled from the left ventricle (LV) is 
proportional to the force generated at LV contraction2.  Other common end-points taken from 
cardiac imaging are: end diastolic volume (EDV), the volume of blood in the ventricle at the end 
of diastole; end systolic volume (ESV), the volume of blood in the ventricle at the end of systole; 
stroke volume (SV), the volume of blood ejected from a ventricle per heart beat (= EDV – ESV); 
myocardial mass (LVM); cardiac output (CO), the volume of blood circulated in a minute.  These 
measurements are influenced by height and weight and are therefore commonly indexed to 
body surface area.  When this is done the parameter is suffixed with “i”.  There are many 
imaging techniques available to assess these parameters and each has its own advantages and 
disadvantages2. 
 
There is evidence that the above parameters correlate with prognosis in a range of cardiac 
conditions, including myocardial infarction3 and heart failure4 and even correlate with cardiac 
prognosis in those without established heart disease5.  A further benefit of using these 
parameters in research is that they are familiar to clinicians, assisting in the ready translation of 
research into clinical practice2. 
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1.2 Growth hormone  
Human growth hormone (GH) is a 191 amino acid single chain polypeptide, coded for by a 66 
kb DNA locus on chromosome 17q22-q246 (Figure 1.1).  It is secreted in a pulsatile manner by 
the somatomammotroph cells of the anterior pituitary gland in response to hypothalamic growth 
hormone releasing hormone. GH induces fetal and postnatal somatic growth and plays a role in 
the maintenance of normal metabolic status7. GH acts via its receptor (GHR), a constitutively 
active homodimer of the cytokine receptor type Ia family.  When a GH molecule binds to the 
GHR dimer, a subtle rotational plane change occurs with consequential signalling via the janus 
kinase (JAK) – signal transducer and activator of transcription (STAT) pathway8,9 (Figure 1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Many of the effects of GH are mediated via insulin-like growth factor-I (IGF-I).  IGF-I, previously 
known as somatomedin, is 70 amino acid peptide, coded for by a 90 kb DNA locus on 
chromosome 1210.  Its receptor (IGF-IR) is a heterotetrameric glycoprotein that is 60% 
homologous with the insulin receptor (IR) and may form heterodimers with the IR11.  As a 
consequence there are many crossovers between IGF-I and insulin systems11. 
 
GH treatment has been shown to have many positive cardiovascular effects.  Acutely, it 
improves cardiac function and attenuates left ventricular (LV) remodelling in rats with 
myocardial infarction12, and improves stroke volume, myocardial contractility and cardiac output 
in rats with heart failure13,14.   Healthy individuals treated with IGF-I show an increase in LV 
ejection fraction and a trend towards increased heart rate, even in the absence of blood 
pressure changes, suggesting that IGF-I can have a direct effect on the heart15.  
Figure 1.1 Schematic of the 2D structure of GH 
(http://haileydawsonbiol4550.blogspot.com/) 
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Figure 1.2 Simplified schematic of GHR activation: GH (blue) acting at its dimerised receptor 
(purple) to phosphorylate and activate the Jak-STAT pathway, resulting in transcription of target 
genes in the nucleus 
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1.3 Acromegaly  
Acromegaly is caused by chronic GH excess, almost always as the result of a benign tumour of 
the pituitary somatomammotroph cells (Figure 1.3).  It is a rare disease with an incidence of 3-
4/million/year and a prevalence 50-80/million16.  The GH excess results in increased soft tissue 
mass, with coarsening of facial features, an increase in size of the hands and feet and 
organomegaly.  Other associated features include increased sweating, impaired glucose 
tolerance and type 2 diabetes mellitus, hypertension, salt and water retention, hirsutism and 
acne.  Co-secretion of prolactin from the tumour may cause galactorrhoea, impotence or 
amenorrhoea.  Local tumour growth may cause compression of the optic chiasm, resulting in 
visual loss in a bitemporal pattern, or destruction of the anterior or even, rarely, the posterior 
pituitary gland, with evidence of hypopituitarism and diabetes insipidus17.  If GH excess begins 
prior to fusion of the epiphyses, the affected individual develops increased long bone length, 
and there is substantially increased height, a disease known as gigantism.  Acromegaly is also 
associated with multi-nodular enlargement of the thyroid gland, which may produce thyroid 
hormone excess.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 T1-weighted MRI scan from a patient with acromegaly demonstrating 
a macroadenoma (*).  The tumour touches the left side of the optic chiasm.  
* 
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The first-line treatment for acromegaly is surgical removal of the tumour17.  If there is evidence 
of visual impairment as a consequence of optic chiasm compression, this becomes a surgical 
emergency.  Patients with larger tumours extending outside the sella may benefit from six 
month pre-treatment with somatostatin analogues prior to surgical intervention18.  Hypothalamic 
somatostatin inhibits GH release and acts at the somatostatin receptor (SSTR1-5).  In 1982, an 
analogue of somatostatin was created; due to its octopeptide structure it was named 
octreotide19.  Octreotide continues to have a role in the management of acromegaly but its use 
is limited by the necessity of subcutaneous dosing three times a day.  Slow-release 
somatostatin analogues, such as octreotide LAR, lanreotide LAR and pasireotide LAR, that are 
given by intramuscular or deep subcutaneous injection once a month, have been developed.  
These have been shown to be effective in reducing IGF-I levels and in improving the signs and 
symptoms of acromegaly20.  They may also be effective in reducing tumour size to allow the 
surgeon the opportunity for maximum tumour clearance18.  Somatostatin analogues are also 
used post-surgery to control residual disease or in the patient in whom surgery is inadvisable.  
These drugs have varying affinities for different somatostatin receptors, a characteristic that 
may be relevant in the targeting of treatment (Table 1.1).  Alternative treatments for acromegaly 
include radiotherapy, which may be given as an adjuvant after surgery, and dopamine agonists 
such as cabergoline. 
  
 SSTR1 SSTR2 SSTR3 SSTR4 SSTR5 
Octreotide 280.0 0.38 7.10 >1000 6.30 
Pasireotide 9.3 1.0 1.5 >1000 0.16 
Table 1.1 Binding affinities of octreotide and pasireotide for human somatostatin 
receptors, shown as IC50, nmol/L. Pasireotide demonstrates broader effect but slightly 
lower SSTR2 affinity than octreotide21. 
 
In contrast to the beneficial cardiovascular effects of acute GH excess, acromegaly, is 
associated with distinct forms of cardiac disease21 and increased cardiac mortality22.  Most 
notably, patients exhibit cardiac enlargement but also demonstrate arterial hypertension, 
arrhythmias and heart failure.  A specific acromegalic cardiomyopathy is described, consisting 
of biventricular hypertrophy, functional changes and fibrosis23.  Such findings can only be 
partially explained by the systemic consequences of GH excess, such as hypertension, insulin 
resistance and increased preload23. 
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1.4 Growth hormone deficiency 
GH deficiency (GHD) may develop in childhood (co-GHD) or in adulthood (ao-GHD).  
Childhood-onset GHD may arise for many reasons (Table 1.2) and may be an isolated 
deficiency or associated with loss of other pituitary hormones.  Incidence is estimated at 1:3,500 
live births24.  
 
Idiopathic  
Genetic 
 
Pit-1 defects 
Prop-1 defects 
Congenital 
 
Associated with structural defects:  
 Agenesis of corpus callosum  
 Septo-optic dysplasia  
 Holoprosencephaly  
 Arachnoid cyst  
Associated with midline facial defects:  
 Single central incisor  
 Cleft lip/palate  
 Nasal dimple 
Hypothalamic or pituitary tumours 
   
Craniopharyngioma  
Glioma/astrocytoma  
Germinoma  
Histocytosis  
Lymphoma  
Trauma Perinatal trauma  
Postnatal trauma  
Infection Tuberculosis 
Other Central nervous system infections 
Cranial irradiation  
Transient 
  
Psychosocial deprivation 
Table 1.2 Causes of childhood GHD, adapted from Camacho-Hübner, Disorders of growth 
hormone in childhood 24 
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The most common cause of GHD in adults is pituitary destruction due to the direct effect of a 
pituitary tumour or its treatment25.  Isolated GHD is difficult to diagnose outside of childhood and 
the presence of multiple pituitary hormone deficiencies makes the diagnosis easier.  GHD 
produces tiredness, reduced muscle strength and poor exercise tolerance, and results in a 
detrimental body composition, with increased fat mass and reduced lean body mass26.   
Recombinant human (h)GH is licensed for the treatment of both GHD and short stature in 
children.  In adults its use is restricted to those displaying evidence of severe GHD27.  This is 
assessed through a combination of dynamic testing of GH reserve and an assessment of the 
clinical and psychological impact of GHD, using the quality of life - assessment of GH deficiency 
in adults (AGHDA) questionnaire28,29. 
 
GHD causes cardiac dysfunction.  Patients with GHD develop a hypokinetic syndrome with loss 
of cardiac response to exercise, which may be ameliorated by GH replacement30,31.  Childhood-
onset GHD (co-GHD) results in reduced cardiac mass32.  Findings are less consistent in adult-
onset disease (ao-GHD); however, the ability to accurately determine the impact of ao-GHD on 
cardiac mass has been limited by historical methods of assessment33.  GHD is also associated 
with an atherogenic biochemical profile, with raised low density lipoprotein (LDL)-cholesterol, 
reduced high density lipoprotein (HDL)-cholesterol and increased inflammatory markers26,34,35.  
Thus, both chronic GH excess and deficiency may result in cardiac disease. 
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1.5 Basic studies: GH & the heart 
The GH and IGF-I receptors are expressed in both human and rat myocardium36-39.  GH 
administration increases cardiac IGF-I content40 and induces cardiac IGF-I expression41.  To 
date, most of the direct actions of the GH/IGF-I axis in the heart appear to be mediated via IGF-I 
action.  IGF-I, but not GH, directly stimulates cardiomyocyte growth42, induces muscle gene 
expression42 and increases cardiac contractility43.  IGF-I treatment is able to increase 
contractility of neonatal rat cardiomyocytes44, isolated rat hearts43 and ferret papillary muscles43 
by increasing calcium ion sensitivity, but not calcium concentration, and may be prevented by 
blocking the phosphatidylinositol 3-kinase (PI3K) pathway.  Increased calcium sensitivity has 
also seen in in vivo models of chronic GH excess45. 
 
IGF-I expression is increased in rat myocardium following both pressure and volume overload, 
suggesting a role for local IGF-I in the development of compensatory hypertrophy even in the 
absence of GH excess46-48.  
 
IGF-I induced cardiomyocyte growth can be inhibited by the addition of IGF-binding protein 3 
(IGFBP3)42.  IGFBP3 is the major circulating carrier for IGF-I and is raised in patients with 
acromegaly49.  IGFBP3 has been shown to promote apoptosis in prostate and breast cancer 
cells50,51 and it has been suggested that IGFBP3 provides a counterbalance to the growth 
induction of IGF-I52.  Therefore, the distinctive cardiac phenotype seen in GH excess is likely to 
result from interactions between both IGF-I induced protein synthesis and IGFBP3 induced 
programmed cell death.  Furthermore, low levels of IGFBP3 are associated with increased risk 
of coronary events suggesting a cardioprotective role for IGFBP353.  However, as IGFBP3-
overexpressing mice demonstrate cardiac hypertrophy the action of IGFBP3 in the development 
of the cardiac changes of GH excess remains unclear54.  Both GH and IGF-I have been shown 
to increase endothelial nitric oxide synthase (eNOS) activation through 
phosphorylation55,56(Figure 1.3).  The eNOS system induces vasodilatation and has been shown 
to be involved in cardiovascular protection. 
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The systemic effects of GH combined with the complexities of the GH/IGF-I system, with both 
paracrine and endocrine effects, necessitate the use of animal models in the investigation of GH 
excess and deficiency.  The oldest model of acromegaly, other than simple injection of GH into 
an animal, a situation which poorly mimics disease, is the GH3-implanted rat57.  GH3 is a rat 
pituitary tumour cell line which, when injected subcutaneously into the flank of a rat, will grow to 
form a GH-secreting tumour.  This model is not completely true to acromegaly, animals do not 
display true cardiac hypertrophy as their cardiac enlargement remains proportionate to body 
enlargement, but has been able to provide a wealth of in vivo data regarding the effects of GH 
on the heart23.  Transgenic mice provide an alternative method of studying chronic GH excess.  
Most commonly, the bovine (b)GH gene is inserted into the mouse genotype resulting in 
ubiquitous expression of the peptide in heterozygous offspring.  This model demonstrates 
marked rises in both GH and IGF-I levels (Table 1.3).  
  
 Non-transgenic littermates bGH transgenic mice 
GH (ng/ml) 1.6 ± 0.5 636.3 ± 136 
IGF-I (ng/ml) 492.5 ± 20.1 868.4 ± 25.1 
Table 1.3 Fasting serum GH and IGF-I levels in the bGH transgenic mice, demonstrating 
both are significantly raised in transgenic mice (p<0.05)58 
Figure 1.3 Potential signalling pathways in GH-mediated activation of 
eNOS.  MAPK = mitogen-activated protein kinse; P = phosphorylation; 
SHC = Src=homology/collagen.  From Thum and Bauersachs67 
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Conversely, transgenic mice with GHD have been developed, including those with a knocked 
out (KO) or disrupted GH receptor gene and those that produce non-functional GH (Figure 
1.4)59.  A spontaneously arising mutation in a colony of AS rats led to the establishment of the 
dw/dw dwarf rat.  These have a paucity of somatotroph cells in the pituitary and produce low 
amounts of GH throughout life.  The remainder of the pituitary hormones are within normal limits 
for the GHD state60.  The dw/dw rat demonstrates low serum IGF-I levels, reduced LV mass to 
tibial length ratio, reduced cardiomyocyte area and reduced myocardial contractility and 
distensibility, which are fully reversible with human GH (hGH) treatment61. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Transgenic mice.  From left to right: bGH-overexpressing, wild type, 
GH antagonist, GH receptor knock out (from Kopchick et al.60) 
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1.6 Acute GH excess in humans 
There are limited studies to show the acute effect of IGF-I and GH in humans.  IGF-I infusion 
(60 µg/kg) given over four hours has been shown to increase cardiac output (+37.3% ± 9% from 
baseline, p<0.01), heart rate (13% ± 2%, p<0.01) and stroke volume (+27% ± 7%, p<0.005) 
when measured by impedance cardiography in healthy volunteers62.  IGF-I given 
subcutaneously (60 µg/kg) also improves cardiac output and stroke volume as well as 
significantly increasing ejection fraction as measured by echocardiography, with no significant 
change in blood pressure63. Even low dose subcutaneous IGF-I injection (20 µg/kg), achieving 
circulating IGF-I levels in the upper part of the normal range, was able to induce a small, but 
significant, improvement in LV ejection fraction when measured by 99mTc-radionuclide 
angiography15.  In these studies, volunteers exhibited the predictable fall in circulating GH levels 
that occurs after exogenous IGF-I administration indicating, and confirming in vitro findings42, 
that it is IGF-I rather than GH that causes these direct cardiac effects.  Similar acute 
cardiovascular improvements are also seen in chronic heart failure patients treatment treated 
with an IGF-I infusion (60 µg/kg)64.   
 
Studies in healthy volunteers demonstrate direct GH action on the vascular system.  GH 
infusion increases local forearm blood flow in the absence of significant change in plasma IGF-I 
levels, muscle IGF-I mRNA expression and muscle Akt phosphorylation65,66. Vascular effects 
are presumed to be mediated through increased eNOS action and suggest that GH directly 
influences this system.  IGF-I is also known to be potent inducer of eNOS but this occurs 
through phosphorylation of Akt in the P13K pathway, which was absent in this experiment.  The 
complex interactions of GH and IGF-I with eNOS and vascular resistance may be tissue-specific 
as well as mediated through multiple pathways, the details of which are not yet fully understood.  
The topic has been reviewed by Thum and Bauersachs67. 
 
There have been attempts to use GH to improve cardiac function in patients with chronic heart 
failure, a disease associated with relative GH-resistance68.  Doses of GH used have often been 
high, resulting in unacceptable side effects, the patient numbers small and studies 
unrandomised, so that conclusions that can be drawn are limited.  Some studies have still 
managed to show benefits in exercise capacity, LV function, vascular reactivity and quality of 
life with six months treatment, whereas others report no improvement69,70.  Large scale, 
randomised control trials are needed to address this more fully71. 
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1.7 Heart disease in acromegaly 
The diagnosis of acromegaly is often made after many years of symptoms72 making it hard to 
establish the early impact of GH on the cardiovascular system.  Even patients who are 
diagnosed relatively early usually have cardiovascular changes73.  These include increased 
plasma volume74, hyperkinesis75 and cardiac hypertrophy in the absence of hypertension76.  In a 
study of ten subjects with less than five years clinical evidence of acromegaly (mean duration 
3.2 ± 1.2 years), patients exhibited cardiac hypertrophy as determined by increased LV mass 
index (LVMi) compared to age-matched controls (110 ± 20 v. 81 ± 16 g/m2; p<0.005) and 
hyperkinesis, as evidenced by increased stroke volume index (39 ± 6 v. 33 ± 2 ml/m2, p<0.01) 
and increased cardiac index (2.85 ± 0.57 v. 2.30 ± 0.34 L/min/m2, p<0.001)77.  There were no 
differences in diastolic function between the two groups.  Twenty, young patients with less than 
5 years acromegaly studied with echo by Colao et al. confirmed these findings, demonstrating 
increased LVMi and increased left ventricular end systolic and end diastolic volumes compared 
to age-matched controls78. 
 
 
 
 
 
 
As acromegaly progresses diastolic dysfunction, disrupted ventricular filling and loss of cardiac 
response to exercise develop76,79,80.  Aortic root diameter increases when compared to 
controls81.  With time, systolic dysfunction occurs and may progress to congestive heart failure.  
Ventricular tachycardia occurs with increased frequency, and possibly increased severity, 
Figure 1.5 Chest radiographs (A) Patient with undiagnosed acromegaly presenting 
with heart failure and ventricular tachycardia (B) Same patient after treatment for 
acromegaly with normalisation of GH and IGF-I levels (from Yakota et al.95) 
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compared to control populations79,82.  Atrial fibrillation is reported as occurring with increased 
frequency, although there are no studies demonstrating this.  Such arrhythmias are thought to 
arise from interruption of myocardial electrophysiological pathways by interstitial fibrous tissue23.  
 
The cardiac hypertrophy that occurs in acromegaly consists of concentric thickening of both the 
ventricular walls, due to cardiomyocyte size increase, without cavity enlargement83 (Figure 
1.6)84.  However, with time cavity dilatation occurs and fulminant heart failure develops.  
Severity of hypertrophy correlates with disease duration and patient age but not with IGF-I 
levels, and is worsened by the presence of hypertension83,85.  Post-mortem studies show high 
levels of mitral and aortic valve abnormalities and extensive interstitial fibrosis86.  Cardiac 
biopsies demonstrate high levels of myocyte apoptosis (495-fold when compared to samples 
from patients without acromegaly) and collagen deposition consistent with previous myocyte 
necrosis.   Apoptosis magnitude and collagen accumulation both correlated negatively with 
ejection fraction suggesting that apoptosis and necrosis each play a role in the development of 
acromegalic cardiomyopathy87. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal   Concentric Hypertrophy Eccentric Hypertrophy 
Figure 1.6  Schematic demonstrating the LV wall and cavity changes in different forms 
of cardiac hypertrophy.  Concentric hypertrophy, as seen in early acromegaly, involves 
enlargement of the ventricular wall thickness with no change in the cavity size, while 
with time cavity dilatation occurs (adapted from Mihl et al.84) 
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There is good evidence that many of the cardiac findings in acromegaly occur as a 
consequence of direct GH/IGF-I action.  In vitro experiments demonstrate that IGF-I treatment 
induces cardiomyocyte hypertrophy42,88.  In vivo studies with the heart-specific IGF-I transgenic 
mouse demonstrate cardiac hypertrophy and improved systolic function with short-term cardiac 
IGF-I excess but systolic dysfunction and fibrosis with chronic exposure, mirroring acromegalic 
heart disease89. 
 
It is probable that secondary effects of GH excess also contribute towards acromegalic 
cardiomyopathy.  Usually, cardiac hypertrophy is a compensatory mechanism for chronic work 
overload, arising as a result of increased pressure overload (raised afterload) or volume 
overload (raised preload).  Acromegaly is associated with both increased afterload, as a result 
of hypertension, and increased preload, due to sodium and water retention90.  However, the 
pattern of acromegalic cardiac hypertrophy is distinctive from hypertensive cardiomyopathy and 
increased LV mass precedes the development of hypertension in young patients with 
acromegaly.  Furthermore, although salt and water retention occur in acromegaly, GH also 
causes a reduction in ventricular wall tension, counteracting the stretch force on cardiomyocytes 
that increased preload should cause.  The secondary consequences of GH excess are 
inadequate in themselves to explain the hypertrophy seen. For reviews of this topic see Sacca, 
Colao and Clayton23,73,91. 
 
The cardiac changes of acromegaly improve with treatment of the underlying disease.  Studies 
with somatostatin analogues demonstrate that lowering GH and IGF-I levels results in a rapid 
reduction of ventricular mass and wall thickness92,93 and an improvement diastolic function93, 
although it should be considered that these drugs may have a direct effect on the heart.  
Retrospective analysis of a cohort of treated acromegaly patients shows that after five years of 
hormonal inactivity ventricular mass does not vary from control levels94. Figure 1.5 shows chest 
radiographs from a patient presenting with heart failure and ventricular tachycardia, who was 
later diagnosed with acromegaly.  Successful treatment of acromegaly resulted in a marked 
improvement in cardiac function and a drastic reduction in heart size95. 
 
Almost all patients with active acromegaly have evidence of cardiac disease76 and ~60% will die 
from cardiac-related deaths96. Despite the increased prevalence of traditional cardiovascular 
risk factors in these patients, such as hypertension and diabetes, ischaemia alone cannot 
explain the distinct functional and morphological findings seen23.  Indeed, it appears that GH 
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may even exert a degree of protection against atherosclerosis97. This may arise from eNOS 
activation, although data demonstrating this are limited and some studies suggest that 
acromegaly may be associated with depressed endothelial function due to reduced nitric oxide 
bioavailability98.  A greater understanding of both the direct and indirect effects of the GH/IGF-I 
axis on the heart is required to help unravel this disease further.  
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1.8 Heart disease in GHD 
Although less extensively studied, GHD is also associated with cardiac disease.  Hypopituitary 
patients, receiving conventional hormone replacement therapy (thyroxine, glucocorticoids and 
sex steroids) demonstrate excessive cardiac mortality which is thought to be attributable, at 
least in part, to GHD99,100.  This is confirmed by observational databases of hypopituitary 
patients which show an improvement in standardised mortality ratio (SMR) back to national 
baseline with recombinant human GH (hGH) replacement (mean length of treatment, 60 
months)101.  However, data are limited and the duration of treatment needed to see changes, 
along with widespread use of GH-replacement therapy in adults with GHD, precludes 
randomised control trials.   
 
GHD causes cardiac hypokinesis, with loss of response to exercise as demonstrated by 
reduced workload achieved, reduced exercise capacity and by patient reporting23.  GH 
replacement ameliorates these findings and may do so even in the absence of increases in 
cardiac mass, demonstrating that these improvements are not simply mechanical102,103.   
 
Interpretation of the effect of GHD on cardiac mass is often confounded by the inclusion of both 
ao- and co-GHD patients in studies.  However, studies that separate these two groups find 
consistently reduced cardiac muscle mass in co-GHD104,105, yet variable results in ao-GHD33,106-
108.   As IGF-I correlates with LVMi in patients with GHD109, the finding of reduced LVMi in co-
GHD patients may simply indicate more severe GHD in childhood-onset disease.  These 
studies used echocardiography to assess LV mass.  Cardiac MRI has now superseded echo as 
the most accurate method of assessment of LV mass and can identify subtle changes in cardiac 
mass and volume that are harder to identify by echo110. 
 
It is clear that GH replacement causes an improvement in exercise tolerance31 but it remains 
hard to extrapolate to what extent this results from improvements in cardiac function, changes in 
circulating volume or increases in cardiac mass.  An additional reason for GH replacement in 
adults is to reduce cardiovascular risk26.  Observational databases of patients on GH 
replacement demonstrate significant improvements in the total cholesterol, LDL-cholesterol and 
HDL-cholesterol with normalisation of IGF-I111.  Other biochemical markers of increased 
atherogenesis, such as C-reactive protein112, interleukin-6112 and homocysteine113, and 
morphological markers, such as intima media thickness114, have also been shown to improve 
with GH replacement.   
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1.9 Cardiac volume and mass measurement 
LV volume and mass has traditionally been measured by echocardiography (echo).  Echo uses 
ultrasound to define the cardiac borders and collect data on cardiac volume and function.  LV 
volume is determined using geometric modelling to account for the complex shape of the heart.  
This is most commonly done using Simpson’s rule115.  This assumes that the volume of an 
object equates the sum of the volumes of multiple slices through it (Figure 1.7).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As echo looks at the heart from two directions, two planes can be used in the calculation, X and 
Y (Figure 1.8).  The biplane Simpson’s rule assumes each slice through the heart is an ellipse, 
with a major axis determined in one plane and a minor axis determined in the other.  The area 
of each disc is multiplied by its thickness to provide its volume2. 
 
 
 
 
 
Figure 1.7 LV volume measurement with echo, using Simpson’s rule. An end-diastolic 
long-axis view (left image) is selected as a reference image. The left ventricle is 
automatically sliced by the paraplane method into eight equidistant parallel short-axis 
slices spanning the left ventricular cavity from the apex to mitral annulus. The 
endocardial border of the left ventricle is traced manually in each of short-axis slices 1-
8 (right panel).  (http://www.hmc.org.qa/hmc/heartviews/h-v-v3%20n1/3-b.htm) 
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To estimate LV volume measurements gathered are entered into a formula, most commonly, 
the modified Simpson’s biplane formula: 
 
V = (π/4) × (LVL/n) ∑ DiX × DiY 
i = 1 
Where, V = volume, LVL = length of LV, n = number of slices, DiX = diameter in plane X and 
slice i, DiY = diameter in plane Y and slice i115.   
 
LV mass is calculated from the LV volume by multiplying it with myocardial density.  Volume 
calculated in this manner refers to the total LV volume and should not be confused with end 
diastolic and systolic volumes, which refer to the volume of blood in the ventricle at the end of 
diastole and systole respectively.  Therefore, the term “volumetric indices”, which includes EDV, 
ESV and SV, refers to blood volume, representing the volume of cardiac chamber, rather than 
myocardial muscle volume.   
 
The weaknesses of echo are image quality, geometric assumptions regarding LV volumes 
taken from two dimensions and a tendency for echo formulae to overestimate LV mass when 
compared to cardiac magnetic resonance imaging116,117.  Foreshortening may also occur, when 
the ultrasound plane is not positioned through the true apex of the LV.   
Figure 1.8  Simpson's rule.  The heart is viewed from two aspects, allowing two planes  
(X and Y) drawn through each slice.  H indicates slice height, the oblique line indicates 
the plane for measurement of LV length.  The formula assumes each ventricular slice to 
be elliptical (http://www.sandersdata.com/QLVATech.htm) 
 
X 
Y 
H 
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1.10 Cardiac magnetic resonance imaging  (MRI) 
Clinical studies to date have mainly used traditional methods of cardiac assessment: 
echocardiography (echo) and radionuclide imaging.  However, cardiac MRI (CMR) is rapidly 
becoming a routine imaging modality in modern cardiological practice and provides a more 
accurate measurement of muscle mass than echo along with excellent soft tissue resolution110.   
 
MRI utilises the polarity of hydrogen nuclei (each a single proton) within the water, fat and other 
body components.  The application of a magnetic force causes the protons to act as magnets, 
aligning themselves with an applied magnetic field and spinning around the axis of this field.  
The frequency of the spin (precession) is related to the strength of the field applied, so that for a 
1.5 Tesla magnet, the hydrogen nucleus spins at 63 MHz, a frequency that is within the 
radiofrequency range.  When radiowaves are applied the net magnetisation vector of the 
nucleus temporarily rotates before returning to its previous position.  While a component of the 
magnetisation is perpendicular to the applied magnetic field, energy is transmitted as a radio 
signal.  This is picked up a receiver coil placed on the patient’s chest, which transmits the 
information to a computer.  A pulse sequence, or timed series of radiowaves and magnetic field 
gradients, is used. This provides the raw data, known as K-space, for the computer software to 
generate an image. 
 
The amount of signal produced is mainly dependent on two relaxation times: T1 and T2.  T1 is 
the time constant that refers to the return of longitudinal magnetisation to baseline; T2 refers to 
the return of transverse magnetisation.  The T1 and T2 of each proton is tissue dependent, 
Water has a long T1 and a short T2, whereas fat has a short T1 and a long T2.  Therefore, on T1 
imaging, water appears dark, fat appears bright and the myocardium appear grey, or iso-
intense118.  To provide further information, additional radiofrequency pulses are applied in a 
pulse sequence.   
 
The information received from the coil is converted into digital images, which may be displayed 
as static, cine (moving) or multi-planar reconstructions.  In order to coordinate the images to the 
correct phase of the cardiac cycle, the images are linked to an ECG recording (ECG-gating).  
To reduce artefact, patients are asked to hold their breath during the acquisition of certain 
images, usually for no more than 20 seconds110. 
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CMR takes a three dimensional approach to measurement of ventricular volume.  As in echo, 
this is based on Simpson’s rule.  Epicardial and endocardial borders are drawn on multiple 
ventricular short axis slices, taken at the end of diastole (Figure 4.9)119.  Computer software 
then calculates the area of the slice, which is then multiplied by slice depth or the distance 
between slices to produce volume data.  This is then multiplied by myocardial density to achieve 
mass2.  This method does not make any assumptions regarding the uniformity of the ventricular 
shape and so there improved accuracy and lower standard deviations when using CMR rather 
then echo to measure LV volumes and mass.  This accuracy is further increased by better 
contrast between blood and myocardium on CMR.  There is also less inter- and intra-observer 
variability.  In 24 hypertensive subjects LV mass was shown to be 319 ± 21g using echo but 
only 232 ± 11g when mass was calculated using MRI120. 
 
CMR images provide details of cardiac function and valve integrity.  Gadolinium contrast is used 
to assess coronary artery flow and to determine the presence of myocardial scarring and 
fibrosis.  Gadolinium is a water-based tracer which freely distributes in extracellular water but 
cannot cross intact cell membranes and so accumulates in areas of expanded extracellular 
space, such as fibrosis, protein infiltration and fibre disarray121.  Such areas demonstrate 
evidence of gadolinium uptake longer than healthy myocardium, a finding known as late 
gadolinium enhancement.  The combination of late gadolinium enhancement with a regional 
wall movement abnormality indicates the presence of previous ischaemic damage.  
 
Figure 1.9 MRI image of a mid-ventricular short axis slice in end-diastole (A) and end-
systole  (B) with traced left ventricular endocardial (red) and epicardial contours 
(green) and right ventricular endocardial contour (red). (from Teo et al.119) 
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In order to examine for reversible myocardial ischaemia, pharmacological stress is used to 
increase blood flow to the myocardium.  Areas of myocardium supplied by coronary arteries 
with flow-limiting atheroma demonstrate reduced contrast enhancement when compared to 
adequately perfused tissues.  Dobutamine, adenosine and dipyridamole are the most commonly 
used agents used in perfusion CMR122.  Dobutamine infusion results in increased rate of 
myocardial contraction, adenosine and dypridamole cause vasodilation and hence hyperaemia.  
Myocardial images are inspected for inducible wall motion abnormalities and for areas that do 
not demonstrate an increase in contrast agent with the induction of hyperaemia.  Both these 
findings are considered to represent reversible myocardial ischaemia. 
 
Magnetic resonance spectroscopy (MRS) is used to detect signals from naturally occurring 
isotopes 31P, 23Na and 13C as well as from hydrogen nuclei, providing data regarding the 
metabolic state of the heart123.  Most commonly, 31P MRS is used to measure the ratio between 
cardiac phosphocreatine and ATP (PCr:ATP) a marker of future viability and function124.  A 
reduced cardiac PCr:ATP ratio has been shown in dilated cardiomyopathy125 and correlates 
with severity of heart failure arising from ischaemic heart disease126.  At present, MRS remains 
a research technique. 
  
CMR is a safe technique and no long-term ill effects have been noted110.  A small percentage 
(about 2%) of patients find claustrophobia prevents them from tolerating the process.  MRI must 
be avoided in patients with ferromagnetic metal implants such as pacemakers, although most 
valves, prostheses and sutures are safe.  Gadolinium injection is avoided in patients with allergy 
and in anyone with stage 4 chronic kidney disease (estimated glomerular filtration rate 
<30ml/min/1.73m2) or worse because of the association with nephrogenic systemic fibrosis127.  
However, CMR has its limitations: RV mass assessment is limited due to difficulty identifying the 
plane of the tricuspid valve118 and at present assessment of diastolic dysfunction is limited.  
There is also need for careful assessment of fibrosis.  CMR identifies fibrosis by assessing for 
differences in the quantity of gadolinium visualised between healthy and fibrosed tissues.  If 
diffuse fibrosis exists, such as may be seen in advanced acromegalic cardiomyopathy86, then 
there is a possibility that it may be missed and hence under reported. 
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1.11 Cardiac MRI and growth hormone-related heart disease 
To date, there are few CMR data reviewing the impact of GH deficiency and excess on the 
heart.  There is only one study, published in 2011, using CMR to assess patients with adult 
GHD128.  This study found patients had smaller LV EDVi (p=0.032) and LV ESVi (p=0.038) than 
controls but no difference in LVMi or EF.  After one year of GH replacement there were no 
significant changes in volume, mass or function indices, despite a good IGF-I response to GH 
replacement.  In addition, CMR has been used to track cardiac changes in patients with dilated 
cardiomyopathy treated with GH129. 
 
 
 
 
 
 
 
 
One study performed CMR on 14 patients with untreated acromegaly (Figure 1.10)130.  This 
found a greater prevalence of cardiac hypertrophy (LVMi) when measured by CMR (72%) as 
compared to echo (36%) and noted the absence of cardiac fibrosis, previously considered to be 
a key feature of acromegalic cardiomyopathy86.  A second study used T2-weighted imaging to 
assess cardiac oedema before and 8-10 days after treatment for acromegaly.  An improvement 
was demonstrated in this parameter but the study only addressed this very narrow time window 
and made no effort to correlate cardiac findings with true extent of acromegaly or its cure131.  A 
final study compared eight patients with acromegaly to matched controls132.  Patients were 
found to have increased LVMi and ESVi compared to controls at baseline.  After three months 
of treatment for acromegaly, patients had a significant increase in ESVi but no change in any 
other cardiac parameters.  All patients were treated with medical therapies, some in addition to 
surgery, and six out of eight received somatostatin analogues.  The size of this study, short 
duration, failure to normalise IGF-I levels in patients make interpretation of these results difficult.  
Figure 1.10 CMR imaging of: (a) normal subject, (b) patient with acromegaly and 
moderate LV hypertrophy, (c) patient with acromegaly and marked LV hypertrophy, 
(d) patient with acromegaly and mild late gadolinium enhancement (indicated by 
arrow). RV, right ventricle; DE, late gadolinium enhancement; the dark ring delimiting 
LV corresponds to the walls of the LV, which, at the boundary with the RV, is the 
interventricular septum (IVS). (from Bogzzi et al.130) 
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Additionally, there is some evidence that somatostain analogues may also have an impact on 
cardiac function over and above their effect on GH levels133. 
 
Three dimensional methods of LV volume estimation are particularly important in conditions 
where a non-uniform ventricular shape is likely to be present, such as heart failure or 
cardiomyopathy, hence the suitability of CMR for the assessment of acromegalic 
cardiomyopathy134.  Furthermore, the high levels of accuracy in assessing volume and mass 
and low inter-observer variability make it particularly suitable for answering questions regarding 
subtle cardiac mass changes that may occur in ao-GHD. 
 
CMR provides an opportunity to gather a broad range of cardiac data in patients with one test; 
furthermore, it does not involve exposure to ionising radiation.  This makes it an ideal tool for 
endocrinologists and cardiologists in the management of their patients, both at diagnosis and 
during follow up.  Further studies are needed in this field to validate this test in these patient 
groups and to answer several ongoing clinical questions, including the accurate assessment of 
adult heart mass in ao-GHD and the presence of fibrosis in acromegalic heart disease135. 
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1.12 AMPK  
The effect of GH on the heart is likely to occur via many mechanisms: through direct GH action 
and through IGF-I; through local paracrine and hepatic endocrine IGF-I; through direct action at 
GH receptors, causing rapid effects, and more slowly via altered gene transcription and 
expression.  One potential mechanism of GH action may be via activation of adenosine 
monophosphate-activated protein kinase (AMPK).  
 
The enzyme AMPK was first discovered in the 1970s136,137.  It plays a key role in energy 
homeostasis and cell response to stress.  Increased ATP consumption or reduced ATP 
production increases the AMP:ATP ratio causing AMPK activation.  A switch from anabolism to 
catabolism then occurs, ATP production is increased and energy-utilising pathways, such as 
cell division and growth, are reduced (Figure 4.12)138,139.  
 
 
 
 
 
Figure 1.11 AMPK activation through physical and metabolic stress acts to 
conserve ATP and through a range of actions. 
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AMPK consists of a catalytic α subunit and regulatory β and γ subunits.  The α subunit contains 
the kinase domain and an autoinhibitory region, the β subunit contains a glycogen domain and 
provides the scaffold for the complex, while the γ subunit contains AMP-binding sites (Bateman 
or cystathione domains)138,140-142.  There are three AMP-binding sites:  two that bind AMP 
(activating AMPK) or Mg•ATP (inactivating AMPK) and one that contains a tightly-bound, non-
exchangeable AMP that is not involved in AMP:ATP sensing ratio.  It has been suggested that 
AMP binding at the two exchangeable sites allows inter-subunit interactions that cannot occur 
when ATP is bound.  The consequential structure changes increase kinase domain activity and 
reduce AMPK dephosphorylation, sustaining activation.  Binding studies indicate that under 
physiological conditions AMPK mainly exists in its inactive form, complexed to Mg•ATP143.   
 
Each subunit is encoded by two (α) or three (β, γ) separate genes resulting twelve potential 
heterotrimeric combinations141.  AMPK isoforms are expressed in tissue-specific manner, with 
different subunit isoforms having preponderance in different tissues.  The isoforms α1, β1 and 
γ1 are expressed ubiquitously, although to varying amounts.  In cardiac and skeletal muscle α2 
complexes account for 70-80% of total AMPK activity, while α1 complexes account for the 
remaining 20-30%144. 
  
 
 Skeletal muscle Cardiac muscle Adipose tissue Liver β cells 
Insulin ↔ ↓ ↓  ↔ 
Adipoectin ↑ ↑ ↑ ↑ ↑ 
Leptin ↑ ↓ ↑  ↔ 
Glucagon    ↑  
Noradrenaline   ↑   
Ghrelin ↔ ↑ ↓ ↓  
Table 1.4 The tissue-specific effects of hormones on AMPK activity. ↑ increased, ↓ 
reduced,  ↔ no change.  Adapted from Kola et al.145 
 
 
AMPK may be activated through both physiological and pathological mechanisms.  
Hypoglycaemia, hypoxia, heat shock, metabolic poisons or ischaemia all reduce ATP 
production.  ATP consumption is physiologically increased through skeletal muscle 
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contraction140.  The metabolic hormones leptin, adiponectin, insulin, adrenaline and ghrelin all 
interact with the AMPK system and do so in a tissue-specific manner142,145 (Table 1.4)145.  The 
diabetic drugs metformin and the thiazolidinediones activate AMPK, thiazolidinediones through 
increasing the AMP:ATP ratio146, metformin through increasing cytosolic AMP concentration in 
the absence of any changes in AMP:ATP ratio147. 
 
AMPK is activated by two main mechanisms, by AMP binding to the γ subunit, resulting in 
allosteric changes, and by phosphorylation of the α subunit at threonine (Thr) 172 by upstream 
kinases.  The combined impact of AMP-binding and Thr172 phosphorylation is that AMPK 
activity increases 1000-fold148.  It appears that AMP binding renders the enzyme a better target 
for kinase activity and reduces dephosphorylation149, although the mechanism by which this 
occurs is not understood150.  Kinases that have been shown to phosphorylate Thr172 include 
LKB1 (a tumour suppresser gene), CaMKK2 (calmodulin-dependent protein kinase kinase 2) 
and TAK1 (mammalian transforming growth factor β-activated kinase)151, and possibly MLCK 
(myosin light chain kinase)152.  LKB1 has been shown to be constitutively active 153, as well as 
present in the majority of tissues.  It may be that, in vivo, the regulation of AMPK activity is 
achieved by changes in dephosphorylation, rather than by kinase action on AMPK itself. 
 
With activation of AMPK, glucose uptake is stimulated via glucose transporter (GLUT)-4 
translocation to the cell surface154 and glycolysis occurs via 6-phosphofructo-2-kinase (PFK2) 
activation155. Acetyl-CoA carboxylase (ACC) is inactivated through phosphorylation (pACC), 
resulting in a reduction in malonyl-CoA and a consequential increase in carnitine 
parmitoyltransferase I (CPT-1), which in turn increases fatty acid oxidation156.  Activation of 
these pathways increase ATP availability for the cell.  Other pathways that utilise ATP are 
suppressed.  Protein synthesis is inhibited through tuberous sclerosis protein (TSC) 1/2 
complex mediated inhibition of the mammalian target of rapamycin (mTOR)157 and eukaryotic 
elongation factor 2 kinase (eEF2K) mediated inhibition of eukaryotic elongation factor 2 
(eEF2)158.  Cell growth is also reduced through p53 accumulation159.  For a summary of some of 
the major effects of AMPK activation, see Figure 1.12. 
 
With longer activation there is increased expression of GLUT-4 and metabolic enzymes 
involved in the TCA cycle and the respiratory chain140.  Micro-array analysis of muscle biopsy 
from mice with a muscle-specific overexpression of dominant negative AMPK-α2 showed up-
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regulation of 234 genes and down-regulation of 130 genes compared to controls, demonstrating 
the immense breadth of interactions this system has160.  
 
 
 
 
 
 
 
 
In the laboratory, AMPK activation can be measured in a range of ways.  AMPK activity levels 
can be measured using a radioactive assay to measure the incorporation of 32P into SAMS, a 
synthetic target peptide for AMPK.  Western blotting can be used to blot for AMPK 
Figure 1.12 Schematic demonstrating some of the major known effects of AMPK 
activation. Red = kinase, green = enzyme, blue = transcription factor, dashed lines 
indicate tentative pathways. (http://www.cellsignal.com/reference/pathway/AMPK.html) 
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phosphorylated at Threonine 172.  To ensure that this value does not simply reflect a general 
upregulation of AMPK, it is corrected to total AMPK, which requires a second Western blot.  
Alternatively, a downstream marker of AMPK can measured on Western blot.  Most commonly 
this is ACC, which again is presented as phosphorylated ACC as a percentage of total ACC.  
ACC is a large protein of 280 kDa, which can make it difficult to run a simultaneous 
housekeeping protein on the same gel. 
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1.13 AMPK and cardiac ischaemia 
The α2 AMPK subunit isoform appears to mediate metabolic function in the heart.  Alpha-1 
knock out (KO) models fail to show any significant metabolic dysfunction151.  However, blocking 
AMPK α2 using tissue-targeted dominant negative increases ATP depletion reduces glucose 
uptake and glycolysis during ischaemia and reduces fatty acid uptake and recovery of LV 
function in reperfusion161,162.  The protective effects of α2 activation require the presence of 
functional LKB1, whereas α1 may be activated, albeit at a mildly reduced level, in the absence 
of LKB1163. 
 
The AMPK system is the sensor of cardiac energy metabolism.  The heart preferentially 
produces ATP though β-oxidation of fatty acids, with approximately 60-90% of its energy 
arriving from this source139.  Under ischaemic conditions the AMP:ATP ratio rises resulting in 
AMPK activation.  This drives glucose uptake via GLUT-1 and GLUT-4 and increases glycolysis 
via PFK-2 phosphorylation and increased PFK-1 activtiy, to increase ATP availability to the 
myocardium and protecting against the consequences of ischaemia (see Figure 1.13, Figure 
1.14 and Figure 1.14151). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13 Cardiac metabolism during normoxia. ATP production from fatty acids 
(~70%) and glucose (~30%) From Viollet et al.151 
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Figure 1.14 Cardiac metabolism during reperfusion. AMPK remains activated, 
phosphorylating and inactivating ACC, inducing fatty acid entry into the mitochondria to 
recommence fatty acid oxidation.  The concomitant stimulation of glycolysis and fatty 
acid oxidation may induce uncoupling of glycolysis and glucose oxidation with the 
detrimental production of protons. (Viollet et al.151) 
Figure 1.13 Cardiac metabolism during ischaemia: AMP:ATP ratio rises, activating 
AMPK and glycolysis becomes the sole ATP-provider.  AMPK promotes GLUT-4 
translocation and PFK-1 stimulation via PFK-2. (Viollet et al.151) 
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Activation of AMPK with metformin in mouse model of ischaemia (left coronary artery ligation) 
demonstrates acute improvement in infarct size and troponin rise in both diabetic and non-
diabetic mice164.  In heart failure produced by a similar technique, metformin is able to improve 
animal survival by 47% and preserve LV dimensions and LV ejection fraction165.  In both 
experiments this effect was lost in animals functionally lacking AMPK (dominant negative AMPK 
α2) or eNOS (eNOS-/-), indicating that these effects are mediated, at least in part, through 
eNOS/AMPK interaction141.   
 
Some of the cardioprotective effects of AMPK activation may arise from a reduction in 
apoptosis139,162,166.  However, studies addressing the effect of AMPK activation on 
cardiomyocyte apoptosis have shown varying results.  Studies in neonatal cardiomyocytes have 
indicated that AMPK activation may be both pro-apoptotic, via Bax translocation to the 
mitochondria, a step that occurs early in ischaemia167 and anti-apoptotic, in palmitate-mediated 
apoptosis168.  Palmitate is a major constituent of circulating fatty acids.  Both AMPK α2 KD 
transgenic mice and adiponectin deficient mice have increased apoptosis following ischaemia 
and reperfusion162,169.  In these adiponectin-deficient mice, adiponectin supplementation was 
shown to inhibit apoptosis secondary to AMPK activation.  AMPK activation has been to be pro-
apoptotic in many other cell types.  In the liver, AMPK activation promotes apoptosis via c-Jun 
N-terminal kinase (JNK) and caspase-3 activation170. The explanation for these apparently 
contradictory effects remains unclear139, although the duration of AMPK activation may play a 
role in mediating different effects170. 
 
Although AMPK activation clearly provides metabolic cardioprotection during ischaemia by 
increasing ATP availability, AMPK activation may also have detrimental effects on the heart, 
especially during myocardial reperfusion.  At reperfusion, β-oxidation of fatty acids increases 
dramatically, due to increased levels of circulating fatty acids and to ACC phosphorylation by 
AMPK, with increased production of fatty acids derived-acetyl CoA.  The presence of high levels 
of fatty acid-derived acetyl CoA reduces the production of glucose-derived acetyl CoA via the 
inhibition of the pyruvate dehydrogenase complex.  This prevents pyruvate entering Randle’s 
cycle and oxidative metabolism is reduced171,172.  Furthermore, the uncoupling of glycolysis and 
glucose oxidation results in a build up of lactate and protons, which themselves require ATP for 
clearance.  This reduces cardiac efficiency and may also decrease cardiac function173 (Figure 
4.15).  For a review see Dyck and Lopaschuk139. 
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1.14 AMPK and cardiac hypertrophy 
Cardiac hypertrophy occurs for a range of reasons and through various mechanisms.  It may 
arise as a result of physiological stimulus, such as exercise, or as a consequence of 
pathological mechanisms, such as pressure overload.  Studies in several animal models of 
cardiac hypertrophy have demonstrated interactions with the AMPK system. 
 
Left ventricular hypertrophy, achieved as a result of pressure overload (aortic ligation), is 
associated with a rise in AMPK activity that is thought to be a compensatory response to 
increased myocardial mechanical stress174,175.  Mice unable to mount an AMPK response to 
pressure overload develop worse heart failure, including heart/body weight ratio, LV ejection 
fraction and mortality, than controls175,176.  AMPK activation with metformin can attenuate 
pressure overload-induced cardiac hypertrophy177,178.  Adiponectin appears to be an upstream 
mediator of this effect175.  Hence, AMPK plays a key role in response to pressure overload and 
may also play a role in protection against the development of cardiac hypertrophy. 
 
The finding that AMPK activation can reduce the development of cardiac hypertrophy might be 
predicted given that the development hypertrophy requires protein synthesis.  Protein synthesis 
utilises energy and AMPK activation drives cell function away from ATP-consuming 
processes179.  AMPK activation with AICAR has been shown to increase phosphorylation of 
eEF2 and reduce phosphorylation of p70S6 kinase and mTOR178, all key regulators of protein 
synthesis.  However, it is interesting to note that short-term AMPK activation (1 week) induces 
cardiac hypertrophy in angiotensin II-infused rats180.  This suggests that either the effects of 
AMPK activation on the myocardium are time-dependent or that both hypertrophy induction and 
inhibition may be driven by AMPK activation, different effects having preponderance in different 
environments.   
 
LKB1 appears to play an important role in the effects of AMPK activation on hypertrophy.  
Increased expression of LKB1 in neonatal rat cardiac myocytes inhibits the increase in protein 
synthesis observed in cells treated with phenylephrine181 and inhibition of LKB1, in LKB1 KO 
mice or cells treated with siRNA to ablate LKB1 function, results in increased cardiac/body 
weight ratio and cardiomyocyte hypertrophy182, with the predicted reduction in phosphorylation 
of AMPK and eEF2 and increased phosphorylation of mTOR and p70SK.  
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An interesting study from Kim et al. looked at exercise-induced cardiac hypertrophy in mice with 
a cardiac-specific KO of the IGF-IR88.  Surprisingly they found that not only was the IGF-I 
receptor necessary for the development of exercise-induced cardiac hypertrophy but that 
exercised IGF-IR KO animals demonstrated a marked rise in cardiac AMPK activity.  Exercised 
KO animals also had reduced cardiac glycogen stores and reduced peroxisome proliferator-
activated receptor-γ coactivator-1α (PGC-1α) levels, potentially limiting exercise-induced 
increases in myocardial fatty acid oxidative capacity and mitochondrial function.  The authors 
suggest these findings indicate increased energetic stress in the myocardium, probably at a 
mitochondrial level, accounting for AMPK activation.  The same paper also reported that AMPK 
activation with AICAR was able to prevent IGF-I-induced hypertrophy in neonatal rat 
cardiomyocytes.   
 
Short-term exercise has already been shown to increase cardiac AMPK activity in normal 
hearts183, yet no difference was seen in this study between the WT exercised and sedentary 
groups, suggesting that exercise may induce transient changes in AMPK, which equilibrate with 
chronic training.  The authors report that they repeated their experiments using transaortic 
constriction to induce pressure-overload hypertrophy and in this situation IGF-IR KO animals did 
not show any reduction in LV hypertrophy, suggesting that the IGF-I-induced hypertrophy 
pathway is specific to exercise-induced hypertrophy, although these data are not given in the 
paper. 
 
In summary, AMPK activation can prevent IGF-I induced cardiomyocyte hypertrophy in vitro and 
can reduce the development of pressure overload-induced cardiac hypertrophy in vivo.  The 
inability to mount an AMPK response to pressure overload results in worse cardiac outcomes.  
The inability to mount an IGF-I response to exercise results in a compensatory rise in AMPK 
activity. 
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1.15 AMPK in the clinical setting 
Several drugs in clinical use have been shown to have effects on the AMPK system.  Most 
notably, metformin is recognised as an activator of AMPK184.  In addition the thiazolidinediones 
(TZDs)146 and statins185 have been shown to activate AMPK.    Metformin and TZDs achieve 
normoglycaemia via different mechanisms; however, both have been shown to inhibit 
mitochondrial complex I activity and reduce cell respiration186-188.  TZDs increase AMPK activity 
through changes in the cell AMP:ATP ratio146; metformin increases AMPK activity by altering 
the cytosolic AMP concentration147.  Metformin has been shown to improve LV EDV and 
fractional shortening in dogs with heart failure produced by overdrive pacing, although it should 
be noted that the dogs received significantly higher daily doses of metformin than is currently 
used in patients166.  Interestingly, these improvements were also seen when the dogs were 
treated with AICAR, indicating that the effect seen is due to metformin’s ability to activate 
AMPK. 
 
Metformin is known to activate AMPK in the clinical setting as well as in the laboratory.  Ten 
weeks metformin treatment has been shown to increase skeletal muscle AMPKα2 activity and 
AMPKα2 phosphorylation at Thr172 in patients with type 2 diabetes mellitus (T2DM).  These 
findings corresponded with increased glucose dispersal and muscle glycogen stores189.  A 
similar study demonstrated increased AMPK activity in adipose tissue from patients taking 
metformin when compared to sulphonylureas190.  TZDs and statins have only been shown to 
increase AMPK activity in animal and cell models. 
 
There is evidence that metformin is able to exert a beneficial effect on cardiovascular outcomes 
in the clinical setting, although the prevalence of both T2DM and metformin use make head-to-
head, long-term studies difficult.  In the UK PDS trial for patients with newly diagnosed T2DM, 
patients receiving metformin showed a greater reduction in any diabetes-related end point 
(p=0.0034), all-cause mortality (p=0.021) and stroke (p=0.032) than patients treated with 
chlorpropramide, sulphonylureas or insulin, despite similar glycosylated haemoglobin levels in 
each group191.  Metformin, used as a single agent in T2DM, is associated with lower rates of 
hospitalisation for myocardial infarction than sulphonylureas or combination therapy192.  
Administration of metformin to patients with T2DM reduces several markers of cardiovascular 
disease, including remnant lipoprotein cholesterol and soluble vascular cell adhesion molecule- 
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1193.  At present, evidence in humans linking the AMPK-activating effects of metformin to its 
cardiovascular effects remains limited.  However, Sasaki et al.’s study in dogs, demonstrating 
that the ability of metformin to improve markers of heart failure found similar cardiovascular 
improvements when dogs were treated with an alternative AMPK activator, AICAR, suggesting 
that AMPK activation is the mechanism by which metformin exerts its beneficial effect on the 
heart 166.  It is clear from ischaemia-reperfusion mouse models that AMPK activation plays a 
central role in cardiovascular protection.   
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1.16 AMPK gamma-2 subunit mutations 
Despite a wealth of evidence that AMPK activation is cardioprotective, chronic constant AMPK 
activation may have deleterious consequences.  Missense mutations in the gene encoding the 
AMPK-γ2 subunit (PRKAG2, located in human on chromosome 7q36194) cause ventricular 
hypertrophy, ventricular pre-excitation and progressive cardiac conduction system disease, 
resulting in Wolff-Parkinson-White syndrome195.  At least ten mutations have been identified in 
the human PRKAG2 gene196, which demonstrate varied clinical expressivity and typically 
present in late adolescence197.  The role of AMPK activation in the development of this disease 
is still poorly understood.  It is thought that constant, increased, unstimulated basal AMPK 
activity occurs, with excessive intracellular glycogen deposition (Figure 1.15)196, yet a loss of 
ability to sense and respond to metabolic changes, with failure of AMPK activation and rising 
AMP concentrations196. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.15 Model explaining glycogen accumulation in PRKAG2 cardiomyopathy. 
Mutations cause inappropriate AMPK activation under resting conditions. AMPK activation 
leads to mobilisation of fatty acids and increased entry of acyl-CoA to mitochondria. 
Concomitantly, there is an increase in glucose uptake. Increased substrate influx is not met 
by increased metabolic demand, allowing storage. Given the existing capacity of the heart 
to store glycogen, and given the preference to use fatty acids for mitochondrial oxidation, 
glycogen is stored. Assuming glycogen can inhibit AMPK a new steady state is reached 
under conditions of glycogen overload. FA indicates fatty acids (from Arad et al.197) 
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There is some evidence that basal AMPK activity may fall later in the disease, perhaps 
influenced by the degree of glycogen accumulation, potentially contributing to hypertrophy 
through increased protein synthesis198,199. 
 
Transgenic mice expressing a human PRKAG2 mutation under the control of a tetracycline-
repressible promoter demonstrate that cardiac hypertrophy can be reversed and cardiac 
dysfunction ameliorated by normalising glycogen content with mutant suppression, but 
ventricular pre-excitation can only be prevented with very early therapy prior to the development 
of accessory pathways200.  Much work remains to understand fully how AMPK is able to 
produce the pathology seen with these mutations. 
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1.17 GH and AMPK 
Thus both AMPK and GH have beneficial effects on the heart with short-term exposure but may 
cause cardiac dysfunction with chronic excess exposure.  It is clear that both have similar 
cardiac effects in certain states: both AMPK activity174 and IGF-I expression46 are increased in 
pressure overload cardiac hypertrophy; both are involved in cardioprotection in 
ischaemia151,169,201; both increase eNOS activity67,141.  
 
Insulin has been shown to inhibit cardiac AMPK activity202 and AMPK Thr172 
phosphorylation203.  In rat cardiac cells, this has been shown to occur through the 
phosphorylation of AMPK serine 485 (α1) or 491 (α2) through an AKT-dependent pathway204.  
More recently, in vascular smooth muscle cells, IGF-I has also been shown to phosphorylate 
AMPK serine 485, with a consequential reduction in AMPK activity and Thr172 phosphorylation, 
via AKT phosphorylation205.   
 
One study did not find any increase in AMPK Thr172 phosphorylation in human aortic 
endothelial cells (HAEC) treated with GH for 3 or 6 hours66.  However, these cells had been 
serum starved for 16 hours prior to treatment with GH, a technique that has been shown to 
increase AMPK phosphorylation, even at 3 hours206.  It may be that the AMPK contained within 
these cells was already maximally Thr172 phosphorylated or that it was phosphorylated to a 
level at which a relatively low dose of GH (30ng/ml) was unable to further increase 
phosphorylation.  No other studies have been published looking at the effect of GH on AMPK. 
 
The interactions between AMPK activity and the GH/IGF-I system are likely to be complicated 
and to alter with length of exposure.  Furthermore, the multi-system impact of the GH/IGF-I axis 
in vivo means that multiple effects may occur synchronously.  This area clearly needs further 
research to help delineate the processes that are taking place and provide a more detailed 
understanding of the chronic effects of GH on the heart and mechanisms by which these occur.  
The interaction of these two systems will be investigated in the following experiments along with 
work to address the role of CMR in states of GH excess and deficiency. 
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1.18 Hypotheses  
 
• CMR will demonstrate increased LV mass and cardiac output in patients with 
acromegaly, which will improve with a reduction in GH levels after disease treatment 
• CMR will demonstrate reduced LV mass in patients with ao-GHD which will improve 
with normalisation of GH levels after disease treatment 
 
• Acute GH excess will increase cardiac AMPK activity in animal and cell models 
• Chronic GH overexposure will result in chronic cardiac AMPK activation in animal 
models of acromegaly 
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The characterisation of growth hormone-related cardiac 
disease with magnetic resonance imaging 
 
 
Objectives 
 
• To use CMR to assess LV and RV volume and function and LV mass in patients with 
adult-onset GHD and acromegaly  
• To use CMR to determine the impact of normalising IGF-I on heart morphology, mass 
and function  
• To assess for fibrosis, as measured by late gadolinium enhancement, in the hearts of 
patients with acromegaly 
• To examine for the presence of ischaemic heart disease using perfusion CMR in 
patients with acromegaly and GHD 
• To assess ascending aorta area in patients with acromegaly and GHD 
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2 Materials & Methods 
 
2.1 Study outline 
Adult patients with GHD and acromegaly about to commence a therapy aimed at normalising 
GH levels (GH replacement, surgery, somatostation analogues or GH antagonists) were 
assessed using CMR.  Cardiac function and morphology was assessed immediately before 
initiation of the chosen therapy and at six and twelve months after treatment.  Echo was 
performed at each time-point and patients’ clinical and biochemical response to their treatment 
was recorded (Figure 2.1).  Power calculations performed on echo data suggested ten subjects 
were necessary for each arm207 (see Section 2.14.1).   
 
 
 
 
 
 
 
 
 
 
 
 
2.2 Ethics 
Multi-centre ethics approval (06/Q0401/53) was applied for and granted.  The following centres 
directly recruited patients or referred patients to St Bartholomew’s Hospital for consideration of 
inclusion in the study: 
• St Bartholomew’s Hospital, London (Prof A Grossman, Prof W Drake, Prof S Chew, Dr 
S Akker) 
• King’s Hospital, London (Dr S Aylwin) 
• The Royal Free Hospital, London (Dr B Khoo) 
• Addenbrooke’s Hospital, Cambridge (Dr M Gurnell) 
• The Lister Hospital, Stevenage (Dr F Kaplan) 
 
Figure 2.1 Study flow chart. Patients attended three visits in total, having a full set of 
investigations at each.  QoL = quality of life assessment 
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2.3 Patient selection  
In patients with pituitary disease, GHD was confirmed using provocation testing with insulin-
induced hypoglycaemia (ITT) or glucagon stimulation.  Both tests have been validated for the 
assessment of GH reserve208,209.  Although the ITT is considered the gold standard in this 
assessment210, the induction of hypoglycaemia with insulin is contraindicated in patients with a 
history of seizure, ischaemic heart disease and with unreplaced cortisol deficiency.  Therefore, 
clinicians selected the choice of provocation test used based on patient suitability and local 
policies.   
 
Age-matched IGF-I levels are not adequate in themselves for the diagnosis of GHD208, although 
a markedly low IGF-I level is suggestive when taken in the clinical context of multiple pituitary 
hormone deficiencies, particularly in younger patients211.  However, serum IGF-I level is used to 
monitor GH replacement in patients receiving recombinant (r)GH therapy and therefore levels 
were recorded at baseline210. 
 
NHS-funded GH replacement has been reviewed by the National Institute for Clinical 
Excellence (NICE)27.  Only those patients exhibiting severe GH deficiency, as determined by a 
peak GH response to stimulation testing of <3.0 µg/L, in addition to impaired quality of life (QoL) 
because of GHD qualify for GH replacement.  QoL is determined as a score of 11 or less on the 
disease-specific Quality of Life Assessment of Growth Hormone Deficiency in Adults (AGHDA) 
questionnaire28.  Referring clinicians determined appropriateness for GH replacement, ensuring 
patients participating in this study fulfilled NICE criteria.   
 
Acromegaly was confirmed clinically and biochemically.  Patients’ signs and symptoms of GH 
excess were documented along with their duration.  The oral glucose tolerance test was used to 
demonstrate biochemical GH excess.  This test looks for failure of GH suppression to <1.0 µg/L 
following an oral 75 g glucose load (GTT).  Serum IGF-I levels were also measured as an 
indirect marker of GH excess.  The referring clinician determined the patient’s treatment, 
treating medically with somatostatin analogues or referring for transsphenoidal surgery as 
appropriate, using serum IGF-I as a marker of treatment success.  Some patients were treated 
initially with somatostatin analogues and then went on to have transsphenoidal surgery later.  
Individual patients’ treatments are given in the Results section (page 65). 
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For both groups of patients, other pituitary hormones were replaced with stable doses of 
medication for at least 3 months prior to entry to the study.  This was an observational study 
only; no interventions were made.  Inclusion and exclusion criteria are shown in Table 2.1. 
 
 
Inclusion criteria  Exclusion criteria 
Male or female  Pregnancy 
Age 18-80 years   Significant renal impairment (eGFR <30) 
Adult GH deficiency (GH <3 µg/L on ITT) or 
acromegaly (GH >1 µg/L on GTT). 
 Any preclusion to undergoing MRI (e.g. 
implanted metalwork, severe claustrophobia) 
Fully replaced for any other pituitary hormone 
deficiencies (stable dosing for >4 weeks) 
 Documented moderate or severe reversible 
airway disease 
Disease symptoms for at least 1 year  Second or third degree heartblock 
Fulfils criteria for GH replacement therapy*  Known heart failure, severe valve disease or 
ischaemic heart disease 
  Systolic blood pressure <90 or >180 mmHg; 
diastolic blood pressure >110 mmHg 
  Childhood onset GHD 
  GH therapy in the two years prior to study* 
Table 2.1 Clinical study inclusion and exclusion criteria.  ITT = insulin tolerance test; GTT 
= glucose tolerance test; *refers to GHD only 
 
2.4 Patient recruitment 
Recruitment took place between December 2008 and February 2010.  Potentially suitable 
patients where identified by the Local Investigator at each site.  The Local Investigator then had 
the choice of recruiting the patient into the study locally or referring to Professor Grossman at St 
Bartholomew’s Hospital to be considered for involvement in the study.  The majority of 
investigators chose the latter method of recruitment.  Once referred, patients were contacted by 
telephone and screened for suitability for inclusion in the study by the researcher.  Once 
eligibility for inclusion had been ascertained, and with their permission, patients were sent 
Patient Information Sheet v3 (Page 197).  Once patients had been given time to read the 
Patient Information Sheet they were contacted again by telephone to determine if they wished 
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to take part in the study.  Patients received the Patient Information Sheet at least 24 hours 
before participation in the study.   
 
2.5 Study visits 
Patients who wished to take part in the study were invited to attend for the First Visit in the 
Department of Endocrinology at St Bartholomew’s Hospital.  At this visit formal written consent 
was taken by the researcher, using the Patient Consent Form (Page 202).  An interview was 
then conducted by the researcher, which included disease and treatment history, past medical 
history, medication details and current symptoms.  Further details were supplied by the referring 
clinician, including previous imaging reports and biochemical results confirming diagnosis.  
Blood pressure (BP), height and weight were recorded.  Patients gave a fasting blood test.  In 
some cases, long travel times precluded fasting prior to the blood test.  When this occurred it 
was noted.  Patients also completed at disease-specific quality of life questionnaire: ACROQoL 
for patients with acromegaly212 (Page 203)  and QoL-AGDHA for patients with GHD28  (Page 
208). 
 
Patients travelled to the London Chest Hospital, Bethnal Green, where they underwent 
echocardiography.  They then atttended the Cardiac MRI department where a screening 
questionnaire for CMR safety was performed (Page 212).  Two intravenous cannulae were 
sited, one for contrast agent and one for adenosine.  Patients then underwent CMR as per the 
protocol below.  Patients were asked to avoid caffeine from midnight to prevent interference 
with perfusion CMR results.  An electrocardiogram (ECG) was performed on all patients who 
received adenosine, to demonstrate the absence of pro-arrhythmic heart rhythms.  Patients with 
a history of significant bronchospasm were not given adenosine.  Some patients declined 
perfusion CMR because of concern regarding side-effects from adenosine.   
 
Six months and twelve months following the first visit, patients were invited to attend for Visits 2 
and 3.  Each visit involved a conversation with the researcher to update history, treatment and 
medication records, BP and weight measurements, QoL assessment and fasting blood tests, 
followed by echocardiography and CMR. 
 
After each visit, patients submitted their receipts for travel costs to the researcher, who 
arranged for them to be reimbursed.  
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Echocardiograms were recorded and stored on CD for analysis at the end of the study.  Each 
CMR was reviewed by a cardiologist as per the protocol for reporting routine clinical CMR 
scans.  A report was issued and a copy of this was forwarded to the patient’s GP and referring 
clinician.  The report was also summarised and sent to the patient with written explanations 
regarding any mild abnormalities, along with the researcher’s telephone number in case the 
individual had questions.  In the case of patients with significantly abnormal scans, arrangement 
was made for follow up with a cardiology consultant for further assessment.  CMR images were 
stored on the computer server to allow for future, detailed analysis. 
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2.6 Cardiac MRI controls 
Age- and sex-match controls were recruited to match each of the study patients.  Posters 
advertising for healthy controls (Page 213) were placed in the medical ward visiting areas and in 
outpatients.  Advertisements were also e-mailed NHS Trust (Barts & the London) and Queen 
Mary University of London college staff.  Applicants were asked to contact the researcher by 
telephone or e-mail.  Each applicant was given brief information about the study and asked to 
complete a short screening questionnaire to assess suitability for participation.  Completed 
questionnaires were used to match volunteers to patients.  Patients were matched for sex and 
age, where at all possible matching within five years of age.  Note was also taken of weight, 
height and any other medical problems and these factors were included in matching.  
Volunteers who were suitable matches were then provided with the Healthy Volunteer 
Information Sheet (Page 214).  If, after reading this, the volunteer was still happy to go ahead 
an appointment time to attend the London Chest Hospital was offered.  At least 24 hours took 
place between reading the Information Sheet and the appointment.   
 
On arrival at the Cardiac MRI unit at the London Chest Hospital, informed consent was taken by 
the researcher.  The volunteer completed an MRI safety questionnaire and then underwent a 
non-contrast enhanced CMR, using the same scanner protocols as the study patients.  Height, 
weight and blood pressure were recorded.  The patient gave a blood sample for IGF-I and 
serum for storage.  CMR images were analysed as per study scans.  Only one CMR was 
performed per volunteer, unlike the study patients who underwent three scans throughout the 
duration of the study.  No intravenous contrast or adenosine was used in the volunteers. 
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2.7 Cardiac MRI 
CMR was performed at the London Chest Hospital by experienced cardiologists using a Phillips 
Achieva CV 1.5 Tesla MRI scanner (Philips Medical Systems).  Standard ECG-gated, weight-
adjusted protocols were used, allowing image gathering to be timed to particular points of the 
cardiac cycle.  To reduce breathing-artefact, patients were asked to hold their breath for up to 
20 seconds at certain points.  All patients received intravenous gadolinium as a contrast agent 
(Dotarem™ total dose 0.2 mmol/kg).  Those patients who underwent perfusion CMR received 
intravenous adenosine 140 µg/kg/min given for 3 minutes, with continuous blood pressure and 
ECG monitoring throughout that time118. 
 
2.8 Image analysis 
CMR images were analysed by a single observer, blinded to the underlying diagnosis.  Images 
were analysed with “cmr42” computer software (Circular Cardiovascular Imaging Incorporated, 
Canada). Volume and mass parameters were measured using images derived from a balanced 
steady state free procession (b-SSFP) sequence.  Perfusion analysis was performed on T1-
weighted images.  Cardiac output and heart rate were both noted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epicardial contour 
Endocardial contour 
Blood pool within left 
ventricle 
Right ventricle 
Myocardium 
Figure 2.2 A short-axis slice in end-diastole with left ventricular 
endocardial and epicardial contours (Courtesy of A. Dattani) 
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To determine LV and RV volumes and LV mass, the scans were imported into cmr42.  The 
series of short-axis cine images was opened.  This is composed of 10-12 short-axis slices 
through the heart.  Each slice represents 20-30 frames through one cardiac cycle118.  The first 
frame was chosen as the end-diastolic frame.  The frame with the smallest blood pool was 
selected as the end systolic frame.  The point at which 50% of the blood pool was surrounded 
by the myocardium was presumed to be the basal slice.  Manual endocardial contours were 
drawn for the end-diastolic and end-systolic slices (Figure 2.2).  These were drawn outside the 
papillary muscles to provide consistent results.  The epicardial contours were drawn for the end-
diastolic slice only as the epicardium deforms in systole, rendering end-systolic epicardial 
contours less accurate in mass calculations213.  From these data, the cmr42 software calculated 
the following cardiac parameters: left ventricle – EDV, ESV, EF, SV, CO, LVM; right ventricle – 
EDV, ESV, EF, SV. 
 
CMR image analysis and measurements were performed by Abhishek Dattani, medical student, 
and Dr Filip Zemrak, cardiology research fellow, under the supervison of Dr Ceri Davies and Dr 
Steffen Petersen. 
 
 
Endocardial contour 
Myocardium 
Blood pool within left 
ventricle 
Right ventricle 
Figure 2.3 A short-axis slice in end-systole with left ventricular endocardial 
contour (Courtesy of A. Dattani) 
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2.9 Perfusion analysis and late gadolinium enhancement 
All images were examined for evidence of late gadolinium enhancement (LGE) to look for 
evidence of fibrosis and myocardial scarring.  Scans from patients who received adenosine 
were examined for areas of reduced myocardial perfusion to look for evidence of reversible 
ischaemia.    Analysis was performed on T1-weighted images acquired ten minutes after 
patients had received gadolinium-based contrast.  Using cmr42 software, endocardial and 
epicardial border contours were drawn on three short-axis slices through the left ventricle.  The 
insertion point of the right ventricle was used as a marker to divide myocardium into 
segments214.  These contours were used in each phase of contrast enhancement to calculate 
data for signal intensity in the different myocardial segments and for the ventricular cavity 
(Figure 2.4).  Areas that demonstrated gadolinium enhancement more than two SD above the 
background myocardial level were recorded as showing LGE.  Areas of reduced gadolinium 
enhancement during induction of hyperaemia with adenosine were recorded as showing 
reduced perfusion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Endocardial contour 
Epicardial contour 
Blood pool contour Right ventricle 
indicator 
Segment lines 
Figure 2.4 Endocardial, epicardial and blood pool contours drawn on a short-axis slice for 
perfusion analysis. The blue dot is the right ventricle indicator, which tells the software where 
the right ventricle inserts onto the left ventricle. This allows the software to produce segments 
separated by the segment lines as shown (Courtesy of A. Dattani) 
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Scans that demonstrated areas of LGE or reduced perfusion were reviewed by a senior 
cardiologist. Individuals who demonstrated evidence of possible reversible cardiac ischaemia 
were referred for cardiological assessment and consideration of additional imaging.  
 
CMR images were analysed for LGE and perfusion by Dr Ceri Davies. 
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2.10 Aortic root analysis 
Aortic dimensions were gathered from MRI scout images.  Internal to internal distances in 
lateral and anterior-posterior planes were measured at the level of the pulmonary bifurcation 
(Figure 2.5).  Area was calculated using the formula πr1r2 to allow for the elliptical nature of the 
aorta.  Results were indexed to body surface area.  Measurements were made by Dr Ceri 
Davies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5 CMR at the level of the pulmonary bifurcation.  Dashed line indicates measurement 
planes, blue = anterior-posterior plane, purple = lateral plane.  A = aorta, PA = pulmonary 
artery, RPA = right pulmonary artery, LPA = left pulmonary artery 
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2.11 Quality of life assessment 
Two well-validated disease-specific quality of life assessments (QoL) were used: the QoL-
AGHDA28 for patients with GHD or the AcroQOL212 for patients with acromegaly.  The QoL-
AGHDA contains 25 yes/no questions regarding the symptoms of GHD.  The presence of the 
symptom is awarded one mark; the absence of the symptom receives zero.  The total score is 
the sum of all results to give a score out of 25, where 25 is the worst possible QoL.  ACROQoL 
consists of 22 questions, each with five answer options.  Answers range from “always” or 
“completely” which score one to “never” or “completely disagree” which score five.  Results are 
summed and then converted to a score out of 100 using the following formula: 
 
ACROQoL =    [total score – min]     * 100 
          (max – min) 
Where min = the minimum score possible (22) and max = the maximum score possible (110).  
The higher the result, the better the QoL. 
 
Patients were given the questionnaire along with its accompanying instructions.  Questionnaires 
have been designed so that patients can complete them independently without input from the 
healthcare provider.  Patients were given adequate amounts of time to complete the 
questionnaire.  Patients who spoke limited English were excluded.  Copies of the questionnaires 
can be found in Appendix I. 
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2.12 Biochemical tests 
IGF-I, fasting lipids, insulin and glucose, thyroid function tests (including T3), 
testosterone/oestrogen (as appropriate), urea, creatinine, blood count and serum for storage 
were taken from patients at each visit.  IGF-I and serum for storage were taken from healthy 
volunteers on the day of their CMR.  Samples were transferred on ice and then frozen at -20°C, 
or spun, separated and then frozen at -20°C, depending on the test required.  All samples were 
processed in the Departments of Biochemistry and Haematology, Barts & the London NHS 
Trust. 
 
2.12.1 IGF-I Assay 
IGF-I levels were measured using a chemiluminescent immunoassay on the Siemens Immulite 
2500 analyser (Surrey, UK).  The assay reports IGF-I levels between 25-1600 ng/ml, with a 
reference range lying between 94-252 ng/ml.  External quality assessment, performed by 
Guildford Peptide Hormones (Surrey, UK), reported the assay performance as “good”.  Internal 
quality assessment demonstrated the following results with two standard solutions: Solution 1, 
result = 48.6 ng/ml, mean 47.5, SD 4.2; Solution 2, result = 188 ng/ml, mean186, SD 15.9. 
 
 
2.13 Biometric measurements 
Blood pressure, weight and height were measured by trained healthcare professionals using 
standardised NHS equipment on Francis Fraser Ward at St Bartholomew’s Hospital or in the 
Cardiac MRI Unit at the London Chest Hospital. 
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2.14 Statistics 
2.14.1 Power calculations 
Power calculations to look for a significant increase in LVMi were performed based on Valcavi 
et al’s study of one year GH treatment on patients with adult-onset GHD207.  As the literature 
suggests that changes in cardiac mass seen with GH replacement in GHD are subtler than 
those seen with normalisation of GH levels in acromegaly, it was felt appropriate to use a GHD 
study rather than an acromegaly study to perform power calculations33,73.  Valcavi’s study used 
echo to determine LVMi changes, however, CMR is reported as a more accurate measure of LV 
mass than echo and so it was felt that standard deviations (SD) seen at echo would be bettered 
by CMR110.  Attempts were not made to determine clinical relevance of changes seen, as at 
present, there is inadequate data regarding this issue in the literature (discussed further in 
Section 4.4.2).  SD produced by Valcavi’s paper were used as a basis to predict changes in 
LVMi that would be seen in our study.  A power of 80% and a significance of 0.05 (α) were 
used, power calculations were performed on StatsDirect.  From these calculations, it was 
determined that ten subjects would be needed in each arm.  Attempts were made to recruit 15 
patients to each arm to allow for dropout.  Two recently published studies also sought the same 
number of patients for the assessment of the effects of GH on cardiac mass, suggesting that 
these calculations were an accurate reflection of the available literature128,215. 
 
2.14.2 Data analysis 
Images from study patients and healthy volunteers were compared to one another. For study 
patients, images before and after treatment were compared to one another.  Additionally, 
published, standardised normal ranges for CMR were used216.  These normal ranges were 
generated from the CMR data taken from 30 males and 30 females aged 20-65 years, who 
underwent CMR specifically to supply normative data.   
 
Height and weight are major contributors to variations in LV between individuals217.  To correct 
LV mass for these variations, results were corrected for body surface area (BSA) using the 
Mostellar formula: 
 
BSA in m2  = ([height in cm x weight in kg] / 3600)½ 
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CMR measurements of left ventricular mass, EDV, ESV, SV and CO were divided by BSA to 
create an indexed result and are notated as LVMi, EDVi, ESVi, SVi and CI.  EF does not require 
indexing as it is reported as a percentage. This not only allows for comparison between 
individuals of the same sex but, with the exception of LVMi, allows for comparison of individuals 
of the opposite sex218. 
 
Serum IGF-I levels vary with age, the highest levels being seen in younger individuals.  To allow 
for comparison, IGF-I standard deviation scores (SDS) were calculated using a standardised 
reference table provided by the assay manufacturer (Siemens, Surrey, UK).  This provided 
mean and standard deviation (SD) results for men and women of different ages.  The following 
formula was applied for each individual’s IGF-I value: 
 
SDS = (x – mean x) / SD 
 
Where x is the IGF-I value, mean x is the mean IGF-I value given for that individual’s age and 
sex and SD is the SD value given for that individual’s age and sex. 
 
To assess for bias and error in the measurement of LV mass and to ensure reliability, 
interobserver variability was assessed. Inter-observer variability was investigated by the 
independent analysis of 34 scans by an experienced colleague, blinded to the original 
measurements. Bland-Altman plots were constructed by plotting the mean of the two values 
generated on the x-axis and the difference between the two values generated on the y-axis, 
subtracting the later value from the original one219. 
 
The Student’s T test was used to compare patients with controls.  Repeated measures ANOVA 
was used to compare patients before and after treatment.  Paired T test was used to compared 
IGF-I SDS at the beginning and end of the study.  A p value of 0.05 or less deemed as being 
statistically significant (* p<0.05, ** p<0.01, *** p<0.001).  Spearman’s rank correlation test was 
used to compare IGF-I SDS and LVMi.  Data are given as mean (standard deviation), except 
where specified.  Error bars on graphs represent standard error of the mean (SEM).  Statistical 
analysis was performed using StatsDirect, Excel and Prism.   
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3 Results 
 
3.1 Patient characteristics 
Ten patients with GHD (2 female, 8 male) and 14 patients with acromegaly (10 female, 4 male) 
were recruited and consented to take part in the study.  A summary of the baseline 
characteristics of patients with GHD is given in Table 3.1 and of the patients with acromegaly in 
Table 3.2.  One female with acromegaly dropped out before Visit One due to travel problems 
(Patient 5).  The remainder of the patients all attended for the First Visit.  All patients with GHD 
attended for Visit Two.  Two patients with GHD did not attend for Visit Three, one (Patient 21, 
male) because he had discontinued GH as he failed to have ongoing clinical benefit, one 
(Patient 19, female) as she did not feel comfortable undergoing further CMR studies.  Of the 
patients with acromegaly, three female patients underwent Visit One and no further visits, one 
because she did not feel comfortable undergoing CMR scans (Patient 8), one because of work 
pressure (Patient 2) and one because of a non-related chronic illness (Patient 12).  One female 
patient could not attend Visit Two due to illness but did attend Visit Three (Patient 7).  One 
female patient did not attend Visit Three as she did not feel comfortable undergoing further 
CMR scans (Patient 11). 
 
3.2 Adverse outcomes 
There were no significant adverse outcomes from this study.  The only reports of side effects 
were of discomfort at venous cannulation (Patients 11 and 21) and of an uncomfortable 
sensation when receiving either the adenosine or the gadolinium contrast infusion.  Effects from 
both were mild.  Two patients requested that they did not have adenosine on future occasions 
and their wishes were complied with (Patient 19, 23). 
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Pt Age Sex Symp  Reason for 
GHD 
Other medical 
conditions 
Medications Smoker Visits 
attended 
1 73 M 3 NFPA 
TSS 2005 
EBRT 2005 
Mild OSA Levothyroxine 
Testosterone 
Aspirin 
Hydrocortisone 
Ex (30) All 
3 49 M 18 Prolactinoma, 
medical 
therapy 
Type 2 DM 
Hypertension 
Ramipril 
Candasartan 
Levothyroxine 
Aspirin 
Bromocripttine 
Metformin 
No All 
14 56 M 10 NFPA 
TSS 1998 
EBRT 1998 
 Levothyroxine 
Hydrocortisone 
Testosterone 
Aspirin 
Lansoprazole 
Ex (30) All 
16 51 M  3 NFPA 
TSS 2006 
Hypothyroidism 
Hypercholesterolaemia 
Levothyroxine 
Testosterone 
Simvastatin 
No All 
17 50 F  4 NFPA 
Craniotomy 
1991 
EBRT 1991 
TSS 1992 
TSS 2005 
EBRT 2008 
Renal stones HRT Yes All 
18 58 M 2 NFPA 
TSS 2003 
Hypercholesterolaemia Levothyroxine 
Hydrocortisone 
Testosterone 
Atorvastatin 
No All 
19 34 F  6 Hypophysitis 
during 
pregnancy 
2003 
Depression Levothyroxine 
Seroxat 
Yes 1,2 
20 76 M 3 NFPA 
Pituitary 
apoplexy 
2007 
 Levothyroxine 
Hydrocortisone 
Testosterone 
No All 
21 57 M 9 Meningioma 
EBRT 2000 
Disordered sleep Levothyroxine 
Carbemazepine 
Amitripyline 
No 1,2 
22 37 M 3 Meningioma 
Surgery 
Radiotherapy 
2006 
Acute lymphoblastic 
leukaemia – 
chemotherapy and 
cranial irradiation 1977 
Levothyroxine 
Hydrocortisone 
Testosterone 
No All 
Table 3.1 Characteristics of GHD patients in the study at the time of enrolment. Pt = 
patient, Symp = symptom duration in years, NFPA = non-functioning pituitary adenoma, 
TSS = transsphenoidal surgery, EBRT = external beam radiotherapy.  Brackets represent 
number of years after stopping smoking 
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Pt Age Sex Symp Proposed 
treatment 
Other medical 
conditions 
Medications Smoker Visits 
attended 
2 46 F 15 Sandostatin Thyroidectomy Levothyroxine 
Alfacalcidol 
No All 
4 49 F 5 TSS OSA 
Asthma 
Lanreotide 
Amlodipine 
Diazepam 
Citalopram 
Tramadol 
Asthma inhalers 
Yes All 
5 30 F 3 Pegvisomant 
(prev TSS) 
Asthma Sandostatin 
Cabergoline 
Octreotide sc 
HRT 
Pregabalin 
Salbutamol 
No None 
6 50 F 10 TSS Hypertension 
Breast cancer 
(treated) 
Ramipril 
Venlafaxine 
No All 
7 58 F  15 TSS Hypertension 
OSA 
Back pain 
Ramipril 
Bendrofluazide 
Amitriptyline 
Oxytosin 
No 1,3 
8 39 F 10 Lanreotide 
(prev TSS) 
Hypertension 
OSA 
Levothyroxine 
Bendrofluazide 
Yes 1 
9 30 M 5 TSS  Lanreotide Yes All 
10 63 M 25 Lanreotide 
(prev TSS) 
Hypertension Cyclopenthiazide 
Amiloride 
Testosterone 
Hydrocortisone 
Ex (15) All 
11 46 F 10 Lanreotide 
(prev TSS) 
  Ex (3) 1,2 
12 58 F 10 TSS Hypertension 
Depression 
Atenolol No 1 
13 67 M 30 Cabergoline Hypertension 
Mild OSA 
Ramipril Ex (30) All 
15 45 M  5 TSS Encapsulated 
parotid 
carcinoma 
Octreotide sc No All 
23 58 F 30 Lanreotide & 
TSS  
Hypertension 
Depression 
Omeprazole No All 
24 76 F  15 TSS Hypertension 
OSA 
Losartan 
Amlodipine 
Doxazosin 
Aspirin 
Simvastatin 
Diclofenac 
No All 
Table 3.2 Characteristics of acromegaly patients in the study at the time of enrolment.  Pt 
= patient, TSS = transsphenoidal surgery, OSA = obstructive sleep apnoea, Symp = 
symptom duration in years.  Brackets represent number of years after stopping smoking. 
Page 68 of 238 
 
3.3 Baseline comparison of patients and controls 
There were no significant differences between the patients and the control group, with the 
exception that male patients with GHD were significantly heavier than their controls (87.8 versus 
71.2 kg, p=0.007) (Table 3.3).  This difference was not seen the female GHD patients or the 
acromegaly patients (Table 3.4).  As might be predicted, acromegaly patients were more likely 
to have hypertension than controls (8 out of 13 versus 2 out of 13). 
 
GHD Controls (n=10) Patients (n=10) p value 
Gender (M/F) 8/2 8/2 NA 
Age (years) 54 (12.1) 55 (13.4) 0.890 
Male weight (kg) 71.2 (9.54) 87.8 (11.6) 0.007 
Female weight (kg) 58.8 (8.14) 75.0 (19.8) 0.395 
Male height (cm)  175.9 (4.6) 173.8 (9.6) 0.580 
Female height (cm) 166.5 (4.9) 156.5 (2.1) 0.120 
Systolic BP (mmHg) 133 (14) 135 (19) 0.863 
Diastolic BP (mmHg) 82 (10) 83 (12) 0.811 
Hypertension (number) 0 1 NA 
Diabetes (number) 0 1 NA 
Smoker Y/N/Ex (number) 3/5/2 2/6/2 NA 
Table 3.3 Baseline characteristics of GHD patients and their controls.  Data are given as 
mean (SD).  BP = blood pressure 
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Acromegaly Controls (n=13) Patients (n=13) p value 
Gender (M/F) 4/9 4/9 NA 
Age (years) 52 (11.2) 53 (12.3) 0.980 
Male weight (kg) 92.5 (18.7) 102.3 (10.6) 0.396 
Female weight (kg) 69.1 (12.2) 79.2 (17.4) 0.176 
Male height (cm) 178.3 (7.7) 181.5 (5.5) 0.517 
Female height (cm) 165.6 (8.2) 163.8 (6.4) 0.614 
Systolic BP (mmHg) 125 (17) 133 (19) 0.280 
Diastolic BP (mmHg) 78 (10) 77 (12) 0.781 
Hypertension (number) 2 8 NA 
Diabetes (number) 1 0 NA 
Smoker Y/N/Ex (number) 1/6/6 3/7/3 NA 
Table 3.4 Baseline characteristics of acromegaly patients and their controls.  Data are 
given as mean (SD).  BP = blood pressure. Patient 5 is excluded as she withdrew from 
the study prior to Visit One. 
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3.4 Baseline LV characteristics 
3.4.1 GHD baseline LV characteristics 
Females with GHD had significantly reduced LVMi when compared to their controls (37.3 v. 
55.4 g/m2, p=0.027) and had an LVMi beneath the lower limit of published normal ranges (44.6 
– 59.4 g/m2)216.  There was no significant difference in LVMi between males with GHD and their 
controls (58.0 v. 60.6 g/m2, p=0.58).  Both male patients and their controls had a mean LVMi 
within the published normal range (55.4 – 74.0 g/m2)216. However, one male patient (Patient 3) 
had an LVMi two SD above the group mean and over upper limit of the normal range (76.0 
g/m2).  This patient had diabetes and hypertension.  When this patient’s LVMi was removed 
from the analysis, the resultant mean LVMi lay right at the bottom of the normal range (55.4 
g/m2). Both control groups had mean LVMi within the normal range, as would be predicted 
(Figure 3.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There were no differences in LV volumetric or functional indices between the GHD patients and 
their controls when all patients were analysed.  However, two patients (Patients 3 and 16) had 
EDVi more than two SD above the group mean.  When these results were excluded from the 
analysis, patients with GHD had significantly reduced EDVi when compared to controls (67.3 v. 
* 
 
X 
Figure 3.1 Baseline LVMi in patients with GHD and their controls.  There is a 
significant reduction in LVMi in females with GHD (p=0.027).  LVMi from Patient 20 has 
been excluded from analysis but is marked on the graph with “X”.  Data are presented 
as means, error bars represent SEM.  Green bars indicated published normal ranges. 
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76.0 ml/m2, p=0.025).  For the other indices, all other measurements were within two SD of the 
group mean.  LV volume indices and EF results are given in Table 3.5. 
 
 
GHD Controls GHD Patients p value 
EDVi ml/m2 76.0 (8.84) 67.3 (5.1) 0.0254 
ESVi ml/m2 27.6 (7.0) 27.5 (5.2) 0.965 
SVi ml/m2 47.6 (5.8) 44.7 (3.5) 0.189 
EF % 62.7 (2.7) 63.6 (6.9) 0.707 
CI l/min/m2 3.32 (0.59) 2.99 (0.55) 0.215 
HR beats/min 69.8 (9.7) 66.7 (9.6) 0.482 
Table 3.5 LV volumetric and functional indices for GHD patients and their controls.  
Values are means (SD).  Two outliers are excluded from EDVi calculations. 
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3.4.2 Acromegaly baseline LV characteristics 
Patients with acromegaly demonstrated increased LVMi when compared to controls, both in 
females (61.8 v. 40.8 g/m2, p=0.0019) and in males (71.5 v. 56.7 g/m2, p=0.0055) (Figure 3.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When all data were analysed, there was a borderline significant increase in LV EDVi in patients 
compared with controls (86.9 v. 72.9 ml/m2, p=0.051).  One female patient (Patient 4) had a 
particularly low EDVi, more than two SD from the mean.  This patient’s CMR demonstrated 
evidence of reversible ischaemia and she progressed to have a stent inserted into the left 
anterior descending coronary artery.  When this patient’s value was excluded from analysis 
there was a significant increase in LV EDVi when patients were compared to controls (90.7 v. 
72.9 ml/m2, p=0.0055).   
 
There was no difference in ESVi between patients and controls (33.7 v. 29.8 ml/m2, p=0.226).  
Once again, Patient 4 demonstrated an ESVi more than two SD from the mean.  When this 
patients result was excluded from the analysis, there was a trend towards increased ESVi in 
patients when compared to controls (35.3 v. 29.8 ml/m2, p=0.062). 
 
Figure 3.2 Baseline LVMi in patients with acromegaly, showing a significant increase 
in LVMI in both male (p=0.0055) and female (p=0.0019) patients compared to controls. 
** 
** 
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When all results were included there was a significant increase in SVi between patients and 
controls (53.2 v. 43.2 ml/m2, p=0.031).  However, when Patient 4 was excluded, whose SVi lay 
more than two SD from the mean, this significance was amplified further (55.4 v. 43.2 ml/m2, 
p=0.0048).  Volume indices are summarised below in Figure 3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients demonstrated a significantly higher CI when compared to controls (3.76 v. 2.91 
l/min/m2, p=0.020).  When Patient 4 was excluded, whose CI was more than two SD from the 
mean, this difference became more marked (3.90 v. 2.91 l/min/m2, p=0.0055). 
 
There was no significant difference in EF between patients and controls (62 v. 59 %, p=0.2643) 
nor any significant difference in heart rate (72 v. 67 bpm, p=0.439). 
 
 
 
 
 
Figure 3.3 LV volume measurements in patients with acromegaly compared to their 
controls.  There is a significant increase in EDVi and SVi and a borderline significant 
increase in ESVi in patients.  Results from Patient 4 have been excluded as they lay 
two SD from the mean. Control group, n=13; Patient group, n=12. 
p=0.0055 
p=0.062 
p=0.0048 
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3.4.3 LVMi and IGF-I SDS 
In both patient groups, IGF-I levels were consistent with the underlying diagnosis: GHD mean 
IGF-I SDS -1.60, acromegaly mean IGF-I SDS +14.3.  To ascertain whether cardiac mass was 
proportional to IGF-I, LVMi was plotted against IGF-I SDS (Figure 3.4 and Figure 3.5).  There 
was no significant correlation between IGF-I SDS with LVMi in male patients with GHD 
(Pearson r -0.462, p=0.249).  There were too few female patients with GHD to calculate a 
correlation.  For patients with acromegaly, there was no significant correlation in females 
(Pearson r +0.389, p=0.301) or males (Pearson r +0.303, p=0.698).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Comparison of IGF-I SDS and LVMi in patients with acromegaly.  Lines are best fit. 
Figure 3.4 Comparison of IGF-I SDS and LVMi in patients with GHD.  Line is best fit. 
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3.5 Baseline RV characteristics 
3.5.1 GHD baseline RV characteristics 
There was no difference in RV EDVi, ESVi, SVi or EF between GHD patients and their controls 
when all data were analysed.  Two male patients had EDVi more than two SD above the group 
mean (Patients 3 and 16).  When these results were excluded from the analysis, patients with 
GHD had lower EDVi than controls (67.8 v. 78.9 ml/m2, p=0.034).  Although Patient 16 had a 
mean ESVi more than two SD from the group mean, excluding this result did not alter 
significance in this parameter.  Patient 3 had a SVi more than two SD from the group mean.  
When this result was removed from the analysis, patients with GHD had SVi that was 
significantly lower than controls (44.1 v. 49.7 ml/m2, p=0.045).  RV mass was not assessed as 
this measurement has poor reproducibility on CMR.  Results are summarised below in Figure 
3.6. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Baseline RV volume indices in patients with GHD.  Patients with GHD had 
significantly lower EDVi (p=0.034) and SVi (p=0.045) than controls.  Outliers >2 SD 
from the mean have been excluded. 
* 
* 
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3.5.2 Acromegaly baseline RV characteristics 
Patients with acromegaly had no difference in RV EDVi, ESVi and EF when compared to 
controls when all results were analysed.  One patient (Patient 4) had an EDVi more than two SD 
below the mean.  When this result was excluded from the analysis, a trend towards increased 
EDVi was seen in patients with acromegaly (88.9 v. 76.5 ml/m2, p=0.101).  All patients had an 
ESVi and EF within two SD of the mean.  Patients with acromegaly showed a significant 
increase in SVi when compared to controls (51.1 v. 43.5 ml/m2, p=0.031).  Patient 4 had an SVi 
more than two SD beneath the group mean.  However, excluding this result did not alter 
significance (53.2 v. 43.5 ml/m2, p=0.029). RV mass was not assessed as this measurement 
has poor reproducibility on CMR.  Results are summarised below in Figure 3.7. 
 
 
 
Figure 3.7 Baseline RV volume indices in patients with acromegaly.  Patients with 
acromegaly had a trend towards increased EDVi (p=0.101) and had significantly 
increased SVi (p=0.031) compared to controls.  Patient 4 has been excluded from the 
EDVi analysis as her result were more than two SD from the mean. 
* 
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3.6 IGF-I changes with treatment  
3.6.1 GHD IGF-I changes 
By Visit Three, patients with GHD demonstrated a significant increase in IGF-I SDS with one 
year of GH treatment (paired T test, p=0.0032).  At baseline mean IGF-I SDS was -1.60 and at 
one year +0.61.  One patient (Patient 16) had an SDS less than -2.73 at Visit Three.  This 
corresponded to a serum IGF-I of 47 ng/ml, a figure significantly lower than any other result, 
including the patient’s own baseline IGF-I.  This result was thought to arise from sample error 
and was excluded from calculations, though changes in IGF-I SDS remained significant even 
when it was included (p=0.037).  Individual patient data are shown in Table 3.6 and Figure 3.7.   
 
Pt Age Sex Final GH dose (mg/day) Initial IGF-I SDS Final IGF-I SDS 
1 73 M 0.30 - 1.70 0.40 
3 49 M 0.30 - 1.47 0.06 
14 56 M 0.50 - 2.23 3.02 
16 51 M  0.35 - 0.46 - 0.01 
17 50 F  0.60  - 3.58 - 1.83 
18 58 M 0.20 - 0.43 0.86 
19 34 F  0.40 - 2.19 - 1.46 
20 76 M 0.50 - 2.39 - 0.27 
21 57 M 0.20 0.41 1.44 
22 37 M 0.30 - 1.97 1.88 
Table 3.6 Treatment of patients with GHD.   Where patients dropped out before the end of 
the study, IGF-I level at Visit 2 is given.  IGF-I values have been converted into SDS to 
allow for comparison of different age and sex patients. 
 
The diagnosis of GHD is made based on the failure of the patient to mount a GH response to an 
appropriate stimulus, such as hypoglycaemia.  IGF-I cannot be used to make the diagnosis as 
there is marked crossover in the results between GH deficient and GH replete individuals.  This 
is seen here, where only four individuals with GHD had baseline an IGF-I SDS of less than two.  
However, IGF-I levels are used to monitor response to treatment and an IGF-I in the upper third 
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of the age- and sex-matched reference range in usually aimed for.  Patient 17 was taking oral 
oestrogen therapy, explaining her relatively low IGF-I SDS of -1.83 with a reasonable dose of 
GH.  It should also be noted that her baseline IGF-I SDS was particularly low at -3.58.  One 
patient was over treated with GH and had an SDS of 3.02.  This result was reviewed by the 
referring clinician and the GH dose was reduced.   
 
 
 
 
 
 
Figure 3.7 Change in IGF-I SDS in patients with GHD treated with GH over 1 year.  
Result from Patient 16 at Visit Three is excluded. 
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3.6.2 Acromegaly IGF-I changes 
Patient with acromegaly had the converse response in IGF-I SDS, with a significant fall at one 
year (paired T test, p=0.036). At baseline mean IGF-I SDS was +14.3, SD 11.3, and at one year 
+3.02, SD 2.41.  Individual patient data are shown in Table 3.7 and Figure 3.8.  Only one 
patient achieved complete disease remission at one year (Patient 7, IGF-I SDS -1.93, treated 
with transsphenoidal surgery).  Patient 11 achieved disease remission at 6 months but did not 
return for the one year scan (IGF-I SDS -2.04).  It is possible that this patient may have had 
disease recurrence by one year.  All patients achieved a marked improvement in SDS when 
compared to baseline with the exception of Patients 10 and 13, both of whom had mild disease 
at baseline. 
 
Pt Treatment prior to 
Visit 1 
Treatment during Study (started 
after Visit 1) 
Treatment after 
Visit 3 
Initial 
IGF-I 
Final 
IGF-I 
2  Sandostatin – withdrew from study  16.2  
4 6/12 Lanreotide  Lanreotide –TSS delayed for medical 
reasons 
TSS 7.46 4.46 
5 TSS Pegvisomant – withdrew from study    
6  TSS Somatostatin 
analogue 
27.0 6.53 
7  TSS  18.7 - 1.93 
8 TSS 6/12 earlier, 
Lanreotide for 6/12 
prior to TSS 
Lanreotide – withdrew from study  7.63  
9 6/12 Lanreotide TSS  10.5 2.12  
10 TSS 1986, intolerant 
of cabergoline 
Lanreotide  3.60 3.36 
11 TSS 1999 Lanreotide  3.55 - 2.04 
12  TSS  23.3  
13  Cabergoline for 6/12 then stopped  1.19 2.05 
15 Octreotide 
 
TSS, followed by Lanreotide, 
Pegvisomant added several months 
later 
 14.1 3.59 
23  Lanreotide for 6/12 followed by TSS, 
restarted lanreotide after TSS 
 41.5 2.61 
24  TSS Somatostatin 
analogue 
10.6 3.53 
Table 3.7 Treatment of acromegaly before, during and after study.  6/12 = 6 months, IGF-I 
levels are given as SDS.  Patient 9 declined blood tests at Visit Three so result from Visit 
Two was used.  Where patients dropped out the IGF-I SDS result is left blank. 
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Patients received a range of treatments, as shown above.  These treatments were determined 
by referring clinicians and were based on clinical disease, clinician and patient choice and local 
guidelines.  As this was an observational study, no attempt was made to influence the 
treatments given.  Three patients were receiving somatostatin analogues when they attended 
for CMR1 (Patients 4, 9 and 15).  Patient 8 had previously received somatostatin analogues but 
was not taking them at the time of CMR1.  Seven patients took somatostatin analogues through 
the study, two of whom also had transsphendoidal surgery (TSS) during the study.  Five 
patients had TSS alone during the study.  One patient was treated with pegvisomant (Patient 
15), in combination with other therapies.  The other patient due to start pegvisomant dropped 
out before CMR1 (Patient 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Changes in IGF-I SDS in patients with acromegaly before and at one year 
after treatment. 
Change in IGF-I SDS in Patients with Acromegaly 
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3.7 LV changes with treatment 
3.7.1 GHD LV changes 
Male patients with GHD showed a strong trend towards increased LVMi with one year of GH 
treatment (repeated measures ANOVA, p=0.052).  There was no difference in LVMi between 
patients after one year of GH treatment and the control group (62.9 v. 60.6 g/m2, p=0.603).  
Patients 3 and 16 continued to have LVMi two SD above the group mean.  Removing these 
data from the analysis, did not improve significance.  
 
There were only two females in the GHD group, one of whom withdrew after the second scan.  
This limited conclusions that could be drawn as paired analyses require at least three pairs.  
However, when unpaired T test was performed, no difference was seen between female 
patients at baseline and after six months of GH treatment (37.3 v. 37.9 g/m2, p=0.8716).  
Furthermore, after six months of GH treatment, the significant difference in LVMi between 
patients and controls persisted (37.9 v. 55.4 g/m2, p= 0.030).  Individual LVMi changes over 
time are shown in Figure 3.9. 
 
When numbers were increased by analysing males and females together, there was a 
significant increase in LVMi with one year of GH treatment (repeated measures ANOVA, 
p=0.023). 
 Figure 3.9 Individual changes in LVMi in patients with GHD treated with GH for one 
year. Females are shown with diamonds and males with squares. 
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Male patients with GHD moved from a mean LVMi right at the bottom of published reference 
ranges at Visit One (CMR1) to a mean LVMi well within the reference range by Visit Three 
(CMR3) (55.4 v. 59.5 v. 61.0 g/m2, reference range 55.4 – 74.0 g/m2).  Patient 3 was excluded 
from this analysis as his LVMi was over two SD above the groups mean at CMR1.  All LVMi 
values for females remained beneath the lower limit of the reference range. 
 
There were no significant changes in LV EDVi, ESVi, SVi, CI, EF or heart rate in GHD patients 
treated with GH for one year.  No difference was found in these parameters when CMR3 was 
compared to control values.  No values were more than two SD outside the group mean at 
CMR2 and CMR3. 
 
Only patient demonstrated evidence of reduced systolic function, as determined by LV EF.  
Patient 10 had an LV EF right at the bottom of the normal range on CMR1 (57%, normal range 
54-68%)220.  By CMR2, EF had fallen beneath the bottom of the normal range and was sitting at 
two SD from the mean (CMR2 44%, CMR3 51%).  All other EF measurements were within two 
SD of the group mean.  Patient 15 had an EF above the upper limit of the normal range on 
CMR1 (71%) but by CMR2 and 3 was within normal limits (both 67%).  
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3.7.2 Acromegaly LV changes 
There were no significant changes in LVMi with one year of treatment of acromegaly in females 
(paired ANOVA p=0.1636) or males (paired ANOVA p=0.4375).  Female patients continued to 
demonstrate a significantly increased LVMi when compared to controls (55.9 v. 41.9 g/m2, 
p<0.001).  For male patients, the significant increase in LVMi was lost and only a trend towards 
increased LVMi was seen (66.6 v. 56.7 g/m2, p=0.1121).  Mean data are shown in Figure 3.10.  
Individual data are shown in Figure 3.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients with acromegaly did not demonstrate any difference in EDVi, ESVi, SVi, CI or EF when 
data from each visit were compared with paired ANOVA.  All results lay within two SD of the 
group mean.  The difference, at baseline, between patients and controls in EDVi was lost by 
CMR3 (78.3 v. 72.9, p=0.478) but the difference in CI persisted (3.51 v. 2.91 ml/min/m2, 
p=0.027).  Heart rate did not change significantly over the year (paired ANOVA p=0.1934).  
 
Figure 3.10 Changes in LVMi in patients with acromegaly over one year.  There is no 
significant difference in LVMi over time.  A significant difference in LVMi between 
patients and controls persists at one year in females (p<0.001) but only a trend towards 
increased LVMi persists in males (p=0.1121). 
Females Males 
*** 
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Figure 3.11 Individual changes in LVMi in patients with Acromegaly.  Females are 
shown with diamonds and males with squares. 
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3.8 RV changes with treatment 
3.8.1 GHD RV changes 
There were no significant changes in RV volume indices in patients with GHD treated with one 
year of GH replacement.  When patients previously excluded from baseline analysis (Patients 3 
and 16) were excluded, changes remained insignificant, although a trend towards increased 
EDVi was seen (70.6 v. 77.6 v. 76.1 ml/m2, p=0.068).  There were no differences between 
results from CMR3 and the control group and the difference in EDVi seen between patients and 
controls at baseline was lost by one year (Table 3.8). 
 
 CMR over three visits CMR 3 v. control 
EDVi ml/m2 0.068 0.543 
ESVi ml/m2 0.146 0.833 
SVi ml/m2 0.774 0.665 
Table 3.8 Change in CMR volume indices in patients with GHD over three visits (p value, 
repeated measures ANOVA) and comparison of volume indices between CMR 3 and 
controls (p value, T test).  Patients 3 and 16 are excluded from EDVi analysis. 
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3.8.2 Acromegaly RV changes 
When all results were analysed there were no significant changes in RV volume indices or EF 
after one year of treatment.  When Patient 4 was excluded from EDVi and SVi analyses, as per 
the baseline analysis, there was a trend towards increased EDVi (92.5 v. 76.5 ml/m2, p=0.060) 
and a significant increase in SVi (54.7 v. 43.5 ml/m2, p=0.040) in patients at CMR3 when 
compared to controls.  Results are given in Table 3.9. 
 
 CMR over three visits CMR 3 v. control 
EDVi ml/m2 0.919 0.060 
ESVi ml/m2 0.926 0.599 
SVi ml/m2 0.973 0.040 
Table 3.9 Change in CMR volume indices in patients with acromegaly over three visits (p 
value, repeated measures ANOVA) and comparison of volume indices between CMR 3 
and controls (p value, T test).  Patient 4 is excluded from EDVi and SVi analyses. 
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3.9 Inter-observer variability 
Thirty-four CMR scans were assessed independently by two observers blinded to diagnosis.  LV 
mass, EDV, ESV, and EF were plotted on Bland-Altman plots (Figure 3.12, Figure 3.13, Figure 
3.14 and Figure 3.15). 
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Figure 3.12 Inter-observer variability in measurement of LV mass.  Mean difference is 
close to zero (-0.6 g).  One result lay >4 SD from the mean difference.  No trend is 
present.  Courtesy of A. Dattani. 
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Figure 3.13 Inter-observer variability in measurement of LV EDV.  Mean difference is 
close to zero (-0.4 ml).  Three results lay slightly more than 2 SD from the mean 
difference. No trend is present.  Courtesy of A. Dattani. 
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Figure 3.14 Inter-observer variability in ESV measurements.  Mean difference is -4.0 ml.  
One result lay outside 2 SD.  No trend is present.  Courtesy of A. Dattani 
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Figure 3.15 Inter-observer variability in EF measurements.  Mean difference is 2.9%. 
Two scans are outside 2 SD.  No trend is present.  Courtesy of A. Dattani 
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3.10 Late gadolinium enhancement 
All images were assessed for evidence of LGE that might be consistent with fibrosis.  Two 
patients with GHD (Patients 1 and 14) and two patients with acromegaly (Patients 10 and 24) 
demonstrated evidence of LGE.  Of the GHD patients, Patient 1 had the most extensive area of 
LGE, measuring 20.1 cm3 at baseline.  This area was transmural in nature, matched to an area 
of very mildly reduced perfusion but not associated with reduced wall motion abnormality.  
Patient 14 had very mild patchy basal and mid-inferolateral LGE on all three scans that was too 
little to quantify.  Of the acromegaly patients, Patient 10 did not have any LGE seen at baseline 
but had patchy LGE in the inferolateral wall seen on both CMR2 and CMR3.  Patient 24 had 
mild, patchy LGE in the mild inferior wall extending <25% transmurally.  Results are 
summarised in Figure 3.16. 
 
 
 
Figure 3.16 Late gadolinium enhancement demonstrated on study patient CMR scans.  
Squares represent patients with acromegaly, circle represents GHD.  Patient 14 data 
are excluded as the cardiologist felt the LGE was too patchy to quantify 
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3.11 Perfusion CMR 
Five patients had evidence of mycordial perfusion deficits when infused with adenosine.  When 
scans were re-reviewed by a consultant cardiologist, three were thought to show mild, 
insignificant findings.  On further questioning, all three patients were completely free from 
cardiac symptoms both at rest and on exertion, and thus no further investigations were 
performed.  The patients were counselled to seek medical advice early in the event of the 
development of any cardiac-sounding symptoms.  Results are summarised in Table 3.10. 
 
Two patients (Patients 4 and 14) demonstrated more marked perfusion abnormalities.  These 
patients each underwent a CT angiogram and clinical review by a consultant cardiologist.  
Patient 14 demonstrated no flow-limiting lesion on CT angiography.  He was advised to follow a 
primary prevention strategy in the form of aspirin and a statin.   Patient 4 demonstrated a 50% 
stenosis of the left anterior descending coronary artery (LAD).  She underwent percutaneous 
stenting of this lesion. 
 
Pt Group Perfusion CMR finding Outcome 
1 GHD Mild perfusion defects matched to an 
area of late gadolinium enhancement 
Changes mild and lay in an area of 
possible previous infarct.  No further 
investigation needed. 
4 Acro Basal anteroseptal and inferoseptal 
perfusion defect  
CT angiogram followed by 
percutaneous stenting of the LAD. 
7 Acro Perfusion defects in the basal to mid-
inferoseptal wall and mid inferior wall. 
Changes patchy, patient asymptomatic.  
No further investigation needed. 
14 GHD Persistence of a perfusion induced 
defect in the mid-inferoseptal segment 
CT angiogram and cardiologist review.  
Primary prevention only. 
20 GHD Mild perfusion defect in the basal 
infero-septum 
Changes patchy, patient asymptomatic.  
No further investigation needed. 
Table 3.10 Patients (Pt) with abnormal perfusion following the induction of myocardial 
hyperaemia with adenosine.  Acro = acromegaly. 
 
Of the five patients who demonstrated perfusion abnormalities, only Patient 4, who required a 
coronary artery stent, was a current smoker.  Two patients were ex-smokers but both of these 
stopped smoking approximately 30 years ago.  Out of these five, only one patient had treated 
hypertension and no patient had diabetes.  No patient was receiving an HMG-CoA reductase 
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inhibitor.  The mean total cholesterol in these five patients was 5.24 mmol/l (Table 3.11).  
Numbers in this group were too small to draw statistically significant conclusions.  However, 
rates of smoking, diabetes, hypertension and hypercholesterolaemia in these five patients did 
not differ noticeably from the rest of the patients.   
 
Patient Group Smoker Diabetes Hypertension Statin Cholesterol 
1 GHD Ex (30 years) N N N 4.5 
4 Acro Yes N N N 5.7 
7 Acro No N Y N 5.6 
14 GHD Ex (30 years) N N N 6.1* 
20 GHD No N N N 4.3 
Table 3.11 Cardiac risk factors in patients with abnormal perfusion following the 
induction of myocardial hyperaemia with adenosine.  Acro = acromegaly, Y = yes, N = 
No, Statin = HMG CoA-reductase inhibitor.  Hypertension, diabetes and 
hypercholesterolaemia refer to known already diagnosed disease.  Total cholesterol 
levels represent mean values over study in mmol/l, within the exception of * which 
indicates total cholesterol at Visit One, after which an HMG CoA-reductase inhibitor was 
started that lowered total cholesterol levels markedly. 
 
All patients received adenosine on at least one of their scans except for Patient 8, who declined 
adenosine at Visit One and then dropped out of the study.  Both patients with acromegaly and 
with GHD demonstrated adenosine-induced perfusion abnormalities. 
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3.12 Aortic area 
Patients with GHD demonstrated reduced body surface area (BSA)-indexed ascending aorta 
area when compared to controls (14.4 v. 18.3 cm2/m2, p=0.039).  One patient with GHD had a 
bicuspid aortic valve, with consequential aortic root enlargement (Patient 21).  This finding was 
felt to be incidental and not related to GHD.  When his result was removed from the analysis, 
significance increased further (p=0.002).  There was no increase in BSA-indexed ascending 
aorta area with one year of GH therapy (ANOVA, p=0.357).  Results are shown in Figure 3.17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There was no significant difference in BSA-indexed aortic area when acromegaly patients were 
compared to controls (p=0.982).  There was no change in aortic area with one year of treatment 
for acromegaly.   
  
 
Figure 3.17 BSA-indexed ascending aorta area in patients with GHD.   Patients have 
significantly lower aortic area than controls.  There is no change in aortic area with 
one year of GH therapy.  Results from Patient 21 are excluded. 
Controls   Visit One      Visit Two        Visit Three 
2  
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3.13 Quality of life 
3.13.1 Quality of life in GHD 
Patients with GHD demonstrated a significant improvement in AGHDA score with one year of 
GH treatment (paired ANOVA p=0.0025). NICE guidelines advise that adults with GHD should 
score at least 11/25 on the AGHDA questionnaire prior to commencement of GH and that over 
the first nine months of treatment, patients’ AGHDA score should reduce by at least seven 
points.  All patients, except one (Patient 18, baseline AGHDA 10/25), started GH treatment with 
a baseline AGHDA of ≥ 11/25.  Four patients achieved an improvement in AGHDA score of at 
least seven AGHDA points (Patients 16, 17, 20 and 22).  Only one patient (Patient 14) had a 
rise in AGHDA score at twelve months, compared to six months.  However, AGHDA score in 
this patient remained lower at 12 months that it was at baseline.  See Figure 3.19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19 Quality of life changes over one year in patients with GHD treated with GH.  
Quality of life was measured using the disease-specific AGHDA questionnaire.  The 
higher the score, the worse the quality of life, with 25 representing the highest score 
possible.  An AGHDA score above 11 (dotted line) is judged by the NICE guidelines to 
represent impaired quality of life because of GHD. 
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3.13.2 Quality of Life in Acromegaly 
Patients with acromegaly did not demonstrate a significant change in ACROQoL score by one 
year (paired ANOVA p=0.1064).  The spread of ACROQoL scores was very broad, ranging from 
7 to 81 out of 100 at Visit Three.  Three patients had an improvement in ACROQoL score after 
6 months treatment (Patients 10, 13 and 24), two patients had an improvement in ACROQoL 
score after one year (Patients 6 and 7).  See figure Figure 3.20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 Quality of life changes over one year in patients with acromegaly.  Quality 
of life was measured using the disease-specific ACROQoL questionnaire.  The lower 
the score, the worse the quality of life, with 100 representing the highest score 
possible.  Patient 9 was excluded as he spoke limited English and was unable to 
complete the questionnaire independently. 
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4 Discussion 
4.1 Background 
The cardiac complications of GHD and acromegaly remain poorly understood23,73.  The multi-
system impact of both these diseases complicates investigation; hypertension, diabetes, altered 
lipid profiles, changes in circulating volume and vascular changes may all contribute to cardiac 
changes; the relative rarity of acromegaly and ao-GHD makes large-scale studies difficult.   
 
Due to these complexities, a form of cardiac assessment that provides highly detailed 
information about both heart structure and function is needed.  CMR provides a more accurate 
assessment of cardiac mass and EF than echo or radionuclide ventography, with highly 
reproducible measurements, and also contributes information regarding reversible ischaemia 
and fibrosis221,222.  It is, therefore, ideally suited to the assessment of GH-related heart disease.  
In order to gather all these data using other methods of investigation, a patient would need to 
attend a range of different cardiological tests, whereas CMR provides this information in a single 
set of scans.  Additionally, CMR does not involve exposure to ionising radiation and is well 
tolerated. 
 
CMR has its limitations: reproducibility of RV mass measurements and assessment of diastolic 
dysfunction are limited223.  Caution is also needed in the assessment of fibrosis.  CMR identifies 
fibrosis by comparing differences in gadolinium-based contrast uptake in healthy and fibrosed 
tissue and if diffuse fibrosis exists there is a possibility that it may be under reported224. 
 
To date, there are few CMR studies reviewing the impact of GH deficiency and excess on the 
heart.  There is one study, published in 2011 just as our study was being completed, which 
used CMR to assess patients with ao-GHD (n=16)128.  This study found patients had reduced 
LV EDVi (p=0.032) and LV ESVi (p=0.038) when compared to controls but no significant 
difference in LVMi or EF.  After one year of GH replacement there were no significant changes 
in volume, mass or function indices, despite a good IGF-I response to GH replacement.  CMR 
has also been used to track cardiac changes in patients with dilated cardiomyopathy treated 
with GH129. 
 
One study performed CMR on 14 patients with untreated acromegaly130.  This found a greater 
prevalence of cardiac hypertrophy (LVMi) when measured by CMR (72%) when compared to 
Page 96 of 238 
 
echo (36%) and noted the absence of cardiac fibrosis, previously considered to be a key feature 
of acromegalic cardiomyopathy86.  A second study used T2-weighted imaging to assess cardiac 
oedema before and 8-10 days after treatment for acromegaly.  An improvement was 
demonstrated in this parameter but the study only addressed this very narrow time window and 
made no effort to correlate cardiac findings with true extent of acromegaly or its cure131.  A third 
study compared eight patients with acromegaly to matched controls132.  Patients were found to 
have increased LVMi and ESVi compared to controls at baseline.  After three months 
acromegaly treatment, patients had a significant increase in EDVi but no change in any other 
cardiac parameters.  All patients were treated with medical therapies, some in addition to 
surgery, and six out of eight received somatostatin analogues.  The size of this study, short 
duration, failure to normalise IGF-I levels in patients make interpretation of these results difficult.  
Additionally, there is some evidence that somatostain analogues may also have an impact on 
cardiac function over and above their effect on GH and IGF-I levels133. 
 
4.2 Patient recruitment  
Both acromegaly and ao-GHD are rare and recruiting affected individuals for studies has its 
challenges.  Power calculations indicated ten individuals would be needed for each arm, hence 
fifteen individuals with each condition were sought for the study128,207.  As previous studies did 
not separate males from females when assessing LVMi, this was not factored into the 
calculations77,83,85,106,107,128,130,132,225.  However, a study of 60 healthy individuals which sought to 
determine normal ranges in CMR, has demonstrated a marked difference in LVMi between 
males and females (males 55.4 – 74.0 g/m2, females 44.6 -59.4 g/m2)226.  Hence it was decided 
to present LVMi separately for males and females.  As the groups did not contain equal 
numbers of males and females, some male/female subgroups were very small, particularly after 
dropout.  Of note, only two female patients with GHD took part, one of whom dropped out after 
six months.  This limited conclusions that could be drawn regarding these smaller subgroups.  
For completeness, combined analysis of males and females together has also been performed 
and is mentioned in the discussion where its findings differ from segregated data.  As it has 
been demonstrated that there is no difference in BSA-indexed cardiac volume indices between 
males and females both males and female data were analysed together for these 
parameters218.  The uneven distribtion of males and females recruited arose by chance, as both 
acromegaly and GHD have equal gender distributions.  Of note, it has been reported that there 
is no gender-related difference in the cardiac response to GH replacement227. 
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There was some patient drop out in both GHD and acromegaly groups.  A range of reasons was 
given for this, including other medical problems, discontinuation of GH treatment and difficulties 
with taking time off work to attend for CMR.  In a few cases, patients did not like undergoing 
CMR.  It is interesting to note that the two patients who dropped out of the GH arm of the study 
had high baseline AGHDA scores that failed to improve with GH treatment and it is possible that 
low mood or lack of motivation influenced their dropout.  The lack of improvement in AGHDA 
score with GH replacement in these individuals suggests that additional factors, other than 
GHD, may have been contributing towards reduced QoL.  In patients with acromegaly there was 
no relationship between QoL and patient dropout. 
 
The results in this study were analysed using paired T-tests and repeated measures ANOVA.  
The limitation of these tests is that they are dependent on a complete data set.  As number of 
patients only attended for two out of three visits, their data sets are incomplete and so were 
excluded from ANOVA analysis.  This reduced the power of the study.  In each of the 
acromegaly and GHD groups the total number of male and females who attended for all scans 
and were included in paired analyses was eight (n=8).  These numbers were less than had 
been planned for the study. 
 
Controls were recruited to match patients for both age and sex.  Controls for both the 
acromegaly and GHD groups were recruited on the same days and using the same recruitment 
method.  CMR scans were performed simultaneously in both groups.  There were no significant 
differences in height, systolic or diastolic blood pressure between patients and controls (Table 
3.3 and Table 3.4).  There was no difference in weight between patients with acromegaly and 
their controls (p=0.396).  However, patients with GHD weighed significantly more than controls 
(88 v. 71 kg, p=0.007) and had a mean BMI in the overweight range (29.4 kg/m2), whereas 
controls had a mean BMI in the healthy range (22.7 kg/m2). This finding most likely represents 
the central adiposity seen in GHD26.  However, individuals volunteering to provide control data 
have a tendency to be motivated individuals.  This characteristic may also express itself as a 
motivation to maintain a healthy weight and the difference seen may reflect the bias seen in any 
group of volunteers.  Alternatively, this is simply a matching failure.  The indexing of ventricular 
mass and volume indices to BSA is designed to overcome this factor and so this difference 
between the two groups should not influence their comparison, although this does not factor in 
any differences in lean body mass that may exist between the groups. 
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4.3 Controls 
Controls were recruited into the study to match the age (+/- 5 years where possible) and sex of 
the patients.   With the exception of a higher body weight in male patients with GHD than 
controls, there were no other statistically significant differences between patients and their 
controls.  However, it should be noted that the groups were very small, especially when female 
GHD patients were compared with their controls.  In this case, the group number of two makes 
drawing statistical conclusions impossible.  It should be noted that more patients with 
acromegaly had hypertension than their controls.  However, it could be argued that this is the 
nature of acromegaly and, as this was treated in all cases so that there was no difference 
between systolic or diastolic blood pressure between groups, it has been corrected for as much 
as is reasonably possible. 
 
The use of matched controls is only one way of comparing patients to normative data.  
Alternative methods include comparing patients to a “normal population” by using standard 
reference ranges and by comparing patients to themselves before and after treatment of 
disease.  All three of these techniques were attempted in this study, to provide the most 
available information.  The use of patients as their own controls was limited in the acromegaly 
group by the failure to achieve biological cure in the majority of the patients.   Standard 
reference ranges are limited to the values that have been published in that field and 
comparisons can only be made when data are available.  In this study, the majority of indices 
investigated, such as LV EDVi, had published normal range values.  However some indices, 
such as RV indices and aortic area were less available.  Matched controls are considered the 
best form of control groups in a study.  However, matching controls to patients induces bias into 
the characteristics of the group that may cause them to deviate away from the “normal range”.  
Furthermore, small study numbers may amplify this, as demonstrated by the control populations 
in this study in whom mean group characteristics were, at times, outside of published normal 
ranges.  Twenty-free controls were recruited, 10 for the GHD group and 13 for the acromegaly 
group.  Although these controls were considered as “normal” controls, the CMR results between 
the two groups were significantly different from one another.  Of particular note was the fact that  
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female acromegaly controls had a mean LVMi beneath the normal range (40.8 g/m2, normal 
range 44.6-59.4), whereas female GHD controls had a mean LVMi in the middle of the normal 
range (55.4g/m2).  Although the female acromegaly patients had a mean LVMi above the 
normal range (61.8g/m2), the significant difference seen between acromegaly patients and their 
controls (p=0.0055) may have been influenced by particularly low LVMi in the control group.   
 
This finding is a consequence of the small numbers present in this study.  Although it does not 
invalidate the comparison of patients with their matched controls, it does suggest a degree of 
caution is required.  By using a range of methods to establish control data, patients themselves, 
normal ranges and matched controls, we have done our best to overcome this limitation. 
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4.4 Growth hormone deficiency 
Recruitment of patients with ao-GHD was particularly difficult.  Since the introduction of 
recombinant GH in 1985, the demonstration of the clinical benefits of GH replacement in adults 
with GHD and the introduction of the NICE guidelines in 200327, most patients fulfilling 
replacement criteria have been started on treatment.  This has reduced the number of patients 
available for studies, a problem noted in another recent study215.  It might be predicted that 
current patients would have shorter durations of GHD prior to replacement than those in 
historical studies, potentially reducing cardiac consequences of GHD.  Our patients had a mean 
duration of GHD of 6.1 years.   Duration of GHD in other studies ranges from similar durations 
to this study103,207 to 13.2 years in Newman’s study215.  Previous studies in ao-GHD have shown 
significant changes in echo-measured LVMi when treated with GH with a sample size of ten, so 
the recruitment of ten patients was felt to be adequate107. 
 
4.4.1 Baseline findings 
Despite there only being two female patients with GHD, these individuals demonstrated reduced 
LVMi when compared to controls, whereas in the larger group of males (n=8) there was no 
significant difference between patients and controls.  When the group size was increased by 
analysing both male and female results together there was a trend towards reduced LVMi in 
patients (p=0.063) but significance was not achieved.  When compared to published normal 
ranges, female patients had mean LVMi beneath the lower limit of normal and male patients 
had mean LVMi at the bottom of the normal range.  These ranges were formulated using 30 
males and 30 females aged 20-65 years, a much larger group than the control group in this 
study216.   
 
The mean age in this group was 55 years (range 34-76).  It is interesting to note that in a 
similarly sized study in older patients with GHD (60-72 years), there was no difference in LVMi 
between patients and their controls, even in the absence of diabetes or long-term 
hypertension228, whereas a study in younger patients showed differences between patients and 
controls107.  This might suggest that differences in LVMi that have been noted in patients with 
GHD may be more marked in younger patients and lost with age when other contributors 
towards increased cardiac mass, such as hypertension, may come into play.  It should be noted 
that the second study contained both ao- and co-GHD patients, which may confound 
Page 101 of 238 
 
comparison.  However, the lack of difference in LVMi between patients and controls in our study 
may, in part, represent the age of the patients enrolled.   
 
4.4.2 One year of GH replacement 
All patients in this study demonstrated an improvement in QoL score between presenting and 
final AGHDA-QoL measurement, itself a prerequisite of ongoing treatment27, and  an increase in 
IGF-I SDS (Table 3.6).  GH dose was titrated locally by the referring clinician according to local 
protocols, so that the timings of dose increases varied from individual to individual.  Those 
patients for whom GH dose was titrated up more rapidly may have had longer degrees of 
exposure to a “normal” GH level, which may have influenced the cardiac findings seen.  
However, it was felt that this variation would be minimal and unlikely to have any impact on 
cardiac findings at CMR.   
 
With only two female patients, one of whom dropped out after Visit Two, it is impossible to 
describe the effects of GH replacement on females alone.  Males alone demonstrated a strong 
trend towards a significant increase in LVMi (ANOVA p=0.052).  When data from males and 
females were pooled together a statistically significant increase in LVMi was seen with 1 year of 
GH treatment (p=0.023).  This change represented a 3.5 g/m2 increase in LVMi.  Whether or not 
this is clinically significant cannot be concluded at present, as there is no published work 
addressing this issue.  Certainly, in males, mean LVMi rose from the bottom of the published 
normal range to the middle of the range (55.4 v. 61.0 g/m2, normal range 55.4 – 74.0), which 
might suggest a clinical impact from this change.  Of the volumetric and function parameters 
measured, only EDVi was reduced at baseline when compared to controls.  Although this did 
not rise significantly with GH replacement, by one year the difference between patients and 
controls was lost, suggesting a subtle improvement in this parameter.  
 
The mechanism behind the reduction in cardiac mass in GHD is likely to be multi-factorial.  
Withdrawal of GH replacement in eight teenagers with GHD resulted in a reduction in skeletal 
muscle fibre diameter to 86% of baseline values229.  Three months GH replacement (12.5 µg/kg, 
to a maximum of 1.0 mg/day) in patients with ao-GHD resulted in increased area of both Type I 
and Type II skeletal muscle fibre area230.  It must be noted that this is a high replacement dose 
of GH and treatment with GH increased the IGF-I levels above the upper limit of the normal 
range.  Although there have not been any publications looking at the cardiac histology in GHD, 
in animal models of GHD cardiomyocyte area is reduced and increases with GH therapy61 
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suggesting that change in cardiac muscle fibre diameter is the likely mechanism for the increase 
in cardiac mass seen in this study.  
 
Previous echo studies in patients with ao-GHD have had contradictory results regarding cardiac 
mass.    Nass et al. found the even with 6 months of high dose GH treatment (12.5 µg/kg/day) 
there was no change in cardiac mass, volume or function, although a trend towards increased 
LVMi was seen (p=0.058) and maximal oxygen consumption and power output at exercise was 
increased103.  The authors suggest that the improvements in exercise performance may 
represent increased cardiac output and increased respiratory muscle strength rather than 
changes in cardiac structure.  Valcalvi et al., using even higher doses of GH (16.7 µg/kg/day), 
reported no difference in cardiac mass in the first six months of treatment but by one year 
reported a significant increase in LVMi, that persisted even at three months after ceasing GH207.  
This study also reports that the reversal of diastolic dysfunction in patients with GHD did not 
persist after stopping GH, suggesting that the increased myocardial contractility seen with GH 
replacement is not simply due to increased cardiac mass.  Colao et al. report reduced LVMi in 
patients with GHD compared to controls and an in increase in LVMi with one year of GH107.  
This paper reports GH titration to IGF-I levels but starts with a dose of 10 µg/kg/day, a dose 
higher than would be used in current UK practice.  Additionally, it combines both co- and ao-
GHD, which is likely to have skewed results.   
 
Current UK practice is not to dose GH replacement on weight but to titrate against IGF-I and 
improvement in symptoms210,231,232.  This reduces the unwanted side-effects of fluid retention, 
carpal tunnel syndrome and arthralgia and seeks to replace patients to physiological GH levels 
as best as can be achieved with a once daily injection.  This usually results in patients receiving 
lower doses of GH than those used in the above studies.  At the end our study, the average GH 
dose for men was 4 µg/kg/day (mean dose 0.35 mg/day) and for the single remaining woman 
was 10 µg/kg/day (0.6 mg/day).  Of note, this female patient was taking oral oestrogen-
containing hormone replacement therapy, which necessitates higher doses of GH to achieve 
equivalent IGF-I levels.  In Maison and Chanson’s review of the impact of GH on cardiac 
structure in 2003, none of the studies utilising lower GH doses, equivalent to those used in our 
study, contained ao-GHD patients, limiting conclusions that can be drawn about the cardiac 
effect of GHD in this population33.   
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Since the above review, studies have taken place using GH doses more consistent with current 
practice.  Some studies show increases in LVM in ao-GHD with one year of GH 
replacement233,234 whereas others show no change235.  However, problems with dose variations 
continue to confound comparison.  Even a very recently published double-blind study seeking to 
examine cardiovascular function in GHD replaced patients with 12.5 µg/kg/day, which had to be 
reduced in a significant number of patients because of side effects, so that the mean dose given 
was 0.64 mg/day at 6 months215.  Interestingly, when the study became open-label after the first 
six months and GH doses were titrated to IGF-I levels, the mean dose of GH given reduced to 
0.5 mg/day.  This study failed to show a difference in LVM in GHD patients treated with GH but 
did not correct the parameter to BSA, making comparison to other studies difficult. 
 
Patients in Andreassen’s CMR study had similar duration of GHD to those in our study (median 
5 years) and received similar GH doses (mean dose 0.34 mg/day)128.  Andreassen’s study 
reported reduced in EDVi and ESVi in GHD patients compared to controls.  The finding of 
reduced EDVi was confirmed in our study, although we failed to demonstrate any difference in 
ESVi.  This may reflect the smaller numbers in our study, a situation which was amplified by two 
patients with volumetric parameters more than two SD from the group mean that were excluded 
from the analysis.  Andreassen analysed LVMi in males and females together demonstrating a 
trend towards increased LVMi (p=0.059) with one year of GH treatment.  When male and 
female data were pooled, we were able to show an increase in LVMi over this time (paired 
ANOVA, p=0.023).  In neither study were any significant differences seen in other volumetric 
parameters or cardiac function at baseline or with one year of treatment.  These two studies are 
relatively concordant in their results, the slight differences between the two may be explained by 
the size of the study population.  A larger study would be necessary to confirm these findings. 
 
Just as it is possible that age my mask cardiac changes in patients with GHD at baseline, it also 
remains possible that increasing age may mask differences before and after GH replacement.  
It is interesting to note that a study treating younger patients (median age 26.5 years)107 saw 
improvements that were not seen in study treating only older patients (mean age 68 years)235, 
although these studies were disparate and measured different parameters.  In our patients, 
there was no correlation between ΔLVMi and age (r=0.5102, p=0.1964).  However, the study 
was not powered to address this question.  CMR studies separating younger and older patients 
would be needed to answer this question. 
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4.4.3 Right ventricular findings 
Patients with GHD demonstrated reduced RV EDVi (p=0.034) and SVi (p=0.045) compared to 
controls.  CMR is considered the most accurate a reproducible method for assessing RV 
volume parameters and has shown to be reproducible223,226,236.  There are no published works 
looking RV parameters in patients with GHD, including the recent CMR study.  Acromegaly is 
known to produce biventricular cardiac involvement73,83.  Therefore, it does not seem 
unreasonable that lack of GH would also produce biventricular changes.   
 
Early studies in hypophysectomised rats showed that GH treatment increased RV mass237.  
Studies in patients with GHD have not sought to examine the RV in depth.  In this study, 
although there were no significant RV changes with one year of GH treatment, a trend toward 
increased RV EDVi was seen (p=0.068) and the difference in EDVi between patients and 
controls was lost (Visit One 70.6 v. 78.9 ml/m2, p=0.034; Visit Three 76.1 v. 78.9 ml/m2, 
p=0.543), suggesting a subtle increase in EDVi.  Larger studies are needed to produce 
demonstrable changes in the RV than in the LV due to technical challenges in calculating 
parameters and consequential increased error236.  As this study was powered to demonstrate 
changes in LV mass, it may have been inadequately powered to demonstrate significant RV 
changes.   
 
4.4.4 Exclusions 
Results more than two SD from the group mean were considered as outliers and excluded from 
the analysis.  Grubbs defines an outlying observation, or outlier, as “one that appears to deviate 
markedly from other members of the sample in which it occurs”238.  These may reflect 
measurement error, non-normally distributed data, a mixture of two result distributions in the 
population sampled or simple chance.  In order to minimise measurement error, two observers 
reviewed the CMR scans, with good concordance of recorded measurements  (Page 87).  To 
confirm normality of data means and medians were compared with negligible difference found 
between the two.  The most likely causes for outliers in this population were the presence of a 
mixed population or simple chance.  GHD is a complex, multi-system disease and is associated 
with a range of other medical problems, such as dyslipidaemia, which may influence cardiac 
findings.  Hence the population examined is likely to be heterogeous in nature.  Additionally, 
chance remains a potential reason for outlying results. 
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Arguments for and against the exclusion of data points from analysis exist.  The decision 
whether or not to exclude an outlier depends in part on the nature of the study.  As our clinical 
study was both observational and long-term and the diseases examining were multi-system, it 
was felt appropriate to exclude outlying data that lay more than two SD from the group mean. 
 
The results excluded from analysis were Patient 3 for LVMi and EDVi and Patient 16 for EDVi.  
Patient 3 was a 49-year-old man with hypertension and diabetes.  His LVMi at CMR1 was not 
only well above the group mean but was above the upper limit of published references ranges 
(76.0 g/m2, normal range 55.4 – 74.0).  It is likely that hypertension contributed towards his LV 
hypertrophy.  Given his risk factors it also is possible that ischaemic heart disease may have 
played a role, although perfusion CMR did not show any evidence of reversible myocardial 
ischaemia, nor was any evidence of previous infarction on perfusion CMR.  Patient 16 had 
increased myocardial volume.  His past medical history included well-replaced primary 
hypothyroidism and hypercholesterolaemia.  He did not have documented hypertension and 
was not on any antihypertensives.  He was not a smoker.  No clear reason was identified for his 
raised EDVi that sat at two SD from the group mean (86.4 ml/m2, group mean 71.0). 
 
4.4.5 Other medical conditions and drugs 
All patients included in the GHD arm of this study had multiple pituitary hormone deficiencies.  
All except one patient were receiving thyroid hormone replacement.  Seven out of ten patients 
were receiving sex steroid replacement.  Five out of ten patients were receiving hydrocortisone.  
No pharmacological hormone replacement exactly mirrors the tight physiological control that 
exists in nature and there will be, at times, supraphysioloigcal levels of that hormone within 
circulation.  The replacement of GH may also impact on the availability of the active component 
of these substances to the cardiac tissues.  GH increases conversion of cortisol to cortisone, 
reducing tissue exposure to the active form of the compound239.  GH also increases conversion 
of levothyroxine to liothyronine, increasing tissue exposure to the active thyroid hormone240.  It 
has not been determined if any of these additional hormonal factors contribute towards the 
cardiac findings in patients GHD. 
 
GHD is associated with an atherogenic lipid and inflammatory marker profile.  Two GHD 
patients in this study had LGE and three patients had evidence of perfusion defects with 
hyperaemia.  Of these, one patient may have had a previously missed myocardial infarct 
(Patient 1). Control subjects did not receive gadolinium contrast or adenosine and so it is 
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impossible to determine if this level of findings was greater than would be expected in 
individuals without GHD.  However, it should be noted that these findings were very similar to 
those seen in the acromegaly group.  The only patient with hypertension and type 2 diabetes 
mellitus (Patient 3) did not demonstrate LGE or perfusion abnormalities with adenosine.  
However, this patient did have LV hypertrophy, presumed hypertensive in origin, and was 
excluded from the data analysis. 
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4.5 Acromegaly 
4.5.1 Left ventricular findings 
Cardiac enlargement is long recognised consequence of acromegaly21.  Both male and female 
patients with acromegaly demonstrated increased LVMi when compared to controls.  Patients 
also exhibited increased EDVi, SVi and CI and a trend towards increased ESVi compared to 
controls.  There was no correlation between IGF-I SDS and LVMi.   
 
Acromegaly is a disease associated with a long duration of symptoms prior to diagnosis72.  
Disease duration correlates with RV free wall thickness and may correlate with LVMi, so that 
early diagnosis is likely to influence the severity of hypertrophy seen83.  Additionally, the 
presence of hypertension significantly increases the degree of LV hypertrophy patients develop 
and it remains unclear whether early treatment of hypertension may modify the development of 
acromegalic cardiomyopathy83,85.  As national programmes, such as the Quality and Outcomes 
Framework (QOF), reward general practitioners for screening for hypertension and diabetes, 
these secondary consequences of acromegaly are being identified and treated earlier, 
potentially influencing the development of cardiac disease even prior to the diagnosis of 
acromegaly being made.  
 
The biventricular, concentric nature of early acromegalic cardiomyopathy is one of the reasons 
that this condition is thought to arise from direct GH/IGF-I action, rather than purely as a 
compensatory response to the secondary features of acromegaly.  If hypertension and diabetes 
mellitus were the only driving factors for the cardiomyopathy, a picture more akin to 
hypertensive cardiac disease might be expected.  The heart disease of GH excess, at least in 
the early stages, differs in a range of ways from simple heart failure as shown below in Table 
4.1 adapted from Sacca et al.68. 
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 Chronic heart failure GH/IGF-I excess 
LVM ↑ ↑ 
LV dimension ↑ ↔ 
LV wall thickness ↔ ↑ 
Relative wall thickness ↓ ↑ 
Afterload ↑ ↓ 
Contractility ↓ ↑ 
Peripheral vascular resistance ↑ ↓ 
Table 4.1 Changes in ventricular geometry, forces and haemodynamics in chronic heart 
failure and after short-term GH/IGF-I excess, from Sacca et al.68 
 
4.5.2 Treatment of Acromegaly 
Whereas in GHD patients recruited into studies may differ from historical cohorts due to shorter 
disease duration, in the case of acromegaly, patients may differ due to changes in treatment 
patterns.  Ten years ago, transsphenoidal surgery, followed by depot somatostatin analogues 
and radiotherapy if GH excess continued, was standard care17.  Now the practice of pre-treating 
tumours not confined to the pituitary fossa with six months somatostatin therapy prior to surgery 
has become more common18.  Somatostatin analogues may influence cardiac disease over and 
above the effect on GH levels.  A study by Colao et al. that compared the cardiac 
consequences of somatostatin analogues or transsphenoidal surgery as primary treatment for 
acromegaly showed that primary somatostatin analogue therapy was associated with an 
improvement in EF that was not seen with surgery133.  Our own data, reported in this thesis, 
demonstrates a reduction in cardiac AMPK activity in GH3-implanted rats treated with 
somatostatin analogues.  This could be a mechanism by which Colao’s findings might be 
explained.  Additionally, pegvisomant, a growth hormone receptor antagonist, has come into 
clinical practice for hard-to-control disease241.  This means that current patients with acromegaly 
may be receiving far more heterogeneous treatment strategies than those involved in past 
studies, making outcomes harder to compare. 
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This variation in treatment strategies is clearly demonstrated in the treatments received by our 
patients in this observational study (Table 3.7).  Patients were exposed to a range of methods to 
attempt to normalise GH levels: somatostatin analogues, TSS and pegvisomant.  It is not clear if 
variation in treatment strategies influenced the findings at CMR.  Furthermore, some of our 
patients were receiving somatostatin analogues on entry into the study, which may have 
influenced baseline CMR findings.  This heterogeneity needs to be taken into account when 
interpreting findings, particularly when no change is seen in patients before and after treatment.  
To overcome this, it may be necessary for future studies to include much larger groups of 
patients, to allow for sub-group analysis. 
 
In addition to heterogeneity in the treatments patients receive, study outcomes may also be 
influenced by variability in treatment success.  The definition of “cure” in acromegaly has been 
debated.  The consensus conference in Cortina d’Ampezzo in 1999 defined controlled 
acromegaly as a nadir GH <1 µg/L following oral glucose tolerance testing, an age-sex-
normalised IGF-I and no clinical disease activity242.  The terms “controlled” or “remission” are 
more appropriate than “cure” as even in the presence of these criteria, there is a 2-3% chance 
of recurrence243.  It has been reported that treated acromegaly patients with basal GH levels 
between 2.5 and 5.0 µg/L have mortality rate twice that of matched controls244.  
Transsphenoidal surgery alone may provide a biochemical cure for half of patients245, the main 
limitation to successful primary surgery being tumour size.  Many patients with macroadenoma 
are now being pre-treated with somatostatin analogues with a view to reducing tumour size and 
increasing the chance of cure at surgery246.   
 
This study did not seek to define “cure” in patients but IGF-I was measured on each visit as a 
marker of disease activity.  Out of 13 patients with acromegaly in this study, only four achieved 
an IGF-I SDS less than two, i.e. age and sex normalised.  For two of these (Patients 10 and 13) 
this reduction had occurred at six months but by one year IGF-I SDS had risen again.  Patient 
11 dropped out the study at six months and so it remains unknown if her IGF-I SDS would have 
remained controlled.  Only Patient 7 had an IGF-I SDS less than 2 at one year (SDS -1.93).  
Interestingly, this patient showed a marked improvement in QoL score, far greater than any 
other acromegaly patient.  All acromegaly patients in this study had macroadenoma, a probable 
factor in the degree of ongoing disease.  Failure to achieve biochemical remission is likely to 
have influenced cardiac mass and volume measurements, with patients failing to demonstrate 
the expected improvement in these parameters by one year.  Inadequate numbers of patients 
Page 110 of 238 
 
achieved biochemical remission in order to be able to analyse the data from these patients 
separately from those who did not.  Hence, only the effect of reducing IGF-I, rather than the 
effect of normalising it, has been assessed by this study. 
 
4.5.3 Findings after one year of treatment 
After one year of treatment for acromegaly, there was no significant difference in LV mass in 
males or females, although when data from both sexes were pooled a trend towards a reduction 
in LVMi was seen (ANOVA, p=0.0817).  Although females continued to demonstrate a raised 
LVMi at one year when compared controls (p<0.001), the difference between male patients and 
controls was lost (p=0.112), suggesting improvement of the cardiac hypertrophy, as has been 
reported elsewhere133.  There were no differences in volume indices.  Some published studies 
report a rapid improvement in LVMi with successful treatment of acromegaly, which persists at 
five years92-95, whereas others failed to see an improvement in the short term132. 
 
The failure to demonstrate significant improvement in LVMi in this study is likely to reflect lack of 
control underlying disease, with persistence of GH and IGF-I excess.  This may also be 
contributed to by loss of power as only 8 patients attended for all three scans.  The paired 
nature of a repeated measures ANOVA test requires a complete data set and hence only data 
from 8 patients were compared for this part of the study, despite higher numbers than this 
taking part. 
 
Patients continued to have a raised cardiac index at one year when compared to controls.  
Given the persistent ongoing raised IGF-I levels in the acromegaly group, this would be 
predicted.  The increased circulatory volume of acromegaly is thought to arise directly from 
increased salt and water retention, mediated via the kidneys90.  Hence, changes in cardiac 
index are likely to be one of the earliest alterations found in GH excess.  Indeed, patients may 
report an improvement in oedema, a symptom mediated via the same mechanism, immediately 
on waking up after successful transsphenoidal surgery.  The patients in this study had evidence 
of ongoing GH excess and therefore the raised cardiac index persisted. 
 
Incomplete disease resolution appears to have caused an ongoing reduction in QoL.  Figure 
3.20 demonstrates that by one year of treatment, most improvements in QoL that were seen at 
six months have been lost (six patients) and that in the case of two patients (Patients 3 and 23) 
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QoL was worse at one year than at baseline.  No statistical correlation was found between IGF-I 
SDS and QoL. 
 
4.5.4 Medications 
It is possible that medication, other than for direct control of GH levels, may also have had an 
impact on the cardiac findings seen.  Of particular note are angiotensin converting enzyme 
(ACE) inhibitors and angiotensin receptor blockers (ARBs).  ACE inhibitors have been shown to 
reduce LV EDV and ESV and increase EF in patients with symptomatic heart failure247 and 
reduce LV EDV in patients with asymptomatic heart failure248.   Reduction in LVM using these 
drugs is associated with a reduction in myocardial infarction and stroke, independent of systolic 
blood pressure249.  These findings may arise from both improvements in myocardial remodelling 
and from a reduction in preload and afterload.  
 
Three patients with acromegaly were taking ACE inhibitors (Patients 6, 7 and 13) and one was 
taking an ARB (Patient 24).  It is interesting to note that three of these patients (Patients 6, 7 
and 24, all female) had baseline LV EDVi and ESVi at the lower end of the results range: mean 
EDVi 90.7 ml/m2 (range 60.2 – 119.8) Patient 6 EDVi 60.2 ml/m2, Patient 7 EDVi 67.7 ml/m2 
Patient 24 EDVi 75.6 ml/m2; Mean ESVi 35.3 ml/m2 (range 23.1 – 47.4) Patient 6 ESVi 24.1 
ml/m2, Patient 7 ESVi 23.1 ml/m2, Patient 24 ESVi 24.2 ml/m2 (Patient 4 results excluded, as 
per previous analyses).  Patient 13 (male) had results close to the mean (EDVi 89.5 ml/m2, 
ESVi 39.2 ml/m2).  Such small numbers make it impossible to draw any conclusions.  The 2008 
Italian meeting of the COMorbities evaluation and Treatment in Acromegaly study (COMETA) 
recommended that ACE inhibitors or ARBs should be the first-line antihypertensives used in 
acromegaly250.  However, further work is needed to address the role of this family in improving 
cardiac indices in patients with acromegaly. 
4.5.5 Other medical conditions 
Obstructive sleep apnoea (OSA) is known to produce cardiac disease; in one study right 
ventricular hypertrophy was demonstrated in 71% of OSA patients251.  Whether OSA causes 
frank heart failure or simply exacerbates pre-existing heart failure remains unclear252.  However, 
untreated OSA is associated with increased cardiac morbidity and mortality253.  Five out of 13 
acromegaly patients in this study had OSA (Patients 4, 7, 8, 13 and 24).  Of these, only Patient 
4 had volume indices greater than two SD from the group mean.  However, rather than these 
being increased, as would be predicted with OSA, this patient had reduced RV EDVi and 
Page 112 of 238 
 
reduced LV EDVi, ESVi and SVi, representing the picture of cardiac constriction.  The other 
three patients with OSA all had LVM and LV and RV volume indices well within the normal 
range.  It must be noted that RV mass, which might be predicted to be increased in OSA, was 
not measured in this study as this measurement is less reproducibly measured on CMR223. 
 
OSA is a common problem in acromegaly.  It is possible that identification of OSA and its 
appropriate treatment in the above patients is the reason that they do not exhibit any significant 
mass or volume changes (with the exception of Patient 4).  It is possible that other patients 
within the study may have the cardiac consequences of undiagnosed OSA.  
 
4.5.6 Exclusions 
Patient 4 had a markedly reduced EDVi and ESVi, even when compared to controls rather than 
other patients with acromegaly, and was excluded from the analysis of these parameters.  
There was evidence of reduced perfusion on induction of hyperaemia and a basal anteroseptal 
and inferoseptal LGE.  Further investigations demonstrated a 50% stenosis of the left anterior 
descending coronary artery, which required stenting.  Additionally this patient had marked LV 
hypertrophy with chordal systolic anterior motion (SAM) of the anterior leaflet of the mitral valve 
and LV outflow tract turbulence.  During systole there was apical and mid-ventricular cavity 
obliteration.  This picture is similar to that found in hypertrophic obstructive cardiomyopathy.   
 
With somatostatin analogue therapy there was a reduction in LVMi (59.6 to 56.9 g/m2) and 
resolution of SAM.  LV outflow tract turbulence persisted.  This patients transsphenoidal surgery 
was delayed due to the discovery of reversible cardiac ischaemia that required intervention and 
then for a thyroidectomy, as a multinodular goitre was compressing the trachea.  Therefore, at 
the end of one year, although there was a mild improvement in IGF-I, her acromegaly remained 
uncontrolled.  Whether or not these cardiac findings will resolve with remission of the 
acromegaly remains to be determined.   
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4.5.7 Right ventricular findings 
As has already been discussed, one of the distinctive features of acromegalic cardiomyopathy 
is biventricular involvement83.  It was predicted that similar changes would be seen in the RV as 
were seen in the LV.  In the LV, both EDVi and SVi were increased but in the RV only SVi was 
significantly increased at baseline (p=0.031), although there was a trend towards increased 
EDVi (p=0.10).  After one year of treatment, there was no change in SVi or EDVi, and results 
remained comparable with baseline findings.   
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4.6 Late gadolinium enhancement 
Whereas reduced wall motion on perfusion CMR strongly correlates with the presence of 
previous ischaemia, for it directly visualises function, the presence of LGE is far harder to 
interpret.  Here, the relationship between perfusion and signal response is not linear, and 
indeed may be inverse 118.  Interpretation of LGE findings is dependent on scanning techniques 
used, timing of gadolinium injection, the pattern of LGE and the presence of other findings, such 
as regional wall motion abnormalities. 
 
Gadolinium-based contrast agents are distributed throughout the extracellular space and are 
excreted renally in an unchanged form.  These agents shorten T1 relaxation times and 
consequentially appear bright on T1 images254.  The reasons for accumulation of gadolinium-
based contrast in damaged tissue remain incompletely understood, but appears to arise from a 
combination of altered contrast wash-in/washout kinetics and expansion of the extracellular 
space255.  The pattern of enhancement is important as LGE may occur in a range of settings, 
including infarction, fibrosis, cardiomyopathies and infiltration256 and needs to be examined with 
care as artifactual high signal may arise from the chest wall, fat or cerebrospinal fluid118.  
Gadolinium-based contrast agents are well tolerated and are generally very safe.  However, 
they are avoided in the presence of reduced glomerulofiltration rate because of an association 
with nephrogenic systemic fibrosis257.  
 
In this study we particularly wished to used LGE to examine the hearts of patients with 
acromegaly for the presence of fibrosis.  Acromegaly has long been reported as being 
associated with increased myocardial fibrosis21.  Fibrosis occurs when myofibroblasts produce 
increased quantities of extracellular matrix components, including collagen, resulting in 
hardening or scarring of tissue258.  This process may occur in a very localised manner, such as 
following a regional myocardial infarction, or be a more diffuse process such as in hypertensive 
cardiomyopathy.  Myocardial tissue collagen content is often used a surrogate for fibrosis and 
the terms are often used interchangeably in the literature.  The point at which increased 
collagen deposition, especially when proportional to myocardial growth, becomes pathological 
has not been determined.  Caution is needed in interpreting the literature in regard to this 
matter.  
 
Original acromegaly autopsy studies report that 50-85% of hearts examined demonstrated 
interstitial fibrosis86,259.  However, these studies demonstrated not only fibrosis but also a 
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lymphomononuclear infiltrate and coronary artery disease, suggesting that myocarditis and 
ischaemic heart disease may have contributed to the findings seen.  Indeed, all these studies 
took place prior to the successful treatment of acromegaly and patients died with active disease.  
It is probable that multiple pathologies, including ischaemic heart disease, were at play in 
producing these findings.  Frustaci et al. performed endomyocardial biopsies on 10 patients with 
acromegaly and compared them to samples from papillary muscles in patients without 
acromegaly undergoing mitral valve replacement87.  This demonstrated a massive increase in 
cell apoptosis in both myocytes and non-myocytes and an eight-fold increase in interstitial 
collagen with small foci of replacement fibrosis.  The mechanism behind these findings remains 
unclear as in other experiments IGF-I excess appears to be protective against apoptosis260,261 
and to cause increased myocardial growth with a proportional increase in collagen content262,263 
and GH excess reduces collagen I and III expression264.  It must be noted that four out of ten 
patients in Frustaci’s study had systolic dysfunction as determined by EF <50% and that 
collagen content and myocyte apoptosis correlated positively with duration of acromegaly and 
negatively with EF.  It may be that collagen deposition is a feature of advanced acromegalic 
heart disease rather than the earlier stages.  Furthermore, although the presence of 
hypertension did not correlate with collagen deposition in the study, whether the use of ACE 
inhibitors and ARBs may play a role in the modification of collagen deposition in acromegalic 
cardiomypathy remains to be determined.  Certainly, both these families of drugs reduce the 
development of increased cardiac collagen content in heart failure265,266. 
 
Echocardiography can be used to assess myocardial fibrosis in patients with acromegaly.  A 
study using interventricular septum echoreflectivity demonstrated evidence of increased fibrosis 
in patients with acromegaly compared to controls, which correlated with procollagen III, a serum 
marker of collagen synthesis.  Control of acromegaly with surgery and somatostatin analogue if 
required normalised both echoreflectivity and procollagen III levels to that of the control 
group267.  A study that used an alternative technique to assess collagen content and to measure 
subtle changes in wall contractility, both thought to reflect the presence of fibrosis, 
demonstrated increased evidence of fibrosis in patients with acromegaly that improved with 
somatostatin analogue therapy268.  Interestingly, some patients demonstrated evidence of 
fibrosis in the absence of increased LVMi, suggesting that in the clinical setting the process of 
fibrosis may precede measurable hypertrophy, a finding that has not been demonstrated in 
animal studies. 
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In the one CMR study in acromegaly, although CMR was able to identify LV hypertrophy that 
was missed by echocardiography it was less successful in identifying fibrosis.  CMR only 
identified one patient out of 14 with mild fibrosis as measured by LGE, whereas echo identified 
six patients with evidence of increased collagen130.  In our study two out of 13 acromegaly 
patients demonstrated mild LGE.  In both cases this was patchy and diffuse.  LGE did not 
correspond with regional wall abnormalities and hence did not arise as a result of previous 
infarction.  We did not assess for evidence of increased myocardial collagen content at 
echocardiography. 
 
CMR utilises normal myocardium as the control against which increased signal from delayed 
gadolinium washout is compared.  A weakness of this method is that it may fail to identify a 
diffuse fibrotic process, in which all the myocardium is affected224.  The patchy fibrosis 
demonstrated in two scans in patients with acromegaly is likely to represented increased 
collagen content in the myocardium of these patients.  However, it may be that biopsy of the 
myocardium of other patients in this study would also demonstrate increased diffuse collagen 
deposition, missed by this CMR.  The lack of concordance seen in Bogazzi’s study between the 
fibrosis demonstrated at echo and CMR suggests that LGE measurement by CMR is not the 
optimum method for identifying fibrosis in patients with acromegaly.  It is possible that levels of 
myocardial fibrosis are less in our study population than in historical controls, due to control of 
risk factors for ischaemic heart disease and better treatments for patients with acromegaly.  
However, the finding of only two patients out of 13 in our study who demonstrated evidence of 
LGE seem to concord with Bozazzi’s and CMR may not be the optimum method for determining 
the presence of fibrosis in the heats of patients with acromegaly.  
 
Cardiac fibrosis is not a feature of GHD.  Of the two patients with GHD who demonstrated LGE, 
one had a missed previous infarct and one had such mild, patchy fibrosis, it was impossible to 
quantify.  Of note, this second patient, (Patient 14) also had a perfusion defect with induction of 
hyperaemia.  Although computerised tomography angiography failed to demonstrate any 
distinct coronary artery lesions, he was felt to be at high risk from ischaemic heart disease and 
managed with a primary prevention strategy.  Therefore, ischaemic heart disease was the 
probable cause of LGE in these two patients with GHD. 
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4.7 Perfusion CMR 
Three CMR techniques are available to assess the myocardium for evidence of coronary artery 
disease: dobutamine infusion may be used to assess for inducible wall motion abnormalities, 
adenosine or dipyridamole may be used to induce hyperaemia to assess for abnormalities in 
myocardial perfusion, or the coronary arteries may be visualised using magnetic resonance 
coronary angiography (MRCA)118.  In this study, the vasodilator adenosine was used.  
 
CMR is a valuable, non-invasive method for investigation for coronary heart disease269.  In a 
study of 513 patients, three-year cardiac event-free survival was 99.2% in those with a normal 
adenosine perfusion CMR, an abnormal scan was strongly associated with cardiac events 
(hazard ratio 12.5)270.  However, just as stress echocardiography, nuclear medicine imaging 
and CT coronary angiography are all imperfect tests for the presence of flow-limiting coronary 
artery disease, so too perfusion CMR has its limitations.  When compared to coronary 
angiography as a gold standard, adenosine perfusion is reported as showing 91% sensitivity but 
only 62% specificity in the detection of epicardial coronary stenoses271.  Additional limitations of 
CMR perfusion studies are that only the most proximal flow-limiting lesion is identified with more 
distal lesions being missed and its qualitative rather than quantitative nature, that and cannot 
determine degree of stenosis118. 
 
In this study only two patients exhibited a reduction in perfusion with induction of hyperaemia, 
one patient with GHD and one with acromegaly.  Further assessment was made with 
computerised tomography angiography and only Patient 4, an acromegaly patient, was felt to 
have evidence of coronary artery disease that required intervention.  This patient was not 
experiencing exertional chest pain.  It is impossible to know whether this lesion would have 
caused complications during the planned pituitary surgery, although its early identification and 
treatment was felt to be in the patient’s best interest.  In this case the use of CMR during the 
pre-operative work-up allowed for the minimisation of peri-operative cardiac risk.  Only one 
patient out of fourteen enrolled in the study had evidence of reversible ischaemia as compared 
to a 30 year old study that showed evidence of reversible ischaemia using thallium scanning in 
eight out of 34 acromegaly patients79.  Only one out of our 14 acromegaly patients was taking 
an HMG CoA reductase inhibitor and so this reduction in ischaemic heart disease is not 
explained by use of these medications.  Using CMR for purely identifying reversible ischaemia 
is unlikely to be cost efficient.  
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Although acromegaly is associated with an increase in two of the main risk factors for ischaemic 
heart disease, hypertension and diabetes mellitus, it is not clear if there is increase in ischaemic 
heart disease in acromegaly, particularly in early disease.  Autopsy studies have demonstrated 
evidence of myocardial infarction and atherosclerosis, although the level of disease seen was 
not thought to exceed background levels in similarly aged populations86; cardiac deaths 
continue to be increased in this patient group96.  Studies looking at carotid intima media 
thickness (IMT), a marker of atherosclerosis, have conflicting results.  One study found that 
patients with acromegaly have lower IMT than controls97 and others that patient have higher 
IMT than controls272,273.  Attempts to predict cardiac events using coronary artery calcium 
scoring and Framingham risk factors have not been successful in the medium term274.  Both GH 
and IGF-I are known to increase eNOS activity in experimental settings and it has been 
suggested that this may have cardiovascular benefit55,56.  However, studies on small arteries 
taken from patients with acromegaly indicate endothelial dysfunction, with reduced eNOS and 
endothelium-derived hyperpolarizing factor bioavailability98.  This suggests that in acromegaly 
the small vasculature does receive the benefit that would be predicted from increased GH/IGF-I 
eNOS activation.   
 
Cardiovascular mortality remains raised in patients with hypopituitarism who are receiving 
glucocorticoid, thyroxine and sex steroid replacement therapy; GHD is thought to be the main 
contributor to this discrepancy99.  Indeed, GH replacement appears to improve this finding.  
Svensson et al., in an open, prospective study, found that after three years of GH replacement 
mortality rates were no different to background population rates and were improved compared 
to mortality rates in an historical hypopituitary cohort not treated with GH275.  In our study, only 
one patient with GHD had evidence of reduced perfusion with the induction of hyperaemia.  
Computerised tomography of the coronary arteries failed to show any flow-limiting lesions and 
the patient was managed with a primary prevention strategy.  In addition, Patient 1, 
demonstrated evidence of a previous myocardial infarction on LGE.  This patient had no known 
history of ischaemic heart disease.  As he remained symptom-free, no intervention was 
performed.    
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The degree to which the mechanisms behind ischaemic heart disease contribute towards the 
development of acromegalic cardiomyopathy remains to be elucidated.  Perfusion CMR 
indicates with a good sensitivity that, whatever is happening at the microvascular level, coronary 
artery flow-limiting lesions do not appear to be playing a role in the development of the 
abnormalities seen in this study.  In acromegaly and GHD, the pharmacological control of any 
cardiovascular risk factors present seems prudent: in GHD a low threshold for statin therapy is 
indicated to counteract the raised LDL-cholesterol and in acromegaly tight diabetes control.  In 
both conditions blood pressure should be closely monitored and kept with target ranges and 
smoking strongly discouraged26,250. 
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4.8 Aortic area 
It has been reported that acromegaly is associated with increased aortic diameter.  Van der 
Klaauw et al. demonstrated increased aortic diameter at the level of the sino-tubular junction 
and ascending aorta in patients with acromegaly when compared to controls81.  These findings 
did not improve with treatment for acromegaly.  Savage et al. reported one case of increased 
aortic root diameter in a series of 25 patients with acromegaly276.   Casini et al. showed 
increased aortic root diameter in patients with acromegaly compared to controls, noting that 
men had greater aortic root diameters than women and that aortic root diameter positively 
correlated with LVMi277.  This study also demonstrated increased levels of aortic root ectasia in 
patients with acromegaly than in controls.  All these studies used echocardiography to make 
these measurements.  Levels at which measurements were taken are shown below in Figure 
4.1, taken from Buchner at al.278. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CMR is recognised as an accurate method for assessing aortic diameter; it has been used to 
study diseases such as Marfan’s and Turners syndromes, both of which are associated with 
aortic abnormalities279,280.  In this study, we measured the diameter of the ascending aorta in 
two planes and then calculated the area to allow for elliptical contours.  Only one individual, a 
patient with GHD (Patient 21), had a significant aortic abnormity.  This occurred due to he 
presence of a bicuspid aortic valve, a finding presumed to be incidental to his diagnosis of GHD. 
Figure 4.1 CMR oblique view showing the four aortic root diameter measurements at 
end diastole: A, aortic valve annulus (root); B, sinus of Valsalva; C, sinotubular 
junction; D, proximal ascending aorta. From Buchner et al.279 
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No difference was seen in this study between ascending aorta areas in patients with 
acromegaly and their controls, even when findings were corrected for body surface area.  In 
Savage’s study only one patient out of 25 demonstrated increased aortic diameter, suggesting 
that this is not a frequent finding of acromegaly.  We were not able to demonstrate the increase 
in ascending aorta diameter demonstrated in Van der Klaauw’s sudy, in which 37 patients were 
compared to controls.  Of these, 18 had active acromegaly and 19 were classified as having 
“inactive” acromegaly.  No differences were found between patients with active acromegaly and 
those with inactive acromegaly, nor were any changes seen after one and a half years.  At 
baseline, the combined acromegaly group had an ascending aorta that was on average 3 mm 
greater in diameter than controls.  This very small difference may only have been significant due 
to the number of patients who took part in the study.  The lack of significance seen in our study 
may reflect a difference in patient numbers. 
 
Patients with GHD demonstrated significantly reduced ascending aorta area (p=0.039).  When 
Patient 21, with a bicuspid aortic valve, was removed from the analysis, significance increased 
further (p=0.0025).  Reduced aortic diameter has been demonstrated in adults with co-GHD, 
which is likely to reflect impaired development, particularly as it does not improve with GH 
replacement281.  The only study that looked at aortic diameter in patients with mainly ao-GHD 
did not report any increase in aortic diameter with 60 months GH replacement but did not 
compare the aortic diameters of patients with GHD to those of healthy individuals234.  To avoid 
variations in aortic diameter with the cardiac cycle measures are taken during diastole, so the 
reduced aortic distensibility seen in GHD should not be the cause of this finding282.  GH 
replacement failed to increase aortic area and a significant difference persisted between 
patients and controls at one year.  In published studies, even up to five years GH failed to 
increase aortic diameter234.  The mechanisms behind the reduction seen in aortic area in 
patients are not clear.  Given the novelty of this finding, further investigation would be valuable. 
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4.9 Inter-observer variability 
Thirty-four patients’ CMR scans were assessed by two independent observers blinded to 
diagnosis.  The resulting Bland-Altman plots demonstrated very few data points more than two 
SD from the mean and for LVM and EDV the majority of data points lay close to zero, indicating 
very good correlation between the two sets of readings.  A little more scatter was seen on the 
graphs for ESV and EF but still only three data points lay outside two SD. 
 
Bland-Altman plots construct their points by subtracting two observers’ measurements from one 
another, so that identical results give a score of zero.  The further a point lies from zero, the 
more different the two measurements are.  The degree of discrepancy that is acceptable is a 
clinical rather than a statistical decision, but it is recommended that results lie within two SD.  
Ninety-five percent of data points lay within two SD of the mean on these graphs.   
 
No trend was seen in the data towards increased difference with increased mean measurement, 
nor did the scatter around the bias line get larger as the mean measurement increased, 
indicating consistent variability283.  It was concluded that these results demonstrated a lack of 
bias and a lack of interobserver variability. 
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4.10 Conclusion & further work 
This study importantly demonstrates that CMR can be used to identify and track the changes 
that occur in patients with GHD and acromegaly.  There has been conflicting evidence 
regarding cardiac mass in patients with ao-GHD.  The accurate assessment of LV mass by 
CMR allows for demonstration of low cardiac mass in females with ao-GHD and cardiac mass 
right at the bottom of the normal range in males with ao-GHD.  Treatment with GH for one 
year caused a significant increase in LV mass.  However, larger numbers are needed to 
demonstrate this finding in comparison to controls.  Patients with acromegaly are known to 
demonstrate increased cardiac mass, a finding that was confirmed in this study.  Patients 
underwent treatment for acromegaly; however, this was unsuccessful in controlling disease 
and LV mass remained increased at one year.   
 
CMR provides a wealth of information regarding the cardiovascular system and here was able 
to demonstrate interesting findings, including reduced volume indices in patients with 
acromegaly receiving ACE inhibitors and ARBS and reduced aortic area in patients with ao-
GHD.  CMR was tolerated well and, in the case of one patient, was able to provide important 
information about reversible ischaemia, allowing for treatment prior to general anaesthetic. 
 
CMR is useful for the identification of fibrosis following myocardial infarction.  However, in 
acromegaly, where fibrosis is diffuse, CMR is not the optimum imaging modality for 
demonstrating this finding.  Indeed, fibrosis may be missed if CMR alone is used for its 
identification in acromegaly. 
 
Several areas have arisen as a result of this study that would benefit from further 
investigation and are listed below. 
 
1. The comparison of CMR and echocardiographic findings  
Patients who took part in this study also underwent echocardiography at each Visit.  These 
results will be analysed and compared to CMR findings.  This will allow for comparison of LV 
mass and volume between the two modalities and will assess for evidence of diastolic 
dysfunction, an early findings in acromegalic heart disease that is not well demonstrated 
using current CMR techniques. 
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2. Further CMR work addressing the effect of GHD on LV mass and volume 
The results from this study suggest LVMi and EDV are reduced in ao-GHD.  Andreassen’s 
recent study demonstrated similar findings, although in that study the reduction in LVMi did 
not reach significance.  A larger study, powered to allow for the separate analysis of men and 
women separately, would help address this finding further. 
 
3. Impact of age on the cardiac consequences of GHD 
Hypertension and ischaemic heart disease are common causes of cardiac disease in older 
patients.  There are indications from several studies that patient age may impact on the 
findings seen, with changes more easily identifiable in younger patients than in older ones.  
This suggestion is confounded by the fact that studies in younger patients are more likely to 
include individuals with co-GHD.  A study designed to measure CMR-determined cardiac 
changes in patients ao-GHD stratified into younger and older ages bands would be helpful in 
addressing this hypothesis further.   
 
4. Aortic dimensions in patients with GHD 
This study is the first to demonstrate reduced ascending aorta area in patients with ao-GHD.  
The mechanism of this finding remains unclear, particularly as aortic areas to do not increase 
with GH therapy in the intermediate timeframe.  It would seen important to confirm this finding 
with further CMR studies in patients with ao-GHD.  Animal studies using dw/dw rats may be 
helpful in determining the mechanism by which this finding occurs and would allow for 
histological examination of the aortic tissue.   
 
5. The impact of ACE inhibitors on acromegalic cardiomyopathy 
The finding that patients with acromegaly in this study taking ACE inhibitors or ARBs have 
lower EDV than those not taking this family of drugs suggests that these agents may have 
disease modifying actions.  However, the numbers in this study were insufficient to draw 
statistically and clinically significant conclusions.  Ideally, this should be studied using a 
randomised control trial.  Given that current guidelines from the Italian COMETA study group 
already recommend these drugs as first-line antihypertensives, there may be ethical issues in 
producing such a study.  However, there may be a role for treating non-hypertensive patients 
with acromegaly with ACE inhibitors or ARBs, with a view to determining if these should be 
given to all patients with acromegaly.  It may also be possible to examine this hypothesis in 
mice, using bGH-transgenics and murine CMR. 
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The effects of growth hormone dysregulation on 
adenosine monophosphate-activated protein kinase in 
cardiac tissue 
 
Objectives 
• To determine the impact of acute GH and IGF-I excess on the cardiac AMPK activity 
in the GHD dw/dw rat and matching wild-type rats 
• To determine the impact of chronic GH excess on the cardiac AMPK activity in GH3 
cell-implanted rats and transgenic bGH-overexpressing mice 
• To determine the impact of chronic GH deficiency on the cardiac AMPK activity in 
GHRKO transgenic mice 
• To use primary neonatal rat cardiomyocytes to confirm the effects of GH and IGF-I on 
cardiac AMPK activity 
• To compare cardiac AMPK activity, as measured by a functional assay, with Western 
blotting for phosphorylated AMPK levels in cardiac tissue and cells 
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5 Materials and Methods 
 
• Full protocols are given in Appendix II 
• Italics indicate buffers and mixes whose exact components are given in Appendix II 
• All chemicals were supplied by Sigma unless specified otherwise 
 
5.1 Experiment summary 
To determine if any changes in cardiac AMPK activity occur with alteration in GH level, a pilot 
study was planned.  This involved the treatment of C57BL mice with six weeks GH treatment.  
This pilot was performed as part of a larger study designed to investigate the effect of GH on 
obesity in high fat diet fed mice, in which the cardiac tissue was not required, and hence 
would be available for the measurement of AMPK activity.  Mice fed with high fat diet 
demonstrated and increase in cardiac AMPK activity when treated with GH.  However, in this 
study, no mice fed with normal chow received GH.  The experiment was therefore repeated, 
this time containing a normal chow-fed arm treated with GH.  In the repeat, neither the chow-
fed nor the high fat diet animals demonstrated an increase in cardiac AMPK activity with GH 
treatment.  It was not clear why this difference was found between the two experiments.  As 
the author was already focussing on the effect of GH on cardiac tissue, and studies into the 
effect of high fat diet had never been planned, it was decided that only normal chow fed 
animals should be investigated in future experiments.  Furthermore, it was not clear whether 
the six week GH treatment reflected acute or chronic effects of GH on the heart.  To be better 
able to distinguish these effects, two separate groups of experiments were planned, to look at 
these timepoints separately.  It was also decided at this time to focus on the effect of GH on 
cardiac AMPK activity.  Other tissues collected from animals would not be studied for this 
thesis. 
 
The second animal model to be studied was the GH3-implanted rat.  These animals were 
raised, treated and sacrificed by Dr Herbert Schmid, Novartis.  The experiment was initially 
designed to address the effects of various somatostatin analogues on tumour size and 
disease control in GH3 rats.  The investigators provided cardiac tissue from these animals for 
AMPK measurement.  The timing for this experiment was determined by Dr Schmid and was 
determined prior to the results from the CB57 black mice being available.   
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In order to address the acute effects of GH on cardiac AMPK activity, rats were injected with 
IP GH or IGF-I.  To amplify any changes that might be seen, this was initially performed in GH 
deficient dwarf (dw/dw) mice.  However, when the experiments were repeated in wild-type 
rats, results were disconcordant.  Hence, the remainder of the acute studies were performed 
in WT animals. 
 
To examine the chronic effects of GH excess and deficiency on cardiac AMPK, two and eight 
month-old bGH-overexpressing and GHRKO mice were studied.  These timepoints were 
chosen to correlate with published studies describing the cardiac structure and function in 
bGH mice.  The ages were felt to represent the early and late effects of GH excess and 
deficiency.  The results from these models were disconcordant with a simultaneously 
published study looking at levels of pAMPK in the cardiac tissue of bGH mice.  As only 
cardiac AMPK activity had been measured in our tissues, they were re-studied by Western 
blotting for pAMPK levels.  This technique was then also applied to the cardiac protein 
solutions from the acute studies. 
 
The opportunity to work with neonatal rat cardiomyocytes became available towards the end 
of the studies.  This allowed for confirmation of the findings of the acute studies in an 
alternative model of GH excess, and allowed the focused examination of the effects of GH 
and IGF-I on the isolated cardiomyocyte.  Both cardiac AMPK activity and pAMPK levels were 
measured in this experiment. 
 
5.2 Animal models 
5.2.1 C57BL/6J and transgenic mice 
Male wild-type (WT) C57BL/6J mice and GH transgenic mice were supplied by Prof J 
Kopchick, Ohio University, Athens, Ohio, USA.  Bovine-GH-overexpressing heterozygotic 
transgenics were produced by microinjection of a gene fusion of a mouse metallothinein 
transcriptional regulatory element and bGH cDNA containing the first intron into the 
pronucleus of C57BL/6J embryos.  DNA analysis was used to confirm genotype.   Age-
matched littermates were used as controls.  This model is fully described in Berryman et al.284  
The GH receptor KO mouse (GHRKO) was made by disruption of the fourth exon of the 
GHR/binding protein gene by homologous recombination.  These mice were backcrossed for 
eight generations with C57BL/6J mice to give transgenics that were >99.61% congenic for the 
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C57BL/6J background.  DNA analysis was used to confirm genotype.  Age-matched 
littermates were used as controls.  This model was originally published by Zhou et al.285 
 
Animals were housed in cages kept on a 12 hour light, 12 hour dark cycle and received 
access to water and food ad libitum.  Animals were housed and treated at the Animal Facility 
of Ohio University (Athens, Ohio, USA). Sacrifice and dissection was performed by the staff of 
Ohio University.  All procedures were approved by the Ohio University Institutional Care and 
Use Committee and fully complied with federal, state, and local policies and UK import laws. 
 
5.2.2 Dwarf rats 
Male AS and dwarf rats were supplied by Prof I Robinson and Dr D Carmignac, the National 
Institute for Medical Research, Mill Hill, UK.  The dwarf (dw/dw) rat arose as a consequence 
of a spontaneous autosomal recessive mutation; the line has been continued for research 
purposes60.  Normal age-matched rats of the same mixed background strain (AS) were used 
as control animals.   
Animals were housed in cages kept on a 12 hour light, 12 hour dark cycle and received 
access to water and food ad libitum.  Animals were housed and treated at the Animal Facility 
of the National Institute for Medical Research, Mill Hill, UK in line with local and national 
animal care policies.  Sacrifice was performed by Dr D Carmignac, dissection was performed 
by the author. 
  
5.2.3 GH3-tumour implanted rats 
GH3-tumour implanted rats were supplied by Dr H Schmid, Novartis, Basil, Switzerland.  This 
is a long-established animal model of acromegaly in which cells from the GH and prolactin 
secreting GH3 cell line, a rat pituitary cell line, are injected subcutaneously in the flank of a 
rat57.  Here they increase in size, exposing the animal to excess GH, simulating acromegaly.  
In this case, female Wistar-Furth (WF) rats were injected with 5 x106 GH3 cells in 100µl 
diluent (50% Hank’s balanced salt solution / 50% Matrigel [BD Biosciences]) subcutaneously, 
in the right flank.  Once tumour size was 100-200mm3 (43-51 days) somatostatin analogue 
treatment was given.  Animals were treated with vehicle only or the somatostatin analogues 
octreotide long-acting release (LAR) or pasireotide LAR.  Animals were sacrificed day 35 post 
treatment with vehicle or somatostatin analogue. 
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Animals were housed in cages kept on a 12 hour light, 12 hour dark cycle and received 
access to water and food ad libitum.  Animals were housed and treated at the Animal Facility, 
Novartis, Basil, Switzerland, in line with local and national animal care policies.  Sacrifice and 
dissection was performed by the staff at Novartis. 
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5.3 Neonatal rat primary cardiomyocytes 
Three-day old Sprauge Dawley rat pups (Charles River) were sacrificed by cervical 
dislocation.  The heart was rapidly removed and placed in ADS buffer on ice.  Hearts were 
minced using fine scissors.  Enzyme solution, containing collagenase (Worthington) and 
pancreatin was added and the mixture was incubated in a 37°C.  The supernatant, containing 
blood and debris, was discarded.  Fresh enzyme was added and the tube returned to the 
waterbath.  After twenty minutes, the supernatant, this time containing released cells, was 
removed and re-suspended in a tube of foetal bovine serum (FBS), to inactivate the enzyme 
solution.  The sample underwent four further cycles of fresh enyme solution, incubation and 
supernatant aspiration, each time adding the supernatant to the flask containing FBS.  The 
contents of the flask were spun and the cell pellet re-suspended in warm FBS and incubated.  
Cells were plated in Primaria (BD Biosciences) petri dishes and cultured for one hour, prior to 
cells being replated and incubated.  Experiments were performed once cardiomyocytes were 
seen to be spontaneously beating on microscopy286,287. 
 
This technique was performed under the supervision of, and with assistance from, Dr S 
Brouilette, Centre for Translational Medicine and Therapeutics, William Harvey Research 
Institute, Queen Mary University of London. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 5.1 Neonatal cardiomyocytes.  Courtesy of Dr Scott Brouilette 
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5.4 Protein preparation  
5.4.1 Protein solution preparation from tissues 
Organs from sacrificed animals were flash frozen in liquid nitrogen and stored at minus 80°C.  
Tissue was homogenised in tissue lysis buffer (see Appendix for details) using the Precellys 
system (Stretton Scientific), which utilises ceramic beads and high-speed agitation. Protein 
content was determined using a bicinchoninic acid (BCA) kit (Pierce Perbio Science, #23227) 
and a Wallac plate reader. 
 
5.4.2 Protein solution preparation from cells 
Once cells had undergone treatment, the contents of each well was lysed with cell lysis buffer 
and wells were scraped.  Well contents were aspirated and then spun at 10,000 rpm for five 
minutes.  The fluid contents of the tube were aspirated and stored.  Protein content was 
determined as above. 
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5.5 Functional AMPK Assay 
AMPK protein was immunoprecipitated from cardiac tissue homogenate using G-protein 
beads (Amersham, #17-0618-01); 300 µg was mixed with AMPK α1 and α2 antibodies (Prof 
G Hardie, University of Dundee).  This was divided into three aliquots.  The first two were 
assayed for AMPK activity with Positive Master Mix, a γ32P-ATP (Perkin-Elmer, 
#NEG002A250UC) containing reaction solution containing SAMS (Upstate, #12-355).  SAMS 
is a synthetic substrate for AMPK which exactly corresponds to the AMPK binding site of 
cyclic-AMP-dependent protein kinase (Serine77) and is highly specific288.  The assay 
measures the ability of the AMPK contained within the protein to phosphorylate the SAMS 
contained within the reaction solution, by measuring the amount of γ32P transferred into the 
SAMS, hence determining AMPK activity.  The third aliquot was assayed with Negative 
Master Mix, an identical reaction solution with the exception that it contains Herpes-Brij buffer 
in the place of SAMS.  This determines the background level of AMPK activity, reflecting 
autophosphorylation, immunoglobulin phosphorylation and residual peptides not removed by 
immunoprecipitation, and acts as a negative control.   
 
The reaction was performed on a shaker for 20 minutes at 30°C.  Samples were then pipetted 
onto squares of P81 phosphocellulose papers (Millipore) and dropped into 1% 
orthophosphoric acid, to terminate the reaction.   Phosphorylated proteins, including SAMS, 
bind to the paper, while the remainder of the reaction solution is rinsed away.  Papers were 
dried and then counted by liquid scintillation (Wallac 1409 DSA).   AMPK activity was 
calculated using the difference in counts between the SAMS positive and the SAMS negative 
samples, expressed as nmol of ATP incorporated per minute per mg of protein. 
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5.6 Western blotting 
Western blotting was performed using 15-40 µg protein per lane, depending on the 
concentration of the protein and the well volume.  When total and phospho-protein were being 
compared, two identical gels were loaded and run simultaneously, to reduce the need for 
stripping.  SDS loading buffer was added to the maximum volume that the well would contain.  
Samples were briefly centrifuged and then heated to 95°C for 5 minutes to denature the 
protein.  Samples were centrifuged briefly again and then placed immediately on ice.  
Proteins were separated by electrophoresis on bis-tris (Invitrogen) gels.  With the exception of 
pACC blots, bis-tris 4-12% gradient gels were used.  A pre-stained molecular weight marker 
was run in parallel.  A commercial 2-(N-morpholino)ethanesulphonic acid (MES) running 
buffer was used (Invitrogen).  Gels were run for 15 minutes at 95 volts and then for an hour at 
125 volts.  Larger proteins were run for longer in an ice box.  
 
Separated proteins were transferred to a nitrocellulose gel using a semi-dry transfer, run for 
40 minutes at 0.4 A for a single gel or 0.8 A for two gels.  The membrane was placed in a 
50ml falcon tube with 40ml of milk-containing blocking buffer.  This was rolled at room 
temperature for 90 minutes to block non-specific binding sites.  The buffer was removed and 
primary antibody, diluted in blocking buffer, was added to the membrane.  Table 5.1 lists the 
primary and secondary antibodies used in these experiments.  The membrane was incubated 
with primary antibody overnight at 4°C.  The membrane was then washed with washing buffer 
before a secondary antibody was added, again diluted in blocking buffer.  As the secondary 
antibody was light sensitive, the falcon tube was wrapped in aluminium foil.  This rolled at 
room temperature for 90 minutes and then washed with washing buffer.   
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Primary Antibodies Company Dilution 
Phospho-ACC (Ser79), Rabbit mAb Cell Signalling, #3661 1:1000  
GAPDH (FL-335), Rabbit pAb Santa Cruz, #25778 1:2000 
AMPKα (23A3), Rabbit mAb Cell Signalling, #2603 1:1000 
Phospho-AMPKα (Thr 172), Rabbit mAb Cell Signalling #4188 1:1000 
Secondary Antibodies   
Anti-rabbit IgG (800CW), Goat pAb  Li-Cor, #926-32211 1:10,000 
Table 5.1 Primary and secondary antibodies 
 
The Odyssey Infrared Imaging System (Li-COR Biosciences) was used to read the 
membrane. The densitometric readings of the resultant bands were analysed using ImageJ 
(Image Processing and Analysis in Java) or directly using the internal Li-COR software. 
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5.7 Statistics 
Data were analysed using GraphPad Prism 5.0a. The Student’s t-test for single comparisons 
and ANOVA was used for multiple comparisons.  Figures are shown as mean ± SEM.  A p 
value of < 0.05 was considered significant.  * p < 0.05, ** p < 0.01, ***p < 0.001 
 
5.8 Suppliers 
 
Company Address 
Amersham GE Healthcare Life Sciences, Amersham Place, Little Chalfont, Bucks.  HP7 
9NA  
BD Biosciences Edmund Halley Road - Oxford Science Park, Oxford.  OX4 4DQ 
Calbiochem c/o CN Biosciences UK Ltd, Boulevard Industrial Park, Padge Road, 
Beeston, Nottingham.  NG9 2JR 
Cell Signalling New England Biolabs (UK) Ltd. 75-77 Knowl Piece Wilbury Way, Hitchin, 
Hertfordshire. SG4 0TY 
Invitrogen 3 Fountain Drive, Inchinnan Business Park, Paisley. PA4 9RF 
Perkin-Elmer Chalfont Road, Seer Green, Buckinghamshire.  HP9 2FX 
Pierce Perbio Science Thermo Fisher Scientific,  p/a Perbio Science UK Ltd, Unit 9 Atley Way, 
North Nelson Industrial Estate Cramlington, Northumberland NE23 1WA 
Li-Cor Li-Cor Biosciences Uk Ltd, St Johns Innovation Centre, Cowley Road, 
Cambridge, Cambridgeshire, CB4 0WS 
Millipore Suite 3 & 5, Building 6, Croxley Green Business Park, Watford. WD18 8YH 
Pharmacia c/o Pfizer Ltd, Ramsgate Road, Sandwich, Kent.  CT13 9NJ 
Santa Cruz Santa Cruz Biotechnology, Inc., Bergheimer Str. 89-2, 69115 Heidelberg, 
Germany 
Sigma The Old Brickyard, New Road, Gillingham, Dorset.  SP8 4XT 
Stretton Scientific Stretton House, Highstairs Lane, Stretton, Derbyshire.  DE55 6FD 
Upstate c/o Millipore, Suite 3 & 5, Building 6, Croxley Green Business Park, Watford. 
WD18 8YH 
Wallac c/o Perkin-Elmer, Chalfont Road, Seer Green, Buckinghamshire.  HP9 2FX 
Table 5.2 Suppliers of chemicals, equipment and antibodies  
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6 Pilot project: the effect of 6 weeks bGH treatment 
on cardiac AMPK activity 
 
6.1 Outline 
To assess the effect of GH on cardiac AMPK activity, 25 week-old C57BL/6J black mice were 
treated with subcutaneous (sc) bGH, 5 µg/g bodyweight daily for 6 weeks.  Animals were 
assigned to one of three treatment arms: normal diet + saline, high fat diet (HFD) + saline, 
HFD + GH.  Animals were housed in cages kept on a 12 hour light, 12 hour dark cycle and 
received access to water and food ad libitum.  Mice were bred and raised as described 
previously.  Mice were sacrificed by cervical dislocation and tissues flash frozen in liquid 
nitrogen.  Tissues were homogenised and protein content determined and cardiac and liver 
AMPK activity was measured by functional assay run in triplicate, using 300 µg per sample, 
as per the protocols in Materials & Methods (page 126).   
  
6.2 Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Mean cardiac AMPK activity in black mice treated normal chow or HFD 
and 6 weeks bGH treatment.  ANOVA 0.0132.  GH treatment caused a significant 
increase in AMPK activity.  Error bars show SEM. 
* 
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Results demonstrated a significant difference (ANOVA p=0.0132) in cardiac AMPK activity 
between the three groups (Figure 6.1) and a significant increase in AMPK activity in HFD + 
GH animals when compared to those treated with saline (0.316 ± 0.04 v. 0.205 ± 0.01 nmol 
ATP incorporated/min/mg protein).  There was no difference seen in liver AMPK activity 
(Figure 6.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.3 Summary 
The pilot study indicated that GH treatment is able to increase cardiac AMPK activity.  
However, the diets given to these animals confounded results that could be drawn and it was 
not clear whether bGH would have an effect on AMPK activity in mice fed a normal diet.  
Therefore, the experiment was repeated, this time including a normal diet + bGH group.   As 
discussed in Section 5.1, this experiment formed part of a larger study, seeking to address 
the effects of GH on obesity in high-fat fed mice, in which the cardiac tissue was available.  
The focus of our study was the effect of GH, rather than the effect of high-fat diet. 
 
The liver was analysed in this study as an example of metabolically active tissue.  As GH 
treatment did not produce a significant effect on liver AMPK activity, and as the focus of our 
clinical study was the effect of GH on the heart, it was decided to focus on cardiac tissue and 
cells in future experiments. 
* 
Figure 6.2 Liver AMPK activity in black mice treated with normal chow or HFD 
and 6 weeks bGH treatment.  No difference was seen between groups. 
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7 The effect of bGH treatment on cardiac AMPK 
activity of C57BL/6J mice receiving normal or high 
fat diet 
 
7.1 Outline 
Three-week old C57BL/6J mice were divided into two groups and received either normal 
chow or high fat diet (HFD) for 16 weeks.  The diet was then continued but half the mice in 
each diet group also received bGH 5 µg/g bodyweight sc daily for 6 weeks. Animals were 
housed in cages kept on a 12 hour light, 12 hour dark cycle and received access to water and 
food ad libitum. Animals were sacrificed at 25 weeks by cervical dislocation.  Tissues were 
homogenised and protein content determined.  Cardiac AMPK activity was measured by 
functional assay run in triplicate, using 200-300 µg per sample, as per the protocols in 
Materials & Methods.  Western blotting was performed on cardiac tissue lysates for pACC 
using 40 µg protein per lane. 
 
7.2 Results 
Neither normal chow-fed or HFD animals showed a significant difference in cardiac AMPK 
activity after 6 weeks bGH treatment when compared with saline-treated controls (ANOVA 
p=0.9425, Figure 7.1).  However, pACC was significantly increased in the bGH treated 
animals (bGH 6908 ± 886 v. controls 1766 ± 268 arbitrary density units; p=0.0005) suggesting 
exposure to increased AMPK activity (Figure 7.2).  These membranes did not respond well to 
stripping and re-blotting for GAPDH and so no housekeeping genes are recorded.   The size 
difference between pACC (257kDa) and GAPDH (37kDa) limits demonstration of both 
proteins on the same membrane.  The Western blot was repeated but this time demonstrated 
only multiple, non-specific bands, presumed to relate to protein degradation (Figure 7.3).  
Insufficient residual tissue was available to re-homogenise further protein solution.   
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257 kDa 
Figure 7.1 Cardiac AMPK activity in chow or HFD mice treated with bGH.  No 
differences was seen between the groups (ANOVA, p=0.943) 
Figure 7.2 Normal chow-fed mice treated with 5 µg/g bodyweight/day bGH (left) or 
saline (right), demonstrating increased pACC (250 kDa) in bGH treated animals 
(p=0.0005).  Gel loaded with 40 µg protein per well. 
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7.3 Summary 
This experiment failed to reproduce the AMPK activity findings of the pilot study, despite 
being done under identical conditions.  The reason for this discrepancy was not clear.  It was 
unclear whether six weeks of treatment reflected the acute effects of GH on AMPK activity or 
the early chronic effects.  Therefore, experiments were designed to examine the acute effect 
of GH/IGF-I on cardiac AMPK activity in dwarf and WT rats, and separate studies in GH3-
tumour implanted rats and transgenic mice were designed to address the chronic effect of GH 
excess and deficiency on the heart. 
 
As discussed in Section 5.1, this experiment formed part of a larger study, seeking to address 
the effects of GH on obesity in high-fat fed mice, in which the cardiac tissue was available.  
The focus of our study was the effect of GH, rather than the effect of high-fat diet. 
 
 
257 kDa 
Figure 7.3 Normal chow-fed mice treated with 5 µg/g bodyweight/day bGH or saline.  
Non-specific bands are seen throughout the gel.  There are no distinct bands at 257 
kDa, which would correspond with pACC. 
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8 Acute studies: The impact of acute growth 
hormone treatment on cardiac AMPK activity 
 
8.1 Outline 
Six week old dw/dw dwarf rats (weighing approximately 100 mg) were treated with 50 µg hGH 
intraperitoneally (ip) and then sacrificed at 1 hour, 6 hours or 24 hours.  Control dwarf rats 
were treated with saline.  Animals were sacrificed by cervical dislocation.  Tissues were 
collected and flash frozen in liquid nitrogen.  Hearts were quickly rinsed in saline prior to 
freezing to remove excess blood.  Cardiac AMPK activity was measured by functional AMPK 
assay.  As results were significant at 6 hours, the experiment was repeated at this timepoint 
but this time giving 25 µg recombinant human IGF-I.  Dwarf rats were chosen for this study to 
amplify any changes that might be seen.  To confirm the findings in animals with intact 
GH/IGF-I axes, the 6 hour experiments were repeated in six week old WT AS rats (weighing 
approximately 120 g).  As results with IGF-I treatment were not significant in these animals at 
6 hours, an IGF-I dose-curve was performed.  The results are given as percentage of controls 
to allow comparison between experiments performed on different days. 
 
8.2 Results 
GH injection produced a fall in cardiac AMPK activity in dwarf rats that did not reach 
significance at 1 hour (p=0.10) but did achieve significance by 6 hours (71% of control value, 
p=0.0038) and remained highly significant at 24 hours (62% of control value, p = 0.0003, 
Figure 8.1).  
 
Similar results were seen when the experiment was repeated at 6 hours using 25 µg human 
IGF-I instead on GH, with an 20% fall in cardiac AMPK activity compared to controls 
(p=0.0025, Figure 8.2).  This dose was chosen as previous work by Prof Robinson’s group 
indicated that a 50% decrease in dose is necessary for equivalent effect when using IGF-I 
instead of GH (personal communication from Prof ICAF Robinson). 
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** *** 
Figure 8.1 The acute effect of hGH on 6 week old dwarf rats when compared to saline-
treated controls, demonstrating a trend towards a reduction at 1 hour and a significant 
fall in cardiac AMPK activity by 6 hours, which decreased further by 24 hours. 
 
Figure 8.2 The acute effect of hIGF-I on 6 week old dwarf rats compared to saline-
treated controls, demonstrating a significant fall in AMPK activity in animals 
treated with hIGF-I for 6 hours 
** 
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Surprisingly, when the 6 hour experiments were repeated with WT AS rats, GH treatment had 
the reverse effect and resulted in a marked rise in cardiac AMPK activity (208% of controls, 
p=0.0027, Figure 8.3).  In WT rats, 25 µg IGF-I IP failed to cause a significant change in 
AMPK activity (p=0.658, Figure 8.3), possibly due to a lower dose/gram bodyweight in these 
larger rats.  Therefore, a dose curve was performed using 50 µg and 100 µg human IGF-I IP.  
Both of these doses resulted in a significant fall in the cardiac AMPK activity (84.64% and 
84.04%, respectively), in line with findings in dwarf rats but of a lesser magnitude (Figure 8.4). 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 8.3 The acute effects of 50 µg hGH and 25 µg hIGF-I on 6 week old AS rats 
showing a marked rise in cardiac AMPK activity at 6 hours with GH but no change 
with this dose of IGF-I. 
** 
Figure 8.4 Treatment of 6 week old AS rats with variable doses of hIGF-I 
demonstrating a significant fall in cardiac AMPK activity at 6 hours with both 50 µg 
and 100 mg doses.  ANOVA, p=0.011. 
 
** 
** 
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When WT and dwarf rats were compared directly with body-weight adjusted GH doses, there 
was no significant difference seen between WT rats treated with saline and WT rats treated 
with GH (p=0.690), and no significant difference between dwarf rats treated with saline and 
dwarf rats treated with GH (p=0.209, Figure 8.5).  There was no difference in cardiac AMPK 
activity between WT rats treated with saline and dwarf rats treated with saline (p=0.930).  The 
multiple groups in this experiment meant each group contained small numbers.   
 
 
 
 
 
 
Figure 8.5 Cardiac AMPK activity in WT (AS) or dwarf rats treated with body-weight 
adjusted doses of saline or hGH IP for 6 hours, demonstrating no significant 
difference between WT rats treated with saline and those treated with GH (p=0.690) 
and no significant difference between dwarf rats treated with saline and those treated 
with GH (p=0.209).  There was no difference between cardiac AMPK activity in WT and 
dwarf rats each treated with saline (p=0.930), suggesting that dwarf rats to do not 
have difference baseline cardiac AMPK activity than WT rats. 
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8.3 Summary 
The initial hypothesis that acute GH exposure causes an acute increase in cardiac AMPK 
activity was confirmed in AS rats, when 50µg hGH IP was able to induce a marked rise in 
AMPK activity at 6 hours.  However, surprisingly the converse finding was seen in dwarf rats.  
The dwarf rat was chosen as the initial model for this experiment as it was predicted that any 
results seen would be amplified by the GH-deficient state.  When experiments were repeated 
with WT animal, converse results were found.  This demonstrates the need for vigilance when 
drawing conclusion from models with altered physiology.   
 
Experiments with both dwarf and WT rats demonstrated a subtle but significant fall in cardiac 
AMPK activity with an optimised dose of hIGF-I treatment.  The finding in WT rats that GH 
and IGF-I induce opposite effects on cardiac AMPK activity suggests that GH and IGF-I have 
different direct actions on AMPK.  Furthermore, whereas GH has an opposite effect on 
cardiac AMPK activity in dwarf rats when compared to WT animals, the ability of IGF-I to 
lower cardiac AMPK activity persists in both models. 
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9 Chronic GH dysregulation model I: GH3-implanted 
rats 
9.1 Outline 
Female WF rats were implanted with 5 x106 GH3 cells, sc into the right flank.  When tumour 
size measured between 100-200 mm3, animals were treated with vehicle, octreotide LAR 80 
mg/kg sc once or pasireotide LAR 80 mg/kg sc once.  Control animals received the same 
treatments with the exception that they were not implanted with a GH3 tumour.  Body weight 
and tumour size were monitored and blood was taken for glucose levels.  Animals were kept 
in cages on 12 hour light – 12 hour dark cycles and had free access to food and water.  
Sacrifice occurred 35 days after treatment under isoflurane 5% anaesthesia.  Tissues were 
frozen in liquid nitrogen.  Animals were bred, treated and sacrificed by staff at Novartis, Basel, 
Switzerland. 
 
9.2 Results 
GH3-implanted animals showed a marked increased in body weight when compared to 
animals without tumours (GH3 & vehicle 354 ± 10.5 g v. Vehicle Only 187 ± 9.75 g) 
demonstrating clinical evidence of GH excess (Figure 9.1).  There was no difference in body 
weight between GH3-implanted rats treated with vehicle and those that received somatostatin 
analogues (incremental area under curve).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Effect of pasireotide LAR and octreotide LAR on body weight in female WF rats 
Figure 9.1 The effect of GH3 tumour implantation on WF rats demonstrating a clear 
increase in body weight with GH3 implantation, which was not ameliorated by either 
octreotide or pasireotide.  ANOVA, p<0.0001 
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Cardiac AMPK activity was significantly different between different groups (ANOVA, 
p=0.0002).  There was no difference in cardiac AMPK activity between Vehicle Only and GH3 
& Vehicle groups but there was a marked reduction in AMPK activity in each group treated 
with somatostatin analogues, Octreotide LAR and Pasireotide LAR, when compared to their 
relevant control group (Figure 9.1).  Neither of the somatostatin analogues was able to induce 
a significant reduction in GH3 tumour size (GH3 Only v. GH3 & Octreotide v. GH3 & 
Pasireotide, mean tumour volume 8.95 ± 1.78 v. 5.35 ± 1.01 v. 5.71 ± 2.82 cm3 respectively, 
ANOVA p = 0.4129, Figure 9.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.1 Cardiac AMPK activity in GH3-implanted WF rats demonstrating a fall in 
AMPK activity with both octreotide and pasireotide treatment. ANOVA, p=0.0002. 
* 
* 
** 
** 
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9.3 Summary 
Rats implanted with GH3 cells developed features of GH excess, as determined by increased 
body weight.  Treatment with long-acting pasireotide or octreotide did not reverse this finding, 
indicating that these animals still had ongoing GH excess. 
 
GH excess did not have any effect on cardiac AMPK activity when control and GH3-implanted 
animals were compared.  However, animals treated with long-acting somatostatin analogues 
had markedly reduced cardiac AMPK activity, whether or not GH excess was present.  This 
finding was unexpected and suggests an interaction between these drugs and the AMPK 
system.  Suppression of AMPK activity may explain some of the influence of these drugs on 
the cardiovascular system in acromegaly.  This is discussed further in section 12.6. 
 
 
Figure 9.2 Tumour growth in GH3-implanted WF rats showing no alteration in tumour size 
with octreotide or pasireotide treatment when compared to controls. ANOVA, p=0.413) 
Effect of pasireotide LAR and octreotide LAR on GH3 tumour size in rats 
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10 Chronic GH dysregulation model II: Transgenic 
bGH-overexpressing and GH receptor KO mice  
 
10.1 Outline 
The transgenic mouse model provides an alternative model of GH dysregulation.  GH excess 
was produced by the introduction of bGH cDNA into the pronucleus of C57BL/6J embryos.  
GHD was produced by disruption of the fourth exon of the GHR/binding protein gene resulting 
in functional knock out of the GHR.  Two groups of bGH-overexpressing mice and GHRKO 
mice were raised with age-matched controls.  The first was sacrificed at two months of age, 
the second at eight months.  These timepoints were chosen to reflect early and late 
acromegaly and to correspond with relevant studies in the literature.  Animals were housed in 
cages kept on a 12 hour light, 12 hour dark cycle and received access to water and food ad 
libitum.  Mice were bred and raised at the animal facility at Ohio University, Athens, Ohio, 
USA.  Mice were sacrificed by cervical dislocation and tissues flash frozen in liquid nitrogen 
by staff at this facility.  Hearts were rinsed in saline prior to freezing to remove excess blood.  
Tissues were homogenised, protein content determined and cardiac AMPK activity was 
measured by functional assay, using 200-300 µg per sample, as per the protocols in Materials 
& Methods. AMPK activity data are presented as percentage of controls to allow for 
comparison between groups of different genetic background and experiments performed on 
different days. 
 
AMPK activity results in this study were disconcordant with recent publications.  These had 
demonstrated increased cardiac AMPK phosphorylation at Threonine172 in three-month old 
bGH mice (n=5), usually considered to be a marker of increased AMPK activity.  Our AMPK 
activity assay did not demonstrate any differences in bGH mouse cardiac tissue.   We 
therefore undertook Western blotting to investigate this further.  This was performed using 
antibodies for pAMPK and tAMPK, with 15-20 µg protein per sample.  Each protein was 
corrected for GAPDH and results were expressed at pAMPK/tAMPK.  Protocols are given in 
Materials & Methods. 
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10.2 Results 
10.2.1 Model comparisons 
GHRKO animals had reduced body weight compared to littermate controls at both two 
months (10.5 v. 23.7 g, p<0.0001) and eight months (18.0 v. 34.9 g, p<0.0001).  Bovine-GH 
transgenics demonstrated increased bodyweight compared to littermate controls at both two 
months (35.9 v. 23.2 g, p<0.0001) and eight months (51.1 v. 35.1 g, p<0.0001).  There was 
no difference in bodyweight at either timepoint between the two control groups (Figure 10.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.1 Comparison of body weights of bGH and GHRKO mice and their littermate 
controls at 2 months and 8 months.  bGH transgenics have significantly increased body 
weight at both timepoints; GHRKO transgenics have significantly reduced body weight at 
both timepoints.  No difference is seen between the two control groups. 
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There was evidence of cardiac hypertrophy, as demonstrated by an increase in heart mass 
as a percentage of total body mass, in bGH transgenics compared to controls at both two 
months (0.52 v. 0.47 %, p=0.0008) and at eight months (0.62 v. 0.52%, p=0.0096).  At two 
months there was no difference in cardiac weight as a proportion of body weight in GHRKO 
mice.  However, by 8 months, transgenics had significantly smaller hearts as a proportion of 
their body weights compared to controls (0.39 v. 0.54%, p=0.0003).  At neither timepoint was 
there any difference in cardiac weight as a percentage of body weight between the two 
control groups (Figure 10.2).   
 
 
 
 
 
 
Figure 10.2 Heart weight as a percentage of body weight in transgenic mice.  At 2 and 
8 months bGH transgenics demonstrate cardiac hypertophy when compared to 
littermate controls.  By 8 months GHRKO transgenics have reduced heart to body 
weight ratio that is not seen at 2 months 
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10.2.2 AMPK activity 
At two months of age there was no difference in cardiac AMPK activity between bGH 
transgenics and their littermate controls (p=0.716) and no difference between GHRKO 
transgenics and their littermate controls (p=0.812) (Figure 10.3).  At eight months there was 
still no difference bGH transgenics and their littermate controls (p=0.196) and no difference 
between GHRKO transgenics and their littermate controls (p=0.846) (Figure 10.4). 
 
 
 
 
Figure 10.3 Cardiac AMPK in transgenic mice at 2 months showing no difference 
between bGH transgenics and their controls (p=0.716) and GHRKO transgenics and 
their controls (p=0.812). 
Figure 10.4 Cardiac AMPK in transgenic mice at 8 months showing no difference 
between bGH transgenics and their controls (p=0.196) and GHRKO transgenics and 
their controls (p=0.846). 
Cardiac AMPK in 8 month old transgenic mice 
Page 153 of 238 
 
10.2.3 Animal age 
Two month old animals were compared directly with eight month old animals, on the same 
assay, to see if age impacted on cardiac AMPK activity.  Healthy control animals (bGH 
littermates) showed a trend towards a reduction in cardiac AMPK with age, so that at eight 
months cardiac AMPK activity was 62.1% of what it had been at two months (p=0.056).    
Bovine-GH transgenics showed a trend towards the opposite finding, so that by eight months 
cardiac AMPK activity was 132 % of two month levels (p=0.083).  
 
10.2.4 Western blotting 
Two month old bGH transgenics demonstrated a significant increase in Thr172 pAMPK levels 
when compared to controls (p=0.014, Figure 10.5, Figure 10.6, Figure 10.7).  However, by 
eight months this finding was reversed and bGH mice had significantly reduced pAMPK levels 
compared to controls (p=0.036, Figure 10.8, Figure 10.9, Figure 10.10).  The findings are 
presented as pAMPK/tAMPK, each corrected for GAPDH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
62 kDa 
37 kDa 
Controls bGH transgenics 
Figure 10.5 Western blot of cardiac protein from 2 month old bGH transgenics and their 
controls, demonstrating pAMPK at 62 kDA, corrected to GAPDH at 37 kDa. 
Figure 10.6 Western blot of cardiac protein from 2 month old bGH transgenics and their 
controls, demonstrating tAMPK at 62 kDA, corrected to GAPDH at 37 kDa. 
Controls bGH transgenics 
62 kDa 
37 kDa 
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* 
Figure 10.7 Results from Western blot for cardiac pAMPK levels in 2 month old bGH 
transgenic mice, showing a significant increase in transgenics compared to controls 
(p=0.014).  Data are given as pAMPK/tAMPK, each having been corrected to GAPDH. 
Controls bGH transgenics 
62 kDa 
37 kDa 
Controls bGH transgenics 
62 kDa 
37 kDa 
Figure 10.8 Western blot of cardiac protein from 8 month old bGH transgenics and 
their controls, demonstrating pAMPK at 62 kDA, corrected to GAPDH at 37 kDa. 
Figure 10.9 Western blot of cardiac protein from 8 month old bGH transgenics and 
their controls, demonstrating tAMPK at 62 kDA, corrected to GAPDH at 37 kDa. 
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Figure 10.10 Results from Western blot for cardiac pAMPK levels in 8 month old bGH 
transgenic mice, showing a significant decrease in transgenics compared to controls 
(p=0.036).  Data are given as pAMPK/tAMPK, each having been corrected to GAPDH. 
* 
Page 156 of 238 
 
Two month old GHKRO transgenic mice demonstrated a trend towards increased cardiac 
pAMPK levels but the levels did not achieve significance (p=0.093, Figure 10.11).  When 
further studies with the four remaining samples in the group were performed and combined 
with these results, the analysis still remained non-significant (p=0.13).  Eight month old 
GHRKO mice demonstrated a trend towards reduced cardiac pAMPK levels, which again 
failed to reach significance (p=0.14, Figure 10.12) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10.11 Western blot for cardiac pAMPK levels in 2 month old GHRKO transgenic 
mice, showing a trend towards increased pAMPK levels in transgenics (p=0.093).  Data 
are given as pAMPK/tAMPK, each having been corrected to GAPDH. 
Figure 10.12 Western blot for cardiac pAMPK levels in 8 month old GHRKO transgenic 
mice, showing a trend towards reduced pAMPK levels in transgenics (p=0.14).  Data are 
given as pAMPK/tAMPK, each having been corrected to GAPDH. 
Page 157 of 238 
 
10.3 Summary 
Functional AMPK assay failed to demonstrate any alteration in cardiac AMPK activity levels in 
bGH or GHRKO transgenic mice at either two or eight months of age.  However, Western 
blotting was able to demonstrate increased pAMPK levels in two month old bGH transgenics 
and reduced pAMPK levels in eight month old animals.  GHKRO transgenics demonstrated a 
similar pattern, increased pAMPK in two month animals and reduced pAMPK in eight month 
animals, although the results failed to achieve stastical significance. 
 
The disconcordance between the functional AMPK assay and Western blotting for pAMPK 
was not expected as usually these methods are reported as being concordant.  This is 
reviewed in the Discussion. 
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11 AMPK activity in neonatal rat primary 
cardiomyocytes treated with GH or IGF-I 
 
11.1 Outline 
Unstarved neonatal rat cardiomyocytes, prepared as given in Methods and Materials, were 
plated in 6 well plates, each containing 2 ml media (6 x 105 cells per well)206.  Three days after 
harvesting, cells were treated with hGH 1 µg/ml (Gentotropin, Pharmacia #0022/0071)289,290, 
hIGF-I 75 ng/ml (Sigma #I3769)88,291,292, AICAR 1 mM (Calbiochem #123040)293 or vehicle 
alone and incubated for six hours.  Cells were lysed using cell lysis buffer and protein content 
quantified using BCA assay.  Functional AMPK assay was performed in duplicate/triplicate 
using the maximum volume of protein solution available.  The experiments were repeated on 
three occasions.  AMPK activity data are presented as percentage of controls to allow for 
comparison of experiments performed on different days.  Western blotting for pAMPK and 
tAMPK was also performed on the protein solution. 
 
11.2 Results 
This experiment was run three times.  On the first two occasions six replicates were used.  
On the third occasion, nine replicates were used.  Only the third experiment demonstrated 
significant findings (ANOVA, p=0.048), with hGH treatment increasing AMPK activity 
compared to controls (p=0.032, Figure 11.0).  When the results of the three experiments were 
combined, hGH treatment resulted in a significant increase in cardiac AMPK activity when 
compared to both controls and to hIGF-I treated cells (Figure 11.1).  There was no significant 
difference between the control group and the IGF-I treated group. 
 
Western blotting for pAMPK levels was performed on protein solutions from the third 
experiment (Figure 11.2, Figure 11.3, Figure 11.4, Figure 11.5).  This demonstrated differing 
results from the functional assay.  Here there was a significance difference across all groups 
with treatment (ANOVA, p=0.0015).  There was a significant increase in pAMPK in the IGF-I 
groups compared to the control group and the AICAR group compared to the control group.  
There was a trend towards increased pAMPK in the GH group compared to the control group 
but this difference failed to achieve significance (Figure 11.6).  However, as can be seen from 
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Figure 11.2, there appears to a slight loss of bands which may have contributed towards this 
disconcordance.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.0 Neonatal cardiomyocytes treated with GH, IGF-I or AICAR from experiment three.  
There is a significant difference between groups, ANOVA, p=0.048.  There is a significant 
difference between the control and the GH-treated group. 
* 
Figure 11.1 Pooled results from experiments with neonatal cardiomyocytes treated with 
GH, IGF-I or AICAR.  There is a significant difference between groups, ANOVA, p=0.016.  
There is a significant difference between the control and the GH treated group and between 
the GH treated group and the IGF-I treated group.  AICAR is not shown as this duration of 
this treatment varied between experiments and so the experiments were not comparable. 
 
* * 
Rat neonatal cardiomyocytes treated with GH or IGF-I for 6 hours 
Combination of three separate experiments 
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Figure 11.4 Western blot of Thr172 pAMPK levels in neonatal rat cardiomyocytes  
treated with IGF-I or AICAR, demonstrating pAMPK at 62 kDA, corrected to GAPDH 
at 37 kDa 
 
Figure 11.5 Western blot of Thr172 tAMPK levels in neonatal rat cardiomyocytes  
treated with IGF-I or AICAR, demonstrating tAMPK at 62 kDA, corrected to GAPDH 
at 37 kDa 
62 kDa 
37 kDa 
Vehicle hGH 
62 kDa 
37 kDa 
Vehicle hGH 
62 kDa 
37 kDa 
IGF-I AICAR 
62 kDa 
37 kDa 
IGF-I AICAR 
Figure 11.3 Western blot of Thr172 tAMPK levels in neonatal rat cardiomyocytes  
treated with vehicle or hGH, demonstrating tAMPK at 62 kDA, corrected to GAPDH at 
37 kDa 
Figure 11.2 Western blot of Thr172 pAMPK levels in neonatal rat cardiomyocytes  
treated with vehicle or hGH, demonstrating pAMPK at 62 kDA, corrected to GAPDH at 
37 kDa 
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11.3 Summary 
Functional assay demonstrated an increase in AMPK activity with GH treatment.  No 
significant difference was seen with IGF-I or AICAR treatment.  When the same protein 
solutions underwent Western blotting, a significant increase in Thr172 pAMPK levels in cells 
treated with IGF-I or AICAR was seen.  Increases in Thr172 pAMPK levels with GH treatment 
did not achieve significance, although a trend was present. 
Figure 11.6 Cardiac AMPK phosphorylation levels as determined by Western blotting.  
There are significant differences between the groups, ANOVA p=0.0015.  Both IGF-I 
and AICAR treatment induced a significant increase in pAMPK levels when compared 
to controls.  GH treatment showed a trend towards increased levels.  Results are 
given as pAMPK/tAMPK, each normalised to GAPDH. 
* 
*** 
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12 Discussion  
 
12.1 Pilot studies 
The pilot study demonstrated that six weeks of GH is able to activate cardiac AMPK in mice 
fed a high fat diet (Figure 6.1).  However, repetition (Figure 7.1) failed to reproduce these 
findings, even though the same conditions were maintained throughout both experiments and 
homogenisation, protein quantification and the AMPK assay were done by the author on both 
occasions, following the same protocols.  The reasons for this are not clear.  Study mice were 
from the same genetic background in both experiments and were raised at the same facility.  
The same doses of bGH were used, although batch numbers differed. 
 
The presence of increased pACC protein in the bGH-treated cardiac tissue in the repeated 
experiment suggests that these tissues have been exposed to increased AMPK activity.  ACC 
is regarded as the main downstream target of AMPK138 and there is no evidence that it can be 
directly phosphorylated by GH/IGF-I, although this is an area not addressed by the literature.  
It is known that amplification occurs along the AMPK pathway so that very subtle increases in 
AMPK activity may have much larger effects on ACC phosphorylation.  This could, in part, 
explain this incongruous finding.  Alternatively, this result could reflect that the tissue has 
previously been exposed to increased AMPK activity, with a persistence of a measurable 
pACC rise.  Acute exposure to exercise has been shown to induce a temporary cardiac 
AMPK activity rise in mice183 that is not longer seen with longer-term training88.  It may be 
hypothesised that duration of exposure to GH affects AMPK activity, with acute exposure 
resulting in an increased activity that is lost as tolerance develops.  By six week of GH 
treatment, AMPK tolerance has developed to acute GH excess but there is inadequate 
development of cardiomyopathy for it to influence AMPK activity.  In order to separate out 
these two timepoints and address this question, experiments to look at both the acute and 
chronic effect of GH/IGF-I on cardiac AMPK activity were designed.  
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12.2 Acute GH excess  
Acute treatment of both dwarf and WT AS rats with GH or IGF-I resulted in significant 
changes in AMPK activity, indicating that the GH/IGF-I axis interacts with the AMPK system in 
the acute setting.  The ability of a single dose of GH to markedly increase cardiac AMPK 
activity in WT rats fits with our initial hypothesis that GH causes an acute rise in AMPK 
activity.  Furthermore, the effect of GH on cardiac AMPK activity appears to be a direct action, 
as treatment with IGF-I failed to reproduce it.  Findings that acute GH treatment increases 
AMPK activity were confirmed by performing similarly timed experiments in primary neonatal 
rat ventricular cardiomyocytes.  Although the HL-1 cardiac cell line expresses the GH 
receptor and has been used with good effect in the study of cardiac functioning, signalling 
and metabolism294, we have not been able to measure AMPK activity this line.  Therefore, we 
chose to use primary neonatal rat cardiomyocytes for these experiments as it was felt they 
would be more suitable for a functional assay.  One weakness of this model is that cells 
mainly express the neonatal V3 myosin isoform rather than the adult V1 form, limiting 
conclusions that can be drawn295.  Interestingly, chronic GH excess in rats with GH3 tumours 
causes the same shift towards foetal myosin isoforms296.  In addition, these cells carry all the 
usual challenges of working with primary cells rather than an immortalised line.  However, 
they are a well-established model and provide reproducible results.  It should be noted that 
Western blotting results in these cells did not appear congruous with functional assay results.  
This may in part reflect some loss of bands on the GH blot.  Insufficient quantities of protein 
remained to perform further blots.  The difference between findings on functional AMPK 
assay and Western blotting is discussed later. 
 
The only published study looking at the direct effect of GH on AMPK failed to show any effect 
of GH on pAMPK levels in endothelial cells66.  As reviewed in the Introduction, this may be 
due to serum starvation that the cells were subjected to prior to treatment206.  Alternatively, 
this may represent tissue specific effects of GH, resulting in variable effects in different cells.  
The lack of published data in this field make the finding that GH increase cardiac AMPK 
activity in two models particularly interesting but clearly indicates a need for further studies in 
this area. 
 
The discovery that GH had an opposite effect on cardiac AMPK activity in GHD dwarf rats 
than in WT rats was not predicted.  These animals are known to have cardiac consequences 
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arising from GHD, specifically, reduced cardiomyocyte size, cardiac structure and myocardial 
contractility, which improve with GH treatment61.  It remains unclear whether the effect seen 
on cardiac AMPK activity in the dwarf animal is a true effect of GH on cardiac AMPK activity 
in a GHD-state or if it represents a peculiarity of this model.  Certainly, any conclusions drawn 
should be done so with caution.  Studies that have been published with these animals tend to 
concentrate on the cardiac effects of GH on the dwarf itself, without any direct comparison to 
WT rats61,297,298.  In order to determine if this is a model-related effect, studies in other animal 
models of GHD are needed.  
 
If GH treatment in patients with GHD is confirmed to be associated with a fall in cardiac 
AMPK activity, it remains to be demonstrated how long this effect persists and why it occurs.  
One potential explanation is that the heart in the GHD individual exists in perpetual state of 
metabolic “stress”; replacing GH ameliorates this stress with a reactive fall in AMPK activity.  
Both defining and determining the presence of metabolic stress cause challenges.  One 
method examining myocardial metabolic stress is to use cardiac MRS to look at PCr:ATP 
ratios, as a marker of energy availability.  A reduction in PCr:ATP ratio occurs in diabetes 
prior to the development of demonstrable heart disease, indicating that this finding is very 
early marker of cardiac problems299.  The only study that has used cardiac MRS to assess the 
GH/IGF-I axis treated isolated rat hearts with IGF-I43.  This study failed to demonstrate any 
effect of IGF-I on myocardial energy supply, although it should be noted that exposure time 
was only 20 minutes.  There are no studies addressing cardiac or skeletal muscle MRS in 
patients with GHD.  This is an area that warrants further research (see page 123). 
 
An alternative method of assessing myocardial stress is to look for early signs of physiological 
dysfunction, which may be done by measuring N-terminal pro-B-type natiuretic peptide (pro-
BNP).  This peptide is a marker of increased ventricular wall stretch, a prelude to systolic 
heart failure, increased volume expansion and diastolic dysfunction300-302.  However, the only 
study to date in this area demonstrated that patients with GHD do not have alterations pro-
BNP, either before or after GH treatment132.  
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Our animal studies did not demonstrate any baseline difference between cardiac AMPK 
activity in WT and dwarf rats, although numbers were small (Figure 8.5).  If chronic GHD 
produced cardiac metabolic stress it would be predicted that dwarf animals would have a 
higher baseline AMPK activity level.  The reasons for the fall in cardiac AMPK activity seen in 
dwarf rats treated with GH remains unclear. 
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12.3 Acute IGF-I treatment 
In both WT (AS) and dwarf rats, acute IGF-I treatment decreased cardiac AMPK activity.  This 
was a consistent finding over several experiments, although higher IGF-I doses were 
necessary to achieve this finding in WT rats, which may relate to an increased volume of 
distribution, secondary to size.  This finding was not seen in neonatal cardiomyocytes, where, 
despite a significant increase in cardiac AMPK activity with GH treatment, there was no 
difference between IGF-I treatment and the control group (Figure 11.1).  Conversely, Western 
blotting demonstrated increased Thr172 pAMPK levels in neonatal cardiomyocytes treated 
with IGF-I  
 
The reduction in AMPK activity with IGF-I treatment seen in the animal studies is likely to 
occur due to IGF-I induced phosphorylation of AMPK serine 485 (Ser485), with a 
consequential reduction in Thr172 phosphorylation reducing AMPK activity.  This effect has 
already been demonstrated in vascular smooth muscle cells treated with IGF-I205.  Insulin, 
which shares many effects with IGF-I due to partial homology and receptor cross-activation, 
has been shown to reduce cardiac AMPK activity through this mechanism202-204.  However, at 
present there is only one published study demonstrating that IGF-I phosphorylats Ser485 and 
this was not performed in cardiomyocytes.  Since human fibroblasts treated with IGF-I 
demonstrate both increased AMPK activity and Thr 172 pAMPK levels the possibility of 
tissue-specific effects of IGF-I on AMPK needs to be considered303.  
 
In this study WT rats required an IGF-I dose 50 µg to elicit a fall in AMPK activity, a dose 
equivalent to 417 µg/kg.  Children with Laron syndrome received IGF-I replacement doses 
that range between 80 – 240 µg/kg a day304,305.  Although, parallels that can be drawn 
between rat studies and human treatment doses are limited, this much higher IGF-I dose 
requirement to induce AMPK activation in rats may indicate that the effect was the result of 
insulin receptor activation rather than IGF-I receptor activation.  In a study of patients with 
type 1 diabetes, IGF-I treatment with 100 µg/kg a day maintained stable glycaemia and yet 
reduced insulin requirements by 45%, indicating that the doses of IGF-I used in our study 
should be adequate to activate the insulin receptor306.  Delineating the respective roles of the 
IGF-I and insulin receptors is complicated by the marked cross-talk between these systems.  
The insulin receptor and IGF-I receptor may exist as a hybrid dimer and in the heart up to 
90% of receptors may exist in the hybrid form307.  In vascular smooth muscle cells these 
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hybrid receptors are activated by physiological concentrations of IGF-I308.  The selective 
cardiac insulin receptor knockout (CIRKO) mouse could be used to address this question 
further.  CIRKO mice are unable to increase cardiac AMPK activity in response to exercise, 
whereas those with cardiac IGF-I receptor KO retain this ability88, suggesting that the insulin 
receptor, rather than the IGF-I receptor, is the doorway to AMPK activation.  CIRKO is a 
cre/loxP mouse that demonstrates a degree of cardiac abnormality, mainly reduced cardiac 
size due to reduced cardiomyocyte area and persistence of foetal β-myosin heavy chain 
isoform but also demonstrates impairment of cardiac output and power, ejection fraction and 
fractional shortening309, hence results from studies need to be interpreted with caution.   
 
An alternative model for studying this question would be the insulin receptor substrates (IRS)-
1 KO mouse.  IRS-1 is the major substrate of the insulin receptor.  IRS-1 knockout mice are 
viable and, although growth-retarded, have histologically normal heart310.  However, it must 
be noted the IRS-2 is still functional in these models and insulin can activate the PI3K 
pathway through phosphorylation of this substrate311.  Furthermore, the reduction of insulin’s 
actions may have a wealth of cardiovascular effects that impact on the AMPK system.  
 
The supraphysiological doses of IGF-I given to these rats might explain the discordance 
between the results from our animal studies and cell studies, in which more doses of IGF-I 
more comparable with human circulating levels were used (75 ng/ml).  However, it should be 
noted that Ning et al. demonstrated an increase in AMPK Ser485 phosphorylation and a 
reduction in Thr172 phosphorylation with only 10 ng/ml IGF-I in vascular smooth muscle 
cells205.  Whether or not this effect also occurs in cardiomyocytes remains to be elucidated.  
Ning only measured AMPK phosphorylation levels and did not demonstrate AMPK activity 
with a functional assay.  One limitation of using neonatal rat cardiomyocytes is the relatively 
low protein yield per pup requiring a large number or pups to be sacrificed to produce enough 
protein for a functional assay, which requires 200 – 300 µg protein per sample.  An alternative 
method for clarifying that the changes in phosphorylation seen did indeed have biological 
effect would be Western blotting for pACC.  Although this method requires much lower 
quantities of protein, pACC is a large protein, measuring 257 kDa, bringing technical 
challenges to producing good results.  Western blotting for Ser485/491 would be useful in 
confirming the effect seen in WT and dwarf rats with IGF-I treatment occurs via the 
mechanism discussed above.   
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12.4 Chronic GH excess 
Transgenic bGH-overexpressing and GHRKO mice demonstrated the phenotype of their GH 
status.  Bovine-GH transgenics had increased body weight and cardiac hypertrophy at both 
two eight months (Figure 10.1 and Figure 10.2).  GHRKO transgenics had reduced body 
weight and reduced cardiac mass as a percentage of body weight at eight months (Figure 
10.1 and Figure 10.2).  However, no alterations in cardiac AMPK activity were seen when 
transgenics were compared to littermate controls at two months or at eight months.  These 
timepoints were chosen to reflect early and late GH-related cardiac disease.  By eight months 
the bGH transgenic already demonstrates metabolic disruption in the heart, as shown by 
reduced PCr:ATP ratio, and evidence of reduced systolic function312. 
 
A recent study from Bogazzi et al. shows increased cardiac pAMPK in three month old bGH-
overexpressing mice when compared to age-matched littermates but this difference was lost 
by nine months174. It should be noted that although pAMPK levels in Bogazzi’s nine month old 
mice were no different from controls, pACC was reduced when compared to controls 
suggesting a fall in AMPK activity.  With only five animals in each group it may be that the 
experiment was insufficiently powered to demonstrate a measurable decrease in cardiac 
pAMPK levels313.  Reasons for the normalisation of AMPK activity with time in these studies 
remain unclear.  It may be that although acute GH exposure is associated with increased 
AMPK activity, cardiac tissue acclimatises to chronic GH/IGF-I excess resulting in 
normalisation of AMPK activity.  Alternatively, a mixed picture may be occurring with falling 
AMPK activity from a failing, cardiomyopathic heart cancelling out the GH/IGF-I drive to 
increased AMPK activity.  However, as eight month old bGH-overexpressing mice have 
reduced cardiac energy status when measured by PCr:ATP ratio312 and falls in PCr:ATP ratio 
have been associated with increased AMPK activity in pressure-overloaded rat hearts174, it 
would be predicted that cardiac AMPK activity would be raised in the hearts of the eight 
month old bGH transgenic mice.   
 
The mice used in Bogazzi’s study were from a different source from ours but were made by 
similar protocol on the same C57B background.  It was predicted that we would demonstrate 
similar findings in our mice when cardiac AMPK activity was measured by functional assay.  
However, no difference in cardiac AMPK activity was seen between bGH transgenics and 
their controls at either two or eight months.  As these results neither seemed consistent with 
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our hypothesis nor the published literature, Western blotting was performed for Thr172 
pAMPK levels.  This showed a significant increase in cardiac pAMPK levels in two month old 
transgenics and a trend towards reduced cardiac pAMK in eight month old transgenics, 
results similar to those published in Bogazzi’s paper.  The incongruent results between 
functional AMPK assay and Western blotting for pAMPK have not previously been reported.  
The functional kinase assay, which utilises the ability of phosphocelluose paper to bind 
phosphorylated protein, is a well established method of quantifying enzyme activity314.  In 
order to achieve specificity for AMPK activity, enzyme is immunoprecipitated using AMPK-α1 
and AMPK-α2 antibodies and SAMS, a specific target peptide for AMPK, is used as a 
substrate for phosphorylation288.  To exclude the consequences of phosphorylation arising 
from basal AMPK activity, samples are run that do not include this target peptide and this 
value is subtracted from the results gained.  However, as with all enzymes measurements, 
the method of collecting the samples remains important.  Stress to the animal prior to 
sacrifice or dissection without extremely rapid cooling to prevent enzyme activity is essential.  
Ideally, samples are processed immediately post-sacrifice, however, often this is not feasible.  
Furthermore, the steps of homogenisation and immunoprecipitation take some time, 
especially when a large experiment is being performed, making freezing between stages 
essential.  In all the experiments performed here, samples were used as early as possible 
and care was taken to expose tissues and protein samples to minimal freeze-thaw cycles.  
Despite these limitations, the AMPK functional kinase assay is still regarded as the gold 
standard in the assessment of AMPK as it measures actual activity, rather than 
phosphorylation, a surrogate marker of activity (Prof G Hardie, personal communication to M 
Korbonits).  For this reason, this method was used as our primary method for investigating 
AMPK in these experiments.  
 
Bogazzi’s paper used the other common method of measuring AMPK, Western blotting for 
Thr172 pAMPK levels.  This method is also well established for the investigation of AMPK.  It 
is based on the assumption that AMPK activity is determined by phosphorylation of Thr172315.  
Publications in the area of AMPK contain a mixture of results from the functional kinase assay 
and Western blotting for pAMPK.  Few papers publish both results, although in those that do, 
results from the two methods are congruous, including those from our labarotory316,317.  There 
have not been any reports of disconcordance between the two methods and the reasons for 
this occurrence here remain unclear.  However, the neonatal cardiomyocyte experiments also 
demonstrated disoncordance.  This was particularly marked with IGF-I treatment, which 
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appeared to trend towards reduced AMPK activity, in line with dwarf rat experiment results, 
but showed significantly increased levels of Thr172 pAMPK.   
 
It has been noted that the method of preparing tissue may affect the levels of pAMPK.  Mice 
killed by cervical dislocation have 8-fold higher levels of brain pAMPK levels than those killed 
by focused microwave irradiation to the brain318.  However, these findings were on Western 
blotting and there is no reason to predict they would differ from a functional assay.  
Furthermore, as all our animals were sacrificed using a consistent method, ongoing enzyme 
activity post-sacrifice does not explain the discrepancy in our results.  It should be noted, in all 
our experiments, functional kinase assay was performed prior to Western blotting for pAMPK 
levels, meaning that samples underwent an additional freeze-thaw cycle prior to Western 
blotting.  If ongoing enzyme activity were occurring, this would reduce the significance of 
findings at Western blotting rather than increase them. 
 
As discussed earlier, insulin and IGF-I are able to reduce AMPK activity through 
phosphorylation of Ser485205.  One possible mechanism for the discordance seen between 
our functional assay and Thr172 pAMPK levels is that the increased levels of IGF-I in these 
chronic models of GH excess is phosphorylating Ser485 in addition to Thr172, resulting in 
increased levels at Western blotting but no increase in activity.  However, experiments 
indicate the mechanism through which Ser485 phosphorylation exerts its inhibitory effect on 
AMPK activity is through reduction of Thr172 phosphorylation205.  Hence even if Ser485 
phosphorylation were affecting AMPK activity, results from Thr172 pAMPK levels and AMPK 
activity assays would be congruous.   
 
Another possible explanations for this incongruity is that the kinase assay was not functioning 
correctly.  However, the author performed all the AMPK assays, using the same protocols 
and chemicals on all occasions.  Other experiments performed simultaneously to these 
demonstrated marked changes in AMPK activity levels indicating the assay was working well.  
There is no reason to believe assay fault contributed towards these findings, although this 
would be the most straight forward answer to the conundrum. 
 
Previous work has demonstrated a clear association between phosphorylation of Thr172 and 
AMPK activity.  It remains possible that further phosphorylation sites exist that do not affect 
Thr172 phosphorylation but impact AMPK activity.  The animal models used in this 
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experiment are chronically exposed to GH, which a consequential increase in IGF-I levels.  
As in acromegaly, it is clear that these animals have multiple chronic metabolic and 
physiological consequences of these changes.  This long duration of exposure may affect the 
AMPK complex in a way that acute exposure to GH and IGF-I did not.  The most commonly 
measured target of AMPK is pACC.  Western blotting for this protein could help determine 
whether or not Thr172 pAMPK levels were actually reflecting AMPK activity.  It should be 
noted that, in common with other kinase systems, amplification occurs along this pathway, so 
even subtle changes should be measurable.  Further work is needed to address this.  
 
The hypothesis that chronic GH hormone excess would increase cardiac AMPK activity has 
not be borne out by our study.  In fact, a more complex picture occurs, with evidence of 
increased cardiac Thr172 pAMPK levels in young “acromegalic” animals but reduced levels in 
older animals.  The ages of these animals, two and eight months, were chosen to reflect early 
and late acromegaly312,313.  In patients with acromegaly the cardiac findings vary with time.  
Early acromegalic heart disease has been likened to athletic cardiac hypertrophy, with 
hypertrophy, a hyperdynamic circulation and reversibility with removal of stimulus.  With time, 
diastolic and then systolic dysfunction develops.  The fibrosis of acromegalic cardiomyopathy 
has been reported as non-reversible, even with good control of GH23.  The AMPK findings in 
our study appear to represent these two stages of disease: early increased AMPK 
phosphorylation but, as cardiac dysfunction develops, a fall in AMPK phosphorylation over 
time. 
 
The mechanism behind the fall in AMPK phosphorylation in advanced acromegalic 
cardiomyopathy is unclear.  As is discussed in the Introduction, ongoing AMPK activation in 
the presence of an ischaemic heart runs the risk of worsening the situation by uncoupling 
glycolysis and glucose oxidation151.  It may be that protective mechanisms designed to switch 
off the AMPK pathway in presence of ongoing acute ischaemia become chronically activated 
in heart failure.  Alternatively, the reduction in pAMPK may arise from downregulation of the 
AMPK pathway in response to chronic AMPK activation in early heart disease.   
 
AMPK activation with metformin is able to prevent the progression heart failure in dogs166.  
There may be a role for the use of metformin for cardiac protection in patients with 
uncontrolled acromegaly.  There have been concerns about using metformin in patients with 
heart failure because of the risk of lactic acidosis319.  However, studies now indicate that not 
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only is metformin safe in chronic heart failure but that cardiac mortality is reduced in heart 
failure patients taking metformin when compared to patients on other diabetes therapies or 
combination therapies320.  In patients with diabetes metformin is associated with less diastolic 
dysfunction than other diabetes medications321.  There are no trials of metformin in patients 
with acromegaly and the rarity of the disease would make recruiting adequate numbers to 
such trials difficult.  Furthermore, as seen in our clinical study, patients with acromegaly are 
often taking many drugs that may modify the development of cardiac disease, such as ACE 
inhibitors or HMG-CoA reductase inhibitors.  However, there is a strong argument, particularly 
given the insulin resistance of this condition, to consider treating acromegaly patients with this 
cheap and relatively safe medication. 
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12.5 Chronic GH deficiency 
There are no published data examining the effect of GHD on cardiac AMPK activity.  Although 
we failed to demonstrate any changes in cardiac AMPK activity using the functional assay, we 
demonstrated a trend towards changes in cardiac AMPK Thr172 phosphorylation.  
Interestingly, the changes seen were similar to those seen in bGH mice, with increased 
cardiac pAMPK in younger animals and reduced cardiac pAMPK in older animals.  This 
finding indicates a U-shaped relationship between GH AMPK: in the younger heart both 
excess and deficient GH levels cause a rise in AMPK activity, in the older heart both excess 
and deficient GH levels cause a reduction in AMPK activity. 
 
The dramatic fall in cardiac AMPK activity seen in the dwarf rats treated with GH in the acute 
studies may indicate that the myocardium in the GHD state is under chronic metabolic stress.  
As GH normalisation improves the metabolic state and AMPK activity falls.  This hypothesis 
fits with the raised cardiac AMPK activity seen in younger GHRKO mice.  It does not explain 
the trend towards reduced AMPK activity in the older heart.  One suggestion it that the 
reduced AMPK found in these samples indicates a failing myocardium.  However, as 
discussed earlier heart failure is associated with falls in PCr:ATP ratios, which in animal 
models have been associated with increased AMPK activity (see Section 12.4).  It is 
interesting to note that bGH animals demonstrate the same finding, with a reduction in AMPK 
activity by eight months. 
 
The findings in GHRKO transgenics were not statistically significant, although a clear trend 
was present.  It may be that these findings are incidental and do not represent any true 
change.  Experiments with larger numbers would be necessary to investigate this further.  
The changes seen in the heart disease of GHD are far subtler than those seen in acromegaly 
and the factor by which GH and IGF-I levels vary from those of healthy individuals is far more 
marked, as discussed in our clinical study.  If pAMPK levels are proportional to the degree of 
alteration in cardiac structure and function, it would be expected that pAMPK changes would 
be more marked in the hearts of animal models of acromegaly than in those of GHD. 
 
The timepoints in this study were chosen to correlate with early and advanced acromegaly in 
humans and to allow for comparison with published data in mouse models of acromegaly312.  
A more recent paper chose similar timepoints for investigation of pAMPK levels and 
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demonstrated cardiac hypertrophy on histology in nine month old bGH mice313.  To allow for 
comparison between animal models of acromegaly and GHD, matching time points were 
chosen with our bGH and GHRKO animals.  Interestingly, GH status affects life span in mice.  
GHRKO mice demonstrate reduced aging and increased longevity, with the longest living 
mouse recorded living to almost 5 years old322,333.  In contrast bGH mice have reduced 
lifespan324.  Therefore, eight month old GHKRO mice and eight month old bGH-expressing 
mice may not be in comparable life stages.  It is possible that ongoing examination of 
GHRKO may demonstrate further and more significant alterations in cardiac AMPK as time 
progresses.  The trend towards reduced cardiac pAMPK may remain, resolve or become 
amplified.  
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12.6 Somatostatin analogue treatment 
The GH3-implanted rat is a well-recognised model of acromegaly325 and the somatostatin 
analogues, such as octreotide LAR and pasireotide LAR, have been shown to reverse, at 
least in part, the biochemical and clinical features of acromegaly326,327.  Our animals 
demonstrated clear gigantism with GH3 implantation (Figure 9.1).  Treatment with 80 mg/kg 
sc somatostatin analogue did not reduce body weight or tumour size.  As rats with GH excess 
represent a model of gigantism, rather than acromegaly, it might be predicted that body 
weight would persist.  Other published work with the same model, treating with a shorter 
acting somatostatin analogue, also do not show any reduction in tumour size but do show a 
reduction in the velocity with which the tumour grows328.   
 
In this experiment, the animals received 69 days of GH excess.  This was not dissimilar to the 
length of GH exposure in the GH-injected mice (Section 7) and was chosen in advance of the 
results from the mouse experiment being available.  As previously discussed, the failure to 
see the predicted increase in cardiac AMPK activity with this period of GH excess may reflect 
acclimatisation of the cardiac tissue to the hormone excess.  Therefore, if the impact of GH 
on cardiac AMPK activity it U-shaped, it may well be that this model’s timings are unsuitable 
to provide further data regarding the question of the influence of GH/IGF-I on AMPK activity. 
 
Despite this, there was a clear effect of pasireotide and lanreotide on cardiac AMPK activity.  
The ongoing effect of a single dose results from encapsulation of the drug in microspheres of 
polyactide-polyglycolide.  When placed as a depot, the drug is released in a biphasic pattern.  
Human studies demonstrate that after a single dose of octreotide LAR, octreotide levels are 
still measurable in the serum for up to 60 days329.  
 
It has been suggested that somatostatin analogues may be superior to surgery in improving 
cardiovascular outcomes in patients with acromegaly, particularly systolic function and lipid 
profile133. The exact mechanism for this finding is unknown but it has been shown that human 
cardiomyocytes express somatostation receptor subtypes (SSTR) 1 and 2 and that cardiac 
fibroblasts express SSTR 1, 2, 4 and 5 and it has been suggested that somatostatin 
analogues may directly affect the heart330.  To date, there is no published work examining the 
interaction between the somatostatin and AMPK systems331. 
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The finding that somatostatin analogues reduce cardiac AMPK activity may supply a potential 
mechanism for this.  Our experiments with young adult bGH mice demonstrate an increase in 
cardiac pAMPK levels.  Somatostatin analogues may exert some of their beneficial cardiac 
effects in acromegaly by acting directly to counteract the effects of increased AMPK activity.  
However, our data raise questions about the long-term safety of such drugs.  A heart unable 
to mount an AMPK response to acute ischaemic stress is likely to have a worse outcome in 
the event of an ischaemic event.  Furthermore, the use of metformin, an AMPK-activator, is 
associated with a reduction in cardiovascular morbidity and mortality191,192.  However, the 
serious deleterious cardiac consequences of acromegaly or carcinoid syndrome, another 
endocrine disease treated with somatostatin analogues, may well outweigh any risks arising 
from drug-induced cardiac AMPK activity alterations.  Whether or not AMPK activity 
normalises with acclimatisation to these drugs remains to be determined.  
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12.7 Conclusion & further work 
This work demonstrates that the GH/IGF-I and AMPK systems interact with one another.  In 
the acute setting, GH increases cardiac AMPK activity, whereas IGF-I appears to act in a 
converse manner to reduce it, possibly acting via the insulin receptor.  With both chronic GH 
excess and deficiency, the picture is less clear.  In early disease cardiac pAMPK levels rise 
but in late disease they fall.  Functional AMPK assay has not been able to demonstrate 
alterations in cardiac AMPK activity in these situations.  This may represent a failure on 
behalf of the assay or arise from additional AMPK modification in a yet unknown manner, 
most likely additional phosphorylation.   The multi-system impact of acromegaly and GHD 
creates challenges in fully investigating and understanding these diseases. 
 
Several areas have arisen as a result of this study that would benefit from further 
investigation and are listed below. 
 
1. AMPK Ser485/491 phosphorylation 
The phosphorylation of Ser485 has been demonstrated as a mechanism by which insulin 
reduces AMPK activity.  I suggest performing Western blotting for Ser485/491 pAMPK on the 
cardiac protein from the animals in the studies described in this thesis.  I hypothesise that 
IGF-I treatment will result in increased Ser485/491 pAMPK levels, whereas levels will be 
reduced with GH treatment.   
 
2. Further work with cells to examine the effect of GH/IGF-I on AMPK 
We demonstrated that acute GH treatment increased AMPK activity in primary neonatal rat 
cardiomyocytes and WT rats.  The only published study looking at the direct effect of GH on 
AMPK didn’t show any effect of GH on pAMPK levels in endothelial cells66.  However, this 
study was confounded by serum starvation of the cells were subjected to prior to treatment206.  
The lack of published data in this field make the finding that GH increase cardiac AMPK 
activity in two models particularly interesting but clearly indicates a need for further studies in 
this area.  I suggest repeating this experiment in HL-1 cells, an immortalised cardiac cell line 
that is known to express the GH receptor332.  Previous work in our group has not been able to 
measure AMPK activity in these cells.  Through using the techniques described in this thesis I 
hope to be able to measure both AMPK activity and pAMPK in these cells.  Confirming our 
neonatal rat cardiomyocyte findings in a second cardiac cell type will add validity to my 
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findings.  Furthermore, the immortalised nature of HL-1 cells will allow for more extensive 
experiments to take place. 
 
3. The effect of GH on AMPK activity in the GHD state 
Dwarf rats demonstrated a fall in cardiac AMPK activity with GH treatment. It remains unclear 
whether the effect seen on cardiac AMPK activity in the dwarf animal is a true effect of GH on 
cardiac AMPK activity in a GHD-state or if the finding represents a peculiarity of this model.  I 
plan to repeat this experiment, treating the GHRKO mouse with injections of GH, using the 
protocol followed with the dwarf rats.  By using an alternative model of GHD I hope to 
determine if the results reported here were due to a peculiarity of the model used or if they 
represent a true finding.  
It remains unclear whether the GHD heart is under a form of constant metabolic stress, 
arising from low basal energy levels.  To investigate this further I plan to perform cardiac MRS 
on patients with GHD before and after GH replacement.  We already have ethical approval for 
this study.  With this I hope to determine the available energy for the myocardium.   
Performing MRS before and after GH replacement will indicate whether GH reverses the 
impact of GHD on the heart but will not address whether the findings corresponded to AMPK 
changes.   
   
4. Further investigation of the activity of the pAMPK in bGH and GHRKO mice 
These transgenic animals demonstrated changes in pAMPK that did not result in measurable 
changes in AMPK function.  Firstly, I plan to repeat this experiment to ascertain assay failure 
did not cause the incongruous results seen.  Additionally, I plan to measure downstream 
makers of AMPK to determine the effect of increased Thr172 phosphorylation.  The most 
commonly measured target of AMPK is pACC.  I suggest performing Western blotting for this 
protein to help determine whether or not the functional AMPK assay was accurately reflecting 
AMPK activity.  Amplification occurs along this pathway, so even subtle changes should be 
measurable
